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Summary 
 
As in many low-resource countries, febrile illnesses are by far the leading cause for pediatric 
outpatient consultations in Tanzania. Only a small percentage of children require antibiotic 
treatment or hospital-based supportive care, such as oxygen therapy. In these settings, the 
key challenge for clinicians is to identify this minority with serious presentations among the 
large number of children with self-limiting infections. Health workers tend to prescribe 
antibiotics in the vast majority of cases, “to be on the safe side”, given the lack of adequate 
diagnostic tools. Despite this high-volume and indiscriminate antibiotic consumption, 
mortality from childhood infections remains high. 
Outpatient providers rely on disease management algorithms, such as the World Health 
Organization (WHO) Integrated Management of Childhood Illness (IMCI) chart booklet. The 
IMCI strategy, with its integrative disease management approach, remains very relevant 
today. Yet its implementation has faced major challenges, largely related to format and 
content related shortcomings. For example, IMCI algorithm over-relies on clinical signs and 
symptoms. These inherently lack diagnostic accuracy in detecting children with serious 
infections and over-burden the short timeframe allocated for consultations. To address these 
challenges, an enhanced electronic IMCI-based algorithm, ALMANACH, was developed and 
evaluated in Tanzania. However, opportunities for improvement remain, especially related to 
the identification of children with serious infections. Host biomarkers, that can help identify 
children with bacterial infections, such as C-reactive protein (CRP) and procalcitonin (PCT) 
have not been considered within the IMCI strategy. In addition, point-of-care tests (POCTs) 
are available that may help detect children with severe presentations where clinical signs 
lack diagnostic accuracy, e.g. hemoglobin testing for identifying children with severe anemia. 
The aim of this project was to improve the clinical outcome of children with acute febrile 
illnesses through the development and evaluation of a novel electronic disease management 
tool. Through this tool we sought to improve the detection i) of children with severe disease 
requiring hospital-referral and ii) of those in need of antibiotic treatment through the 
integration of key clinical signs with point-of-care host biomarkers into an electronic 
algorithm. Through this approach we also aimed to increase the rational use of antibiotics 
and antimalarials. The project had two major components: 
 
(1) Development of a novel, evidence-based electronic algorithm, e-POCT, that 
integrates clinical signs with point-of-care biomarkers.  
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(2) Evaluation of this novel algorithm through a controlled, randomized, non-
inferiority trial in Tanzania. 
The first step of the e-POCT project was to review comprehensively existing evidence on the 
management of acute febrile illnesses in children, and to identify existing disease 
management tools. For this purpose we conducted a structured literature review that 
included both clinical signs and the use of host biomarker POCTs. Though there was a large 
body of published studies, ‘actionable’ evidence was scant. This was primarily because the 
few validation studies with sufficient quality were either performed at inpatient-level, or 
included clinical signs that would not be assessable by health workers with limited training. 
Furthermore, validation studies had inherent limitations due to the lack of adequate gold 
standards (e.g. serious bacterial infection) that could be used as proxies for important 
clinical outcomes (e.g. cure or death). Outcome-based research and studies at the 
outpatient level in low-resource settings were scarce. We then assessed the diagnostic 
accuracy of existing disease management tools identified in detecting serious bacterial 
infections. We validated retrospectively four prediction rules and five guidelines (including 
IMCI and ALMANACH) using a dataset from a study that assessed causes of fever in 1,005 
febrile Tanzanian children. The diagnostic accuracy of all tools was surprisingly low with 
positive and negative likelihood ratios ranging from 1.04-1.87 to 0.47-0.92, respectively. 
Tools that included both clinical and laboratory elements performed better than those using 
either one only. This retrospective validation exercise further confirmed our overall strategy 
for the development and validation of e-POCT in that i) the integration of key clinical 
elements with simple host biomarker POCTs would be the best way forward and ii) outcome-
based evaluation, and not gold-standard based validation, would be the most adequate 
methodology to assess e-POCT against current best practice.  
Next, we constructed e-POCT based on the evidence retrieved, complemented with expert 
experience when requisite. Despite the limitations of available evidence, we could identify 
several key areas of improvement and innovation. The major innovations of e-POCT were 
as follows; first, we integrated POCTs to identify children with severe disease (oximeter 
directly connected to the electronic tablet, hemoglobinometer) and those requiring antibiotic 
treatment (CRP and PCT rapid tests). Second, we reduced the overall number of clinical 
elements to include a greater number of clinical signs that can be measured objectively (e.g. 
heart rate). Third, we made use of the software’s ability to incorporate more calculations as 
background software steps while maintaining simple user interfaces. For the evaluation 
phase, e-POCT was programmed into an android-based smartphone application 
(Mangologic).  
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Next, given its innovative nature, we sought to evaluate e-POCT’s safety when compared to 
the current best available electronic algorithm (ALMANACH). To this end, we performed a 
randomized (at patient level), controlled, non-inferiority study among children aged two to 59 
months presenting with acute febrile illness to nine outpatient clinics in Dar es Salaam, 
Tanzania. The primary outcome was the proportion of clinical failure by day seven of follow-
up. The secondary outcomes were the proportion of antibiotics prescribed on day 0 and 
severe adverse events by day 30 (secondary hospitalizations and deaths). We planned a 
non-inferiority comparison between e-POCT and ALMANACH since we did not necessarily 
expect benefits in terms of clinical outcome, but rather in terms of antibiotic prescription and 
the efficiency of the disease consultation process. We enrolled 3192 patients between 
December 2014 and February 2016. 3169 patients (e-POCT: 1586; control: 1583) 
completed the intervention and day 7 follow-up. Using e-POCT, the absolute proportion of 
clinical failure by day 7 was reduced from 4.1% to 2.3% compared to the control arm (risk 
ratio [RR] 0.57, 95% confidence interval [CI] 0.38-0.85), and the proportion of severe 
adverse events from 1.5% to 0.6% (RR 0.42, 95% CI 0.20, 0.87). The proportion of antibiotic 
prescription was substantially lowered from 29.7% to 11.5% (RR 0.39, 95% CI 0.33, 0.45). 
Using e-POCT, the most common indication for antibiotic prescription was severe diseases 
(57%, 103/182 prescriptions). With ALMANACH it was non-severe respiratory infections 
(70%, 330/470 prescriptions). e-POCT identified more patients with severe disease through 
the use of hemoglobin testing and the improved identification of children with severe 
malnutrition. The largest reduction in antibiotic prescription occurred in children with 
respiratory infections. For children with a cough, but without severe symptoms requiring 
hospital-referral, e-POCT recommends antibiotic treatment using a two-step diagnostic 
approach of refined age and temperature based respiratory rate cut-offs followed by CRP 
testing. ALMANACH uses the IMCI-based clinical diagnostic strategy for pneumonia 
(dichotomous respiratory rate cutoff and lower chest indrawing). In this patient subgroup, the 
use of antibiotics was reduced from 41% in the ALMANACH arm to 2% in the e-POCT arm. 
Interestingly, the clinical outcome of children was also improved in the e-POCT arm 
compared to the control arm. This may have resulted from the enhanced consideration of 
viral respiratory disease presentations in the e-POCT arm (such as the provision of 
bronchodilator treatment for viral-induced wheeze). Through the randomized, controlled trial 
we also showed that the use of host inflammatory marker testing to determine antibiotic 
prescription in patients with respiratory symptoms (CRP) and fever without source (PCT) 
was safe in terms of clinical outcome. Though these biomarkers were developed more than 
30 years ago, this was the first clinical outcome-based evaluation of these biomarkers in 
children, which is indeed a crucial step before their routine use in clinical practice.  
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In conclusion, this project allowed for the development of an innovative electronic disease 
management algorithm, e-POCT, which has the potential to improve the clinical outcome of 
children with febrile illnesses in low-resource settings while substantially decreasing the use 
of antibiotics. Through the integration of key clinical elements with host-biomarker POCTs, 
e-POCT improved identification of children with severe disease and increased targeting of 
those in need for antibiotic prescription. This disease management tool will be an important 
asset to improving the rational use of antimicrobials. This project indeed re-emphasized that 
very few children with acute febrile illnesses in outpatient settings benefit from antibiotic 
treatment. Electronic algorithms in general are an important prospect to increase compliance 
to IMCI—the integration of POCTs would make even better use of such technologies. As 
implemented in the e-POCT algorithm, POCTs should include both tests for identification of 
patients with severe disease and for the detection of children with bacterial infections. To 
make best use of these POCTs they should be integrated into a patient management tool 
that will not only help to select patient subgroups for which testing is useful, but also help 
interpret results within an overall patient assessment. This will also promote the continuation 
of an integrated approach to the treatment of childhood infection, which has been a 
cornerstone of IMCI. Though areas of further improvement and future research remain, the 
focus should now shift towards the implementation of novel electronic disease management 
tools, including e-POCT, in close collaboration with WHO and local governments.  
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Background 1
1. Background 
 
1.1. Acute febrile illnesses at peripheral health care level: decreasing 
prevalence of bacterial infections, increasing antibiotic use 
 
In Tanzania, as in many low-resource countries, febrile illnesses are by far the leading cause 
for pediatric outpatient consultations (D’Acremont, Lengeler and Genton, 2010; Feikin et al., 
2011). At this level only a small percentage of children require antibiotic treatment or referral 
for hospital-based supportive care, such as oxygen therapy (Shao et al., 2015). There is 
increasing evidence that a large proportion of acute febrile illnesses in these settings are 
caused by viral infections (Chapter 4). A study in Tanzania conducted by Swiss TPH 
researchers in 2008 as part of a larger project around malaria rapid diagnostic test (mRDT) 
implementation (IMALDIA) investigated the etiology of febrile illnesses among 1005 children 
(D’Acremont et al., 2014). In this study, 70.5% of patients had microbiologically confirmed 
viral infections with a significant overlap between disease etiologies (Figure 1). 
 
After the introduction of the pneumococcal conjugative vaccine in Tanzania in 2013, the 
proportion of bacterial infections has likely decreased further, as it has in other countries 
(Bressan et al., 2012; Hernandez-Bou et al., 2015). Both viral and bacterial infections 
caused severe disease: only 20% (16/81) of children with referral criteria had a documented 
bacterial infection. For example, children with bronchiolitis (a viral infection of the lower 
respiratory tract) may require hospital-based supportive care such as oxygen therapy and 
Figure 1 Causes of fever in 1,005 febrile children in Tanzania, % of total diagnoses (D’Acremont et al., 2014) 
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rehydration.  
In these settings, clinicians are challenged to identify and manage the few children with 
serious infections amongst the large number of children with self-limiting disease. The many 
causes of fever are difficult to distinguish clinically in children without adequate diagnostic 
tools and extensive training. The clinical assessment of a child with an acute febrile illness 
requires integration of a multitude of information such as epidemiological, demographic, 
clinical, and laboratory data. Several diagnoses have to be considered at once, as children 
will often present with several concurrent complaints and signs (Horwood et al., 2011). Out 
of the fear of missing a serious infection, clinicians tend to prescribe antibiotics for the vast 
majority of children (D’Acremont et al., 2011; Baltzell et al., 2013) “to be on the safe side” 
(Rambaud-Althaus, Shao, et al., 2015).  
The 
increasing availability of antibiotics in low-resource settings has accelerated this widespread 
over-use, most notably all at the peripheral health care level where most patient 
consultations occur (Risk et al., 2013). Despite this non-differential approach to antibiotic 
prescription, mortality from childhood infections remains high (Liu et al., 2014). On the 
patient-level, over-relying on antibiotic treatment has resulted in the neglect of the correct 
supportive management of severe infections, such as provision of bronchodilator treatment 
and rehydration (Østergaard et al., 2012). Antibiotics may also cause life-threatening side 
effects, such as allergic and immune reactions. From a public health perspective, antibiotic 
misuse has contributed to the alarming spread of antibiotic resistance in developing 
countries (Sosa et al., 2010). For example, in studies investigating resistance patterns of 
Pneumococcus in Ghana, Tanzania and Uganda, decreased susceptibility to penicillin was 
found in 45%, 68%, and 84% of isolates (Joloba et al., 2001; Moyo et al., 2012; Dayie et al., 
Figure 2 Medical record of an 18-month-old study patient. Since birth, the child had consulted for 12 
minor illness episodes, of which 11 were treated with antibiotics (orange). He was febrile during 3 visits only. 
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2013). This compares to 35% in the United States (Jenkins, Brown and Farrell, 2008) and 
12% in Switzerland (Kronenberg et al., 2006). Currently, antibiotic resistant strains are 
mostly affecting older, inexpensive antibiotics. However, the increasing availability and 
unregulated use of antibiotics in developing countries will most certainly result in resistance 
to newer agents as well (Sosa et al., 2010). Mitigating the rapid emergence of antibiotic 
resistance has become a major public health priorities. The World Health Organization 
(WHO) has initiated a global action plan against antimicrobial resistance (World Health 
Organization, 2015). The launch of Tanzanian country-level antimicrobial resistance strategy 
is imminent (Wiedenmayer, personal communication). Having effective disease 
management tools for the primary health care level will be an important ingredient to any 
strategy targeting a more rational prescription of antibiotics. 
 
1.2. IMCI and ALMANACH are available disease management algorithms- 
why is the development of a novel algorithm required? 
 
1.2.1. IMCI 
 
WHO and its partners developed the large Integrated Management of Childhood Illnesses 
(IMCI) program in the 1990s with the goal to tackle the five major causes of childhood death 
in high mortality, high malaria transmission settings at the time: diarrhea, pneumonia, 
measles, malaria, and malnutrition. The program combined existing vertical child health 
programs into one, horizontal strategy (Gove, 1997). Such an integrated approach to the 
classification and treatment of childhood illnesses has been a cornerstone of IMCI, and 
remains very relevant today. At the heart of the program is a set of paper-based case 
management algorithms, the IMCI chart booklet. The IMCI algorithm relies on simple clinical 
signs for case detection, without laboratory tests other than mRDT (World Health 
Organization, 2014). Impact studies of the IMCI program as a whole on child mortality and 
quality of care were performed through a multi-country evaluation program in several high 
mortality settings—Tanzania was one of the study sites (Victora et al., 2006). In such high 
mortality settings, effective implementation was associated with reduction in child mortality 
(pooled estimate from two studies RR 0.85, 0.78-0.93, Gera et al. 2016). Tanzania was a 
“poster child” for IMCI implementation as one of the only countries that rolled out 
countrywide expansion.  
However, IMCI implementation has faced major challenges through a spectrum of obstacles 
within the health system, from the macro (policy) to the micro (patient-provider interaction) 
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level. At the micro level, adherence to the IMCI algorithm is low across geographical settings 
(Arifeen et al., 2005; Horwood et al., 2009; Baiden et al., 2011). In Tanzania, the IMCI 
algorithm is hardly applied in practice and clinicians prefer relying on their ‘own experience’ 
(Walter et al., 2009; Lange, Mwisongo and Mæstad, 2014; Rambaud-Althaus et al., 2017). 
This lack of adherence is certainly multifactorial. In a comprehensive qualitative study 
among health workers in the Dodoma and Morogoro region (Tanzania), Lange et al. found 
the lack of intrinsic and extrinsic motivation to be crucial contributors for non-adherence, 
rather than capacity, patient load, or IMCI knowledge (Lange, Mwisongo and Mæstad, 
2014); this included the lack of “motisha” (Swahili for financial motivation). However, the 
general disbelief in the usefulness of following the IMCI guidelines was also an important 
factor (Lange, Mwisongo and Mæstad, 2014). Here, format and content related 
shortcomings of the IMCI algorithms play an important role. As for format related barriers, 
the current IMCI algorithm requires multiple manual disease classifications, treatments, and 
reporting. It asks health workers to follow flow diagrams, understand and use accessory 
information on each page, and navigate through 39 pages of the chart booklet (World Health 
Organization, 2014). Health workers face challenges to manage the complexity of a febrile 
illness syndrome using IMCI in the 5-6 minutes allocated to a visit. As a result, providers 
often fall back to narrow diagnoses and the integrative IMCI approach of treating several 
illnesses at once is not implemented (Walter et al., 2009). This is further accentuated by 
national reporting requirements where only one diagnosis has to be noted (Rowe et al., 
1999). Electronic IMCI versions (e-IMCI) provide a user-friendlier format compared to paper-
formats. They may thereby increase algorithm adherence and the consistency of clinical 
assessments (Mitchell et al., 2013; Rambaud-Althaus et al., 2017). Beyond e-IMCI, 
electronic algorithms also have the potential to integrate more complex information while 
maintaining a simple user interface.  
In addition to format-related barriers, IMCI implementation also faces content-related 
challenges. First, the algorithm lacks guidance for about one quarter of febrile children: children 
without localizing symptoms (fever without source [FWS], also called undifferentiated fever). 
For such children, IMCI instructs to “give appropriate antibiotic treatment for an identified 
bacterial cause of fever” but provides little guidance on how to identify a bacterial cause of 
fever (World Health Organization, 2014). Even if their actual contribution to morbidity and 
mortality is not well known, negative outcomes of these infections are feared by health care 
workers and a major motivation for clinicians to over-prescribe antibiotics (Rambaud-Althaus, 
Shao, et al., 2015). Second, the IMCI algorithm over-relies on clinical signs and symptoms, 
which inherently lack diagnostic accuracy in detecting children in need for antibiotic treatment 
or referral for hospital-based supportive care (Thompson et al., 2012, see Chapter 5 for a full 
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discussion). Third, the clinical signs included into IMCI were either based on small derivation 
studies, or on expert opinion alone; data from larger, systematic studies was not available at 
the time of development of IMCI (Gove et al., 1999). These clinical signs need to be 
reconsidered since the epidemiological context of infections has changed (D’Acremont et al., 
2014) and a considerable amount of novel evidence has emerged (Thompson et al., 2012). 
Fourth, there is concern that IMCI lacks sensitivity for detection of children with severe disease. 
This is because the limited clinical ‘danger signs’ to detect children with severe disease are 
generally specific, but not sensitive (Chapter 5.4). 
 
1.2.2. ALMANACH, an algorithm developed by the research group 
 
Previous work from our group, the PEDIATRICK project, sought to address some of these 
challenges through creating a revised, IMCI-based algorithm (ALMANACH), including an 
electronic version (Rambaud-Althaus, Shao, et al., 2015). Its efficacy and usefulness was then 
evaluated in Tanzania (Shao et al., 2015; Rambaud-Althaus et al., 2017). The major changes in 
ALMANACH from IMCI were the addition of two clinical signs for severity (jaundice and 
cyanosis), the introduction of a separate chart for patients without fever, as well as the inclusion 
of a clinical sign for typhoid (abdominal tenderness) and urine dipstick testing for patients with 
FWS. The ALMANACH algorithm was compared to routine care in a cluster-randomized trial in 
Tanzania (Shao et al., 2015). In the control arm, no intervention was done (such as an IMCI 
refresher training or provision of an IMCI chart booklets). In this study ALMANACH achieved 
better clinical outcome when compared to routine care (clinical failure was defined as death or 
secondary admission or lack of clinical cure at day 7 per parental report). At day 0 antibiotics 
were prescribed to 15% using ALMANACH versus 84% using standard practice. The 
ALMANACH study included patients with, and without febrile illness. The majority in reduction 
of antibiotics (67%, 266/395 of reduced antibiotic prescriptions) was achieved through not 
recommending antibiotics to children without fever or severe disease (Shao, 2015). During a 
pilot implementation phase, the use of smartphones versus paper was associated with a 
significant increase in children checked for severe symptoms (Rambaud-Althaus et al., 2017). 
Both the paper and electronic ALMANACH form resulted in a reduction of antibiotic 
prescriptions when compared to routine care; the effect was most pronounced in the electronic 
arm (Rambaud-Althaus et al., 2017). Since this pilot implementation phase, ALMANACH has 
not been implemented in Tanzania. However, efforts are underway for implementation 
elsewhere (Table 28), including a revised version in collaboration with Médecins Sans 
Frontières (MSF e-CARE, Rambaud-Althaus, personal communication). In summary, the 
PEDIATRICK project generated the following important findings; first, few children at the 
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outpatient level benefit from antibiotic treatment. Second, antibiotics should be considered only 
in children with fever (presentation of history) or severe disease. Third, electronic algorithms 
may lead to more consistent clinical assessment, and hence improve the quality of care.  
 
1.2.3. Persistent challenges 
 
On the other hand, several major persisting challenges were identified, which were the basis for 
the development of the e-POCT research project. First, the identification of children with severe 
disease presentations should be improved further. Less children were diagnosed as having 
severe disease in the ALMANACH arm (0.2%, 2/842) versus the routine arm 1.6% (10/623), 
p=0.002 (Shao et al., 2015). Though this may have been due to a bias introduced through the 
cluster design of the study, it raised concern about ALMANACH’s performance in detecting 
children with severe disease. ALMANACH did not appear to improve identification of children 
with severe disease, which was an aim in developing the algorithm; health workers were unable 
to detect the additional clinical signs proposed for severe disease (cyanosis, jaundice, Shao, 
2015). Second, a large number of patients still received antibiotic treatment for non-severe 
respiratory infections: 81% (100/124) of antibiotic prescriptions for febrile patients at day 0 were 
for non-severe respiratory infections (Shao, 2015). In the pilot implementation study, only one 
third of patients categorized by an expert as ‘pneumonia’ were identified as having ‘pneumonia’ 
by health workers. This proportion did not differ between the routine and ALMANACH arms 
(Rambaud-Althaus et al., 2017). A large proportion of this diagnostic disagreement was likely 
due to variability of respiratory rate measurements over time, which is a well-known 
phenomenon (Simoes et al., 1991). This raised concern again about the usefulness of 
respiratory rate alone as a criterion for bacterial pneumonia. Overall, the findings from both 
studies called for an improved targeting of children with non-severe respiratory complaints in 
need of antibiotic treatment. Third, ALMANACH still relies mainly on clinical signs and 
symptoms, which lack diagnostic accuracy in detecting children in with bacterial infections or 
severe presentations (Chapter 5.4). Asking providers to perform such detailed clinical 
assessment without an evidence base for their usefulness overburdens the short time allocated 
to consultations. Length was indeed an important factor for non-adherence to the electronic 
algorithm identified in a qualitative study on tablet use performed during the PEDIATRICK 
project (Shao et al., 2014). Fourth, the management of children with FWS should be improved. 
The diseases ALMANACH considers in children with FWS, typhoid and urinary tract infections, 
only represent a fraction of bacterial infections that would need to be taken into account 
(D’Acremont et al., 2014). In addition, health workers were unable to detect the proposed 
clinical sign for typhoid (abdominal tenderness, Shao, 2015).  
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1.3. Opportunities for improvement of existing algorithms 
 
In addition to updates on disease epidemiology since development of IMCI, evidence on the 
diagnosis and management of febrile illnesses in children has also evolved. As mentioned 
earlier, little evidence was available at the time of IMCI development and more recent data 
suggests that some of the backbones of the IMCI strategy may have limited diagnostic 
accuracy (Kalter, Burnham, et al., 1997; Kalter, Schillinger, et al., 1997; Weber et al., 1997; 
Zucker et al., 1997; Pringle et al., 2011; Wingerter et al., 2012; Rambaud-Althaus, Althaus, et 
al., 2015). In recent years, a large number of clinical predictors for serious bacterial infections 
(SBI) were studied in children through large primary research efforts in developed countries 
(Van den Bruel et al., 2010). This calls for a careful revision of the disease management charts 
that form the basis of syndromic diagnosis and treatments. However, in these recent research 
efforts, no common set of clinical predictors for identification of SBI could be identified: many of 
the identified predictors lack external validity. This is not surprising since a uniform 
pathophysiological disturbance in all serious infections is unlikely, at least at the relatively early 
stage seen at primary care level. Moreover, given the large number of potential predictors and 
the relative low prevalence of SBI, data- driven analytical approaches may have resulted in a 
number of predictors identified by chance but miss true predictors and contribute to the 
observed lack of external validity (Oostenbrink et al., 2012). In summary, management 
algorithms of fever in resource-poor settings built on clinical predictors alone will likely remain 
unsatisfactory given the limited diagnostic value of a small set of clinical predictors that could 
be assessed reliably by health care workers. 
Host biomarkers that can help identify children with bacterial infections, such as C-reactive 
protein (CRP) and procalcitonin (PCT), have not been considered within the IMCI strategy (Van 
den Bruel et al., 2011); this is in part because the safety of using CRP or PCT cutoffs to decide 
on antibiotic prescription in children has never been evaluated. Besides the one trial in Vietnam 
that evaluated the use of CRP (without provision of additional clinical guidance) to guide 
antibiotic prescription in mild respiratory infections (Do et al., 2016), all studies of CRP and PCT 
in children have focused on analytical performance; none have assessed whether using these 
tests would change patient outcome. These biomarkers are available as point-of-care tests 
(POCTs) that are implementable at peripheral level (Van den Bruel et al., 2011). They have 
been routinely used in pediatric care in Europe and may help identify children in need of 
antibiotic prescriptions. 
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Other POCTs may help detect children with severe symptoms where clinical signs lack 
diagnostic accuracy: for example hemoglobin (Hb) testing can detect children with severe 
anemia. Severe anemia is one of the major presentations of severe malaria in children under 
five and a major contributor to the morbidity and mortality attributable to malaria; in a study 
among children with malaria in Malawi, between 32 and 54% of malaria-related deaths were 
associated with severe anemia (Tayiog et al., 1994). Severe anemia was also a strong 
predictor of bacterial diseases in the IMALDIA Fever study project (De Santis and D’Acremont, 
2017). Simple field-applicable Hb testing tools are widely available in resource-poor settings.  
The combination of the: i) content and format related challenges of IMCI, ii) the ALMANACH 
experience where important challenges remained after the algorithm’s development and 
evaluation, and the iii) availability of new tools and evidence called for the development of an 
innovative, novel disease management algorithm, rather than additional small modifications of 
existing disease management tools. The way forward would be to move away from subjective 
and inaccurate clinical signs and to replace them with more objective diagnostic tools. The 
diagnostic tools should remain simple and implementable at the point-of-care (POC) level. The 
novel electronic decision chart would hence include only few critical clinical parameters 
complemented by key etiologic tests (such as malaria) and several host biomarkers POCTs 
that could identify children at risk for life-threatening infections and those in need of antibiotic 
treatment. It would improve identification of children with severe disease presentation and 
increase targeting of those in need of antibiotic prescription, while being simple and user-
friendly.  
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2. Goals and Objectives 
 
2.1. Goal  
 
The goal of this project was to improve the health outcome of children with acute febrile 
illness through rapid and accurate identification of those children at increased risk of life-
threatening infections and those children that would most likely benefit from antibiotic 
treatment. We also aimed at a more rational use of antimicrobials, which would contribute to 
mitigating the development of antimicrobial resistance, and at reducing the misallocation of 
scarce health resources that are the result of inappropriate drug use. 
 
2.2. Objectives 
 
The project had two, closely related primary objectives. 
Primary Objectives 
• To develop a novel, evidence-based electronic algorithm, e-POCT, that integrates 
key clinical signs with POC host biomarkers. 
• To compare the clinical outcome of febrile children 2-59 months of age managed 
either by e-POCT (intervention arm) or ALMANACH (control arm). 
 
Secondary Objectives 
• To compare the use of antimicrobials between e-POCT and ALMANACH.  
• To evaluate the safety and benefit in terms of reduction of antibiotic prescription of 
using CRP and PCT testing to decide on antibiotic prescription in children with non-
severe respiratory symptoms and children with fever without source.  
• To gain further insight into the utility of POCTs to detect children with severe disease. 
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3. Methodological overview 
 
The project was conducted in two phases, which were implemented sequentially. Phase 1 
involved the development of novel, electronic evidence-based algorithm, e-POCT; this novel 
algorithm was then evaluated in a randomized, non-inferiority study in Dar es Salaam 
(Phase 2).   
3.1. Phase 1: development of a novel decision tree  
 
For the development of the novel algorithm, a structured literature review was carried out 
with the aim to identify: i) areas that could be modified based on existing evidence, and ii) 
components amenable for innovation and the generation of new evidence (Chapter 5.3). 
Where little published evidence was available, information was complemented with input 
from pediatric specialists from Tanzania, the Unites States, and Switzerland. We also 
assessed the theoretical performance of existing prediction rules and guidelines identified 
through the structured literature review in detecting children with SBI through a retrospective 
validation study on the dataset from the IMALDIA study (Chapter 6.3).  
Figure 3: Example pages of the reference manual. 
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Cough and tachypnea (≥75
th
 %ile)
1
 OR cough and lower chest indrawing
vii
 
(=children with D2=pneumonia OR D38=viral pneumonia) 
D8 osteomyelitis/septic arthritis 
D9 neck mass (if yes to neck mass in 12.1) 
D10 dental abscess (if yes to dental abscess in 12.1) 
D5 uncomplicated malaria 
9.1 >5 loose stools/over past 24hrs 
Or ≥3 loose stools/over past 24hrs and emesis 
Or >3 emesis/over past 24hrs 
 
Obtain samples (P29.8) 
  
15.2.1 CRP result 
15.2.2 PCT result 
15.2.3 mRDT result 
15.2.4 Hb result 
 
 
N 
P23 
 
EXIT 
  
Y P23 
 
EXIT 
N 
14.1 
 ≥3 loose stool/day? 
cough 
D14 cellulitis  
D15 extensive impetigo  
D18 extensive ecthyma/pyderma 
D 13 abscess requiring antibiotic treatment 
D6 Dysentery 
14.7 IM artesunate
ii
 
  
14.8 IM ceftriaxone 
  
14.5. ALu 
  
14.4.1 Hb <6g/dL 
  
Y 
N 
14.6  EXIT  
  
14.4 Hb result 
 
14.3 mRDT result  
  
  
N 
D5 uncomplicated malaria 
  
P 
14.6.1 HIV result 
 
D44 severe malaria 
  
14.10  EXIT-REFER (P12) 
14.4.1 Hb <6g/dL 
  
Y 
14.4 Hb result 
 
14.10.1 HIV result 
 
N 
14.9 IM ceftriaxone 
  
D45 severe anemia 
  
15.1 blood tests (P6.5) 
CRP  
PCT 
  
Y 
14.2 blood tests (P6.4) 
  
Obtain samples (P29.9, 
P29.11) 
14.11 cough? 
Y 
N 
D46 URTI 
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T5. High dose amoxicillin 
T5.1. Text: 
T5.1.1. amoxicillin by mouth, three times a day (roughly every 8hrs)  for 5 days  
T5.1.2. you may either prescribe amoxicillin caps (250mg) or amoxicillin suspension (125mg/5mL) 
T5.1.3. the cap form should be preferred over suspension if the child is able to take caps. 
T5.1.3.1. Amoxicillin cap: [dose mg]mg=[dose cap] cap of 250mg every 8hrs for 5 days 
T5.1.3.2. Amoxicillin suspension: [dose mg]mg=[dose mL] mL of 125mg/5mL suspension every 
8hrs for 5 days 
T5.1.4. it best to take amoxicillin with food. 
T5.1.5. It is important that the child finishes the treatment course even if the symptoms improve 
T5.2. Reference: medication dosage table (HD amoxicillin) 
 
T6. Vitamin A 
T6.1. Vitamin A text 
T6.1.1. Vitamin A dose : [dose in IU: age 6 months to <12 months: 100,000IU, age ≥12months: 200,000 
IU]IU by mouth.  
 
T7. Asthma 
T7.1. Salbutamol text 
T7.1.1. Continue salbutamol: 2 puff roughly every 4hrs for 2 days, then 2 puff roughly every 6hrs for 2 
days, then 2 puff in the morning and at night for 2 days 
T7.1.2. if the child has severe trouble breathing the caregiver may give up to 6 puffs at home, asks 
caregiver to  bring child back to the clinic in case he/she needs to give 6 puffs 
T7.1.3. ask cargiver to use spacer with inhaler,  review correct  spacer use 
T7.1.4. make sure caregiver has a spacer (otherwise help him/her to make one from a bottle) 
T7.1.5. It is important that the child finishes the treatment course even if the symptoms improve 
T7.2. dexamethasone text: 
dexamethasone by mouth[image_medicine] 
use dexamethasone 0.5mg tabs, the dose for this child ([weight in kg]kg)is: 
[dose in mg] mg=[dose in tab]tab of 0.5mg  PO 
 
 
T8. ALu 
T8.1. ALu text 
T8.1.1. dispersable artemether/lumefantrine tabs (120mg/20mg)  
T8.1.1.1. today (Day 1): [dose mg]mg=[dose cap]tab of 120mg/20mg 8hrs after first dose (give 
caregiver exact time) 
8.1.1.1.1. tomorrow (Day2): [dose mg]mg=[dose cap]tab of 120mg/20mg in the morning and at 
night 
8.1.1.1.2. day after tomorrow (Day3): [dose mg]mg=[dose cap]tab of 120mg/20mg in the 
morning and at night 
8.1.1.1.3. dispersible artemether/lumefantrine tablets may be dispersed in a cup with some 
clean water (one soup spoon per tablet). Ask caregiver to  
8.1.1.1.4. wait until the tablet(s) dissolve(s), and stir carefully before he/she give the liquid to 
your child to drink.  
8.1.1.1.5. Then add some more water (about 10 ml) to the cup and have his/her child drink all of 
it.  
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A detailed paper reference manual was developed, which served as the basis for the 
software programming (Figure 3). Since the novel algorithm included background software 
calculations that could not be done manually by health-workers, we did not develop a 
consultation paper chart booklet for clinicians. The 63-page paper reference manual for 
programming contained the overall logical flow of the algorithm, and also detailed the 
screen-text for each procedure and treatment (Figure 3). The algorithm was then 
programmed into an android-based decision support tool for the purpose of this study. 
  
Figure 4 Validation of the e-POCT algorithm 
We initially attempted programming of the algorithm into the open-source Open Data Kit 
(ODK) software, but were limited by the software’s simple skip logic. For example, having 
several disease classifications required permutations of the antibiotic treatment (to prescribe 
one antibiotic that would work for both disease classifications, instead of a separate 
antibiotic for each classification). Also, several branches of the algorithms had to be entered 
at once. We then collaborated with ThingsPrime, a software company that had developed 
Mangologic, a software aimed at supporting decisions trees. The algorithm was 
programmed by ThingsPrime into Mangologic. We performed detailed internal validation of 
the software after each modification against a standard set of theoretical patients.  
After careful internal validation of the software, the tool was then piloted in 100 patients 
meeting eligibility criteria to allow final revisions. A local medical doctor and myself 
supervised all consultations during that phase to assure patient safety. A final version was 
then created for use in phase 2 (Chapter 5.3). We also attempted to connect several 
sensors to the algorithm so that the information could be directly fed into the algorithm 
software without manual input. This was successful for the oximeter probe using the XPod 
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USB hub (Nonin Medical Incorporated). However, the electrical power supplied by the tablet 
USB ports was not sufficient to run the oximeter. An external USB power hub had to be 
connected in between. The direct USB oximeter feed failed intermittently with software 
updates, requiring the use of a backup, manual oximeters.  
 
Figure 5 Oximeter connected to tablet (left) and back-up oximeter (right) 
As for the lateral flow tests, we tried integrating an automated reader (DekiReader, Fio 
Corporation). However, the reader could not be calibrated for the CRP test. In addition, the 
software was required to be maintained within the reader (instead of the smartphone). Using 
the Dekireader instead of an electronic tablet would not have been suitable.  
 
3.2. Phase 2: evaluation of e-POCT in a randomized, controlled trial 
 
Next, we carried out a randomized, controlled, non-inferiority trial comparing the clinical 
outcome of febrile children between e-POCT (intervention) and ALMANACH (control arm). 
The methods of this trial are described in detail in Chapter 7.3. To better assess the impact 
of CRP-testing on clinical outcomes and antibiotic use among children with non-severe 
respiratory infections, we performed a subgroup analysis. The methods for this analysis are 
detailed in Chapter 8.4.  
IMCI, and its electronic version ALMANACH, is currently the standard of care for treatment 
of febrile illnesses in children in resource-poor settings. ALMANACH, instead of the paper-
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based IMCI, was chosen to control for the ‘electronic support tool effect’. In addition, 
ALMANACH contains several improvements compared to IMCI (see Chapter 1.2.2).  
Our choice of a non-inferiority trial design was based on the expectation that the advantage 
of e-POCT in terms of antibiotic prescription would be sufficient to tip the risk-benefit ratio in 
its favor of e-POCT. We expected that e-POCT would achieve similar clinical outcome while 
further reducing antibiotic prescription.  
 
3.2.1. Ethics 
 
The study protocol and related documents were approved by the Institutional Review Board 
of the Ifakara Health Institute and the National Institute for Medical Research Review Board 
in Tanzania, by the Ethikkommission beider Basel in Switzerland, and the Boston Children’s 
Hospital Ethical Review Board. An independent Data Monitoring Committee oversaw the 
study. The trial was registered in ClinicalTrials.gov, identifier NCT02225769. Major issues 
discussed with the local Institutional Review Boards were the storage and transfer of 
samples, including tests to be done in Tanzania, and blood draw volumes.  
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4. Study setting: Dar es Salaam, Tanzania 
 
Patient recruitment took place in the outpatient department (OPD) of primary health facilities 
(health centers, dispensaries, and district hospitals) in Dar es Salaam (Figure 6). We chose 
the Dar es Salaam region because of its relative low endemicity for malaria (allowing better 
investigation of febrile episodes caused by other diseases than malaria (Figure 7). Several 
previous studies had already been carried out in the area by our group, which provided 
additional infrastructural advantages. This was especially important because the innovative 
character of e-POCT required close monitoring of adverse events, which may have not been 
possible in more remote areas with the resources at hand for this project. Study sites were 
selected to represent the general pediatric outpatient population of the region.  
 
Figure 6 Study sites. 1: Sinza Health Center, 2: Tandale Dispensary, 3: Mwananyamala Hospital, 4: Magomeni 
Health Center, 5: Mburahati Dispensary, 6: Amana Hospital, 7: Temeke Hospital, 8: Kizuiani Dispensary, 9: 
Rangi Tatu Health Center.  
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Figure 7 Tanzania malaria prevalence in children by region. % of children who tested positive by mRDT in a 
2011/12 survey (Tanzania Commission for AIDS, 2013) 
4.1. Child health in Tanzania 
 
Tanzania’s under-five mortality was estimated at 48.7/1,000 live births in 2015 by the Child 
Mortality project (UN Inter-Agency Group for Child Mortality Estimation, 2017), and at 
66.5/1,000 live births in a 2012 Tanzanian census (Tanzania National Bureau of Statistics 
and Tanzania Ministry of Finance, 2015). The country experienced one of the most 
important declines in child mortality over the past 20 years in Sub-Saharan Africa (Figure 8). 
A significant proportion of this decline is certainly attributable to improved childhood 
vaccinations: Haemophilus influenza type B (Hib) was introduced in 2009, the pneumococcal 
conjugate vaccine (PCV) and rotavirus vaccine in 2013. Official coverage reports are above 
95% for all three vaccines (World Health Organization, 2017a).   
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The 
largest proportion of children under-five die at less than of one year old, largely due to 
complications in the neonatal period: an estimated 41% of children under-five die within the 
first months of life. After the neonatal period around 70% of deaths between 1-59 months 
are estimated to be due to infections (UN Inter-Agency Group for Child Mortality Estimation, 
2017). Under-five mortality varies by Region (Figure 9). Dar-es-Salaam’s under-five mortality 
rate is with 72.3/1,000 live births above the national average. Interestingly, in the Tanzanian 
2012 census the estimates of under-five mortality rates were higher in urban areas (71 
deaths/1,000 live births) in 2012 than those observed in rural areas (66 deaths/1,000 live 
births). This pattern was reversed from a previous 2002 census (Tanzania National Bureau 
of Statistics and Tanzania Ministry of Finance, 2015).  
Figure 3 Estimated deaths per 1,000 by age and sex, Tanzania 2012 Census (Tanzania National Bureau 
of Statistics and Tanzania Ministry of Finance, 2015) 
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Figure 9 Under-five mortality rate (Tanzania National Bureau of Statistics and Tanzania Ministry of Finance, 
2015)  
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4.2. Causes of fever and antibiotic prescription 
 
Since the IMALDIA project (Chapter 1.1, D’Acremont et al., 2014), several studies to 
determine the causes of fever in children have been conducted at the outpatient level in 
Tanzania (Table 1). They varied primarily in the amount and types of investigation performed 
and none were as comprehensive as the IMALDIA project. 
Table 1 Studies on etiologies of acute febrile illness at the outpatient level in Tanzania since the IMALDIA 
project 
Author, year Location Time period Age range 
(months) 
N Investigations Documented 
infections 
Msaki et al., 
2012 
Mwanza City, 
primary health 
care facility 
February-
June 2011 
2-60 231 Blood culture, 
urine culture, blood 
microscopy 
 
BSI=7.4% 
UTI=20.3% 
Thriemer et 
al., 2012 
Pemba Island, 
District Hospital 
OPDs 
 
March 2009-
December 
2010 
2-59 3,105 Blood culture 
Blood microscopy 
Mal= 1% 
BSI= 4% 
Mahende et 
al., 2014 
Korogwe District 
Hospital OPD 
 
January-
October 2013 
2-59 863 Blood culture, 
urine culture,  
blood microscopy  
Mal= 8.3% 
BSI= 3.2% 
UTI= 7.6% 
Chipwaza et 
al., 2014 
 
Chipwaza et 
al., 2015 
 
Kilosa district 
hospital, OPD 
March -
October 2013 
24–59 364 Blood microscopy, 
Leptospirosis/ 
brucellosis serologies, 
Widal, 
Urine microscopy 
ELISA (Dengue, 
Chikungunya, 
Rota/Adenovirus), 
PCR (Dengue) 
 
Mal= 23% 
Lepto=11.6% 
Bruc= 7.0% 
UTI= 18.6% 
Dengue= 20.9% 
Chik= 4.7% 
Influenza=1.4% 
Rota/Adeno=1.9% 
 
Hildenwall et 
al., 2016 
Muheza District 
Hospital, OPD 
July 2011- 
November 
2012 at 
3-59 281 Blood culture 
Urine culture 
CXR 
Mal not assessed* 
BSI= 1.4% 
UTI= 5.6% 
CXR consolidation= 
2.5%** 
 
Elfving et al., 
2016 
Zanzibar, North 
A district. 
Primary health 
care facilities 
April-July 
2011 that 
2-59 677 mRDT 
Blood microscopy 
Malaria PCR 
Rickettsia/arbovirus 
blood PCR 
Streptococcus A throat 
RDT 
Pneumococcus urine 
RDT 
NPS viral PCR 
Stool PCR (viral and 
bacterial) 
CXR 
Mal= 0.2% 
RSV = 24.5% 
Influenza= 22.3% 
Rhinovirus= 10.3% 
Enterovirus= 8.7% 
CXR consolidation= 
6.2% 
Shigella stool infection= 
4.3% 
UTI= 1.6%*** 
*mRDT negative patients included only, **CXR not available in 22 patients with IMCI pneumonia, ***see original 
publication for additional causes. Outpatient department (OPD), malaria (Mal), blood stream infection (BSI), 
urinary tract infection (UTI), Leptospirosis (Lepto), Brucellosis (Bruc), Chikungunya (Chic), polymerase chain 
reaction (PCR), adenovirus (Adeno), rapid diagnostic test (RDT). nasopharyngeal swab (NPS), Respiratory 
Syncytial Virus (RSV) 
Overall, the reported prevalence of bacterial blood stream infections was low, ranging from 
1% to 7.5%. Gram-negative bacteria (including Salmonella) were the most frequently 
isolated pathogens (Msaki et al., 2012; Thriemer et al., 2012; Mahende et al., 2014; 
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Hildenwall et al., 2016). The prevalence of positive urine culture ranged from 1.6% to 20.3%. 
This large range was likely due to the differences of urine collection techniques and criteria 
used to define a positive culture. Chipwaza et al. found a high prevalence of zoonotic 
bacterial infections (Leptospirosis and Brucellosis) in a study conducted in an area in 
proximity to livestock. Generally, the large variation in the types of viral and zoonotic 
bloodstream infections reflects their large seasonal and geographic variability, even within a 
single country in Africa.  
Despite increasing evidence that very few children at the outpatient level benefit from 
antibiotic treatment (Shao et al., 2015), antibiotic overuse at the outpatient level remains 
high. During the duration of the clinical trial in Dar es Salaam, we also monitored routine 
care in a cohort of 547 febrile children (same inclusion/exclusion criteria as for main trial, 
Chapter 7.3). Children were treated by three routine clinicians at Magomeni health center 
and Tandale dispensary. No intervention was done besides mRDT testing and weight 
measurements for all children before the consultation. Routine clinicians were asked to 
document their diagnoses and treatments prescribed. 95% (518/547) of children were 
prescribed an antibiotic treatment at D0. Table 2 lists the types of antibiotics prescribed at 
D0.  
Table 2 Antibiotics prescribed to 547 children treated per routine care in Dar es Salaam during the study 
period.  
Antibiotic Name % of 518 patients 
with antibiotic 
prescription at day 0 
(n) 
Amoxicillin 54.4% (282) 
Cephalexin 25.9% (134) 
Penicillin G* 13.7% (75) 
Cotrimoxazole** 10.1% (55) 
Ampicillin/flucloxacillin 5.8% (30) 
Erythromycin*** 3.1% (16) 
Azithromycin 1.2% (6) 
Amoxicillin/clavulanic acid 1.2% (6) 
Ciprofloxacin 1.2% (6) 
Metronidazole 0.8% (4) 
Gentamicin* 0.4% (2) 
Chloramphenicol 0.2% (1) 
Ceftriaxone 0.2% (1) 
Antibiotics that are part of the 2014 IMCI 
recommendations are bolded. *For severe infections 
only, **prophylactic treatment for HIV positive children 
only, ***treatment for cholera only 
Amoxicillin was the antibiotic most frequently prescribed. Second was cephalexin, an 
antibiotic that is not part of the IMCI recommendations (as were most antibiotics prescribed). 
Table 3 lists the diagnoses given by the clinicians as reasons for antibiotic prescription. Only 
4% of prescriptions (11/282) had a diagnosis for which amoxicillin is an adequate antibiotic 
choice.  
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Table 3 Clinician diagnoses for children who were prescribed amoxicillin at day 0 
Diagnosis % of 282 patients 
prescribed amoxicillin at 
day 0 (n) 
Upper respiratory tract infection 69.5% (196) 
Urinary tract infection 11.0% (31) 
Gastroenteritis 8.9% (25) 
Pneumonia 3.6% (10) 
Fever without source 2.5% (7) 
Skin infection, other than 
abscess 
1.8% (5) 
Oral thrush 1.4% (4) 
Ear infection 0.4% (1) 
Abscess 0.4% (1) 
Bronchiolitis 0.4% (1) 
Viral illness 0.4% (1 
Gingivitis 0.4% (1) 
Diagnoses for which amoxicillin is an adequate antibiotic choice are bolded. 
About one quarter of children were prescribed weight-based daily dosing within the range of 
international guidelines. Only 8% (23/272) were prescribed the exact dose recommended by 
the 2008 IMCI chart booklet, which was implemented in Tanzania at the time of the study. 
Alarmingly, most children were under-dosed, which may not only lead to treatment failure, 
but also accelerate the development of antibiotic resistance.  
Table 4 Appropriateness of amoxicillin weight-based dosing at day 0 
Reference Dosing 
 Within range Too big Too small 
IMCI 2014 29% (78/272) 0% (0/272) 71% (194/272) 
IMCI 2008 22% (69/272) 0% (0/272) 78% (213/272) 
Red Book* 25% (68/272) 1% (3/272) 74% (201/272) 
Dosing prescribed was available for 272 children. *based on American Academy of Pediatrics, 2015. The 
following dose ranges were considered within range: for respiratory infections 80-100mg/kg/day, all other 
infections 25-80mg/kg/day.   
In summary, antibiotic overuse in the study area remained high during our study. In addition, 
quality of prescriptions in terms of indications and dosing was low.  
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5.1. Abstract 
 
Objective 
To review available evidence of key areas of management of children with acute febrile 
illnesses at outpatient level, including the use of point-of-care host biomarkers, as a basis for 
the construction of a novel electronic algorithm that can guide clinicians through the 
consultation process in resource-poor, outpatient settings. This aim of this novel electronic 
tool is to improve clinical outcome and rational antibiotic use among children with acute 
febrile illness.  
Methods 
We performed a structured literature review focusing on the i) identification of children with 
severe infections requiring referral, ii) detection of children with serious bacterial infections, 
including the use of C-reactive protein (CRP) and procalcitonin (PCT) to predict the need for 
antibiotic treatment and iii) detection of children with dehydration. Using the evidence 
retrieved, a novel electronic algorithm (e-POCT) was designed.  
Findings 
The following main changes were made from the 2014 Integrated Management of Childhood 
Illness version: i) pulse oximetry to identify children with hypoxemia and severe tachycardia; 
ii) hemoglobin to detect children with severe anemia; iii) construction of a ‘severe respiratory 
distress’ classification; iv) refinement of criteria for severe malnutrition; v) two-step approach 
including respiratory rate and CRP for diagnosing bacterial pneumonia; vi) CRP and PCT to 
decide on antibiotic prescription for children with fever without localizing symptoms. We 
constructed a novel electronic algorithm, e-POCT, that was programmed into an android-
based mobile tool. The electronic version allowed integrating a greater amount of data, more 
elaborate calculations and direct connection to the oximeter, without increasing the 
complexity of the consultation process for the health worker.  
Conclusions 
We developed a novel, innovative algorithm, e-POCT, that has the potential to improve 
management of the febrile child in low-resource settings.  This new tool should be validated 
in real conditions of outpatient care in resource-poor settings 
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5.2. Introduction 
 
Mitigating the rapid emergence of antibiotic resistance has become one of the public health 
priorities (Sosa et al., 2010). The increasing availability of antibiotics in low-resource settings 
has been accompanied by a widespread over-utilization, above all at the peripheral health 
care level where most patient consultations occur and presumptive treatment is the rule 
(Risk et al., 2013). Among children, acute febrile illnesses make up the bulk of outpatient 
visits (Shao et al., 2015). There is increasing evidence that at this level the majority of such 
infectious episodes are attributable to viral infections (D’Acremont et al., 2014) and very few 
require antibiotic treatment (Shao et al., 2015). Health workers with limited skills are 
challenged in identifying this minority of children with bacterial infections by the lack of 
adequate diagnostic tools. As a result, they tend to prescribe antibiotics for the majority of 
children, just “to be on the safe side” (D’Acremont et al., 2011; Baltzell et al., 2013). Despite 
this non-differential approach to antibiotic prescription, mortality from childhood infections 
remains high (Liu et al., 2014). Over-relying on antibiotic treatment has resulted in the 
neglect of the correct management of severe infections, which can be of viral, parasitic, and 
bacterial origin (D’Acremont et al., 2014).  
The Integrated Management of Childhood Illness (IMCI) chart booklet, a series of disease 
management algorithms, was developed by the World Health Organization (WHO) in the 
1990s with regular improvements (Gove, 1997; World Health Organization, 2014). Besides 
the rapid diagnostic test for malaria (mRDT), it recommends presumptive treatment based 
on clinical signs and symptoms (World Health Organization, 2014). Key to IMCI is the 
concomitant consideration of multiple disease classifications (e.g. malaria and pneumonia). 
The IMCI strategy remains very relevant today but its implementation has faced major 
challenges (Arifeen et al., 2005; Horwood et al., 2009; Baiden et al., 2011) related largely to 
four format-and content related shortcomings. First, the short timeframe attributed to 
outpatient consultation is overloaded by the number and logical flow of questions and 
information in the paper chart booklet (Lange, Mwisongo and Mæstad, 2014). Second, IMCI 
lacks guidance for about a quarter of febrile children, namely the children without localizing 
main IMCI symptoms, fever without source (FWS). Here, IMCI suggests to “give appropriate 
antibiotic treatment for an identified bacterial cause of fever” but provides no clear directions 
on how to identify such an etiology (World Health Organization, 2014). Third, the IMCI 
algorithm over-relies on clinical signs and symptoms which inherently lack diagnostic 
accuracy in detecting children in need for antibiotic treatment or referral for hospital-based 
supportive care (Thompson et al., 2012). Fourth, the diagnostic value of clinical signs that 
were included into IMCI (based on expert opinion and small derivation studies) needs to be 
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reconsidered. This is because the epidemiological context of infections has changed 
(D’Acremont et al., 2014) and a considerable amount of novel evidence has emerged 
(Thompson et al., 2012).  
Some challenges have already started to be addressed. Electronic, “smartphone”, IMCI 
versions (e-IMCI) have a user-friendlier format and may thereby increase algorithm 
adherence and the consistency of clinical assessments (Mitchell et al., 2013; Shao et al., 
2015). One improved e-IMCI-based algorithm, ALMANACH, has already been evaluated in 
clinical studies in Tanzania (Shao et al., 2015; Rambaud-Althaus et al., 2017) but 
opportunities for improvement remain. Host biomarkers, that can help identify children with 
bacterial infections, such as C-reactive protein (CRP) and procalcitonin (PCT) have not been 
considered within the IMCI strategy (Van den Bruel et al., 2011). Furthermore, point-of-care 
tests (POCTs) are available that may help detect children with severe symptoms where 
clinical signs lack diagnostic accuracy: e.g. hemoglobin (Hb) testing for detecting children 
with severe anemia.  
Based on the challenges and opportunities identified in the management of children with 
febrile illnesses, and building on the experience acquired through the construction and 
evaluation of the ALMANACH algorithm (Rambaud-Althaus, Shao, et al., 2015; Shao et al., 
2015; Rambaud-Althaus et al., 2017), we sought to develop a novel electronic disease 
management algorithm that would make use of POCTs (e-POCT). The overall goal of this 
algorithm was to i) improve identification of children with severe disease, ii) increase 
targeting of children in need for antibiotic prescription and iii) enhance the efficiency of 
outpatient consultations. For the latter we aimed at simplifying clinical elements to few 
relevant signs and symptoms, as well as using the algorithm’s electronic features to 
integrate data and perform background calculations, while maintaining simple user 
interfaces. The objective of this paper is to provide a summary of the evidence and rationale 
used for the construction of e-POCT.  
5.3. Methods 
 
Structured Literature Review 
We undertook structured literature searches to review publications on the key elements that 
required update from ALMANACH and IMCI.  We focused on the following areas in an 
ambulatory care setting: 
1) Identification of children with severe infections using clinical signs and/or available 
POC laboratory tests. 
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2) Management of children with respiratory infections, including identification of children 
with severe respiratory infections and those in need for antibiotic treatment. 
3) The use of clinical signs and available POCTs to decide on antibiotic prescriptions for 
children with fever without focal symptoms (FWS).  
4) Symptoms and signs for dehydration.  
5) Diagnosis of severe malnutrition 
We constructed three separate searches for questions 1-3, 4, and 5 (Table 5) and merged 
the resulting records. 
Table 5 Search terms 
Search PubMED Embase 
Severe 
infections/ 
serious bacterial 
infections 
("Community-Acquired Infections"[Mesh] OR 
"Sepsis"[Mesh:NoExp] OR "Bacterial Infections"[Mesh] 
OR "Respiratory Tract Infections"[Mesh] OR "Shock, 
Septic"[Mesh] OR "Status Asthmaticus"[Mesh] OR 
"Meningitis"[Mesh:NoExp] OR "Meningitis, 
Bacterial"[Mesh] OR "Arthritis, Infectious"[Mesh] OR 
"Bone Diseases, Infectious"[Mesh] OR 
"Cellulitis"[Mesh] OR "Skin Diseases, 
Bacterial"[Mesh:NoExp] OR "Skin Diseases, 
Infectious"[Mesh:NoExp] OR "Ecthyma"[Mesh] OR 
"Erysipelas"[Mesh] OR "Staphylococcal Skin 
Infections"[Mesh] OR "Soft Tissue Infections"[Mesh] 
OR "Diarrhea, Infantile"[Mesh] OR "Dysentery"[Mesh] 
OR "Urinary Tract Infections"[Mesh] OR 
"Pyelonephritis"[Mesh:NoExp] OR "Typhoid 
Fever"[Mesh] OR "Fever of Unknown Origin"[Mesh] OR 
bacterial infection*[tiab] OR serious infection*[tiab] OR 
severe infection*[tiab] OR invasive infection*[tiab] OR 
(death[tiab] AND infection[tiab]) OR severe 
malaria[tiab] OR severe bronchiolitis[tiab] OR 
sepsis[tiab] OR meningitis[tiab] OR dehydration[tiab] 
OR pneumonia[tiab] OR pyelonephritis[tiab] OR urinary 
tract infection*[tiab] OR typhoid[tiab] OR 
leptospirosis[tiab] OR rickettsia*[tiab] OR 
osteomyelitis[tiab] OR cellulitis[tiab] OR 
bacteremia[tiab] OR bacteraemia[tiab] OR otitis 
media[tiab]) AND ("Signs and Symptoms"[Mesh:NoExp] 
OR "Seizures"[Mesh] OR "Abdominal Pain"[Mesh] OR 
"Vomiting"[Mesh] OR "Pallor"[Mesh] OR 
"Jaundice"[Mesh] OR "Tachypnea"[Mesh:NoExp] OR 
"Respiratory Sounds"[Mesh:NoExp] OR 
"Dyspnea"[Mesh:NoExp] OR "Vital Signs"[Mesh] OR 
"Tachycardia"[Mesh:NoExp] OR "Diagnostic Tests, 
Routine"[Mesh] OR "Physical 
Examination"[Mesh:NoExp] OR 
"Diagnosis"[Mesh:NoExp] OR "Clinical Decision-
Making"[Mesh] OR "Medical History 
Taking"[Mesh:NoExp] OR "Symptom 
Assessment"[Mesh] OR "Odds Ratio"[Mesh] OR 
"Sensitivity and Specificity"[Mesh:NoExp] OR 
"Predictive Value of Tests"[Mesh] OR "ROC 
Curve"[Mesh] OR "Severity of Illness Index"[Mesh] OR 
"Decision Trees"[Mesh] OR "C-Reactive Protein"[Mesh] 
OR "Anemia"[Mesh:NoExp] OR clinical sign*[tiab] OR 
clinical syndrome* [tiab] OR "syndromic diagnosis"[tiab] 
OR clinical variable*[tiab] OR clinical predictor*[tiab] 
OR vital sign*[tiab] OR clinical feature*[tiab] OR "signs 
and symptoms"[tiab] OR red flag*[tiab] OR danger 
sign*[tiab] OR "abnormal mental status"[tiab] OR 
"altered mental status"[tiab] OR convulsion*[tiab] OR 
"stiff neck"[tiab] OR meningeal sign*[tiab] OR 
prostration[tiab] OR "chest wall retraction"[tiab] OR 
"chest indrawing"[tiab] OR stridor[tiab] OR 
tachypnea[tiab] OR "fast breathing"[tiab] OR 
('bacterial infection'/de OR Infection/de OR 
'Enterobacteriaceae infection'/exp OR 'Gram 
negative infection'/exp OR 'Gram positive 
infection'/exp OR 'pyonephrosis'/exp OR 
'rickettsiosis'/exp OR 'Staphylococcus infection'/exp 
OR 'Streptococcus infection'/exp OR 'community 
acquired infection'/exp OR 'sepsis'/de OR 
'bacteremia'/de OR 'septic shock'/de OR 
'septicemia'/de OR 'respiratory tract infection'/exp 
OR 'pneumonia'/de 'bronchopneumonia'/exp OR 
'asthmatic state'/exp OR 'meningitis'/de OR 
'bacterial meningitis'/exp OR 'Haemophilus 
meningitis'/exp OR 'pneumococcal meningitis'/exp 
OR 'bone infection'/de OR 'bacterial arthritis'/exp 
OR 'soft tissue infection'/exp OR 'cellulitis'/exp OR 
'bacterial skin disease'/de 'erysipelas'/de OR 
'impetigo'/exp OR 'skin abscess'/exp OR 
'staphylococcal skin infection'/exp OR 
'dysentery'/exp OR 'urinary tract infection'/exp OR 
'acute pyelonephritis'/exp OR 'urinary tract 
infection'/exp OR 'typhoid fever'/exp OR ((bacterial 
NEXT/1 infection*) OR (serious NEXT/1 infection*) 
OR (severe NEXT/1 infection*) OR (invasive 
NEXT/1 infection*) OR (severe NEXT/1 malaria) OR 
(severe NEXT/1 bronchiolitis) OR sepsis OR 
meningitis OR pneumonia OR pyelonephritis OR 
(urinary NEXT/1 tract NEXT/1 infection*) OR typhoid 
OR leptospirosis OR rickettsia* OR osteomyelitis 
OR cellulitis OR bacteremia OR bacteraemia OR 
(otitis NEXT/1 media)):ab,ti) OR ('pallor'/exp OR 
'seizure'/de OR 'convulsion'/de OR 'abdominal 
pain'/de OR 'vomiting'/de OR 'jaundice'/de OR 
'abnormal respiratory sound'/exp OR 'dyspnea'/de 
OR 'tachypnea'/de OR 'vital sign'/exp OR 'heart 
rate'/de OR 'breathing rate'/de OR 'oxygen 
saturation'/exp OR 'tachycardia'/de OR 'diagnostic 
accuracy'/de OR 'diagnostic test accuracy study'/de 
OR 'classification algorithm'/exp OR 'practice 
guideline'/de OR 'predictive value'/exp OR 
'diagnostic value'/de OR 'diagnostic accuracy'/de 
OR 'C reactive protein'/exp OR 'procalcitonin'/exp 
OR 'anemia'/de OR ((clinical NEXT/1 sign*) OR 
(clinical NEXT/1 syndrome*) OR (clinical NEXT/1 
variable*) OR (clinical NEXT/1 predictor*) OR (vital 
NEXT/1 sign*) OR (clinical NEXT/1 feature*) OR 
"signs and symptoms" OR (red NEXT/1 flag*) OR 
(danger NEXT/1 sign*) OR "abnormal mental 
status" OR "altered mental status" OR convulsion* 
OR "stiff neck" OR (meningeal NEXT/1 sign*) OR 
prostration OR "chest wall retraction" OR "chest 
indrawing" OR stridor OR tachypn*a OR "fast 
breathing" OR "respiratory rate" OR tachycardia OR 
"fast heart rate" OR "capillary refill time" OR 
vomiting OR pallor OR fever OR algorithm* OR 
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tachypnoea[tiab] OR "respiratory rate"[tiab] OR 
tachycardia[tiab] OR "fast heart rate"[tiab] OR "capillary 
refill time"[tiab] OR vomiting[tiab] OR pallor[tiab] OR 
fever[tiab] OR algorithm*[tiab] OR decision tree*[tiab] 
OR prediction rule*[tiab] OR imci[tiab] OR "integrated 
management of childhood illness"[tiab] OR "severe 
anemia"[tiab] OR "severe anaemia"[tiab] OR 
procalcitonin[tiab] OR "C-reactive protein"[tiab] OR 
"Urine dipstick"[tiab] OR Urine leucocyte*[tiab] OR 
Urine nitrite*[tiab] OR "diagnostic accuracy"[tiab]) AND 
("infant"[Mesh] OR "Child, Preschool"[Mesh] OR 
infant*[tiab] OR child*[tiab] pediatric*[tiab] OR 
paediatric*[tiab] OR under-five*[tiab] OR 59 
month*[tiab] OR under-5[tiab] OR babies[tiab] OR 
baby[tiab]) 
 
(decision NEXT/1 tree*) OR (prediction NEXT/1 
rule*) OR imci OR "integrated management of 
childhood illness" OR "severe an*emia" OR 
procalcitonin OR "C-reactive protein" OR "Urine 
dipstick" OR (Urine NEXT/1 leucocyte*) OR (Urine 
NEXT/1 nitrite*) OR "diagnostic accuracy"):ab,ti) 
 
Dehydration (dehydration[tiab] OR "Dehydration"[Mesh]) AND 
("Signs and Symptoms"[Mesh:NoExp] OR "Vital 
Signs"[Mesh] OR "Tachycardia"[Mesh:NoExp] OR 
"Diagnostic Tests, Routine"[Mesh] OR "Physical 
Examination"[Mesh:NoExp] OR 
"Diagnosis"[Mesh:NoExp] OR "Odds Ratio"[Mesh] OR 
"Sensitivity and Specificity"[Mesh:NoExp] OR 
"Predictive Value of Tests"[Mesh] OR "ROC 
Curve"[Mesh] OR "Severity of Illness Index"[Mesh] OR 
"Decision Trees"[Mesh] OR clinical sign*[tiab] OR 
clinical predictor* [tiab] OR vital sign* [tiab] OR clinical 
feature* [tiab] OR "signs and symptoms"[tiab] OR 
algorithm* [tiab] OR decision tree* [tiab] OR prediction 
rule* [tiab] OR imci [tiab] OR "integrated management 
of childhood illness"[tiab] OR "diagnostic 
accuracy"[tiab]) AND (infant*[tiab]  OR child* [tiab] 
pediatric*[tiab] OR paediatric*[tiab] OR under-five* [tiab] 
OR 59 month* [tiab] OR under-5 [tiab] OR babies[tiab] 
OR baby[tiab] OR "infant"[Mesh] OR "Child, 
Preschool"[Mesh]) 
 
(dehydration:ti,ab OR 'dehydration'/exp) AND 
((clinical sign* OR clinical syndrome* OR clinical 
predictor* OR vital sign* OR clinical feature* OR 
"signs and symptoms" OR algorithm* OR decision 
tree* OR prediction rule* OR imci OR "integrated 
management of childhood illness" OR "diagnostic 
accuracy"):ti,ab OR 'vital sign'/exp  OR 'heart 
rate'/de  OR 'tachycardia'/de OR 'diagnostic 
accuracy'/de  OR 'diagnostic test accuracy study'/de 
OR 'classification algorithm'/exp OR 'practice 
guideline'/de  OR 'predictive value'/exp OR 
'diagnostic value'/de  OR 'symptom assessment'/de 
OR 'diagnostic accuracy'/de) AND ((infant*  OR 
child* pediatric* OR paediatric* OR under-five* OR 
59 month* OR under-5 OR babies OR baby):ti,ab 
OR 'preschool child'/exp OR 'infant'/exp) 
 
Malnutrition (malnutrition[tiab] OR "Malnutrition"[Mesh]) AND 
("Anthropometry"[Mesh:NoExp] OR "Body Weights and 
Measures” [Mesh] OR weight*[tiab] OR *height[tiab] OR 
*length[tiab] OR MUAC[tiab] OR “mid upper arm 
circumference”[tiab]) AND (infant*[tiab] OR child* [tiab] 
pediatric*[tiab] OR paediatric*[tiab] OR under-five* [tiab] 
OR 59 month* [tiab] OR under-5 [tiab] OR babies[tiab] 
OR baby[tiab] OR "infant"[Mesh] OR "Child, 
Preschool"[Mesh]) 
(malnutrition:ti,ab OR 'malnutrition'/exp) AND 
('anthropometric parameters'/exp OR (weight* OR 
length OR height OR muac OR “mid upper arm 
circumference”):ti,ab) AND ((infant*  OR child* 
pediatric* OR paediatric* OR under-five* OR 59 
month* OR under-5 OR babies OR baby):ti,ab OR 
'preschool child'/exp OR 'infant'/exp) 
 
 
Papers reviewed were in English, and published between inception to June 2014 (which was 
when the construction of e-POCT was completed). We also checked publications since June 
2014 for relevant updates to the retrieved evidence. Databases searched were PubMed and 
Embase. The literature search was supplemented by hand-checking references of filtered 
papers, and by snowball search of key papers in Google Scholar. Studies involving only 
infants below 3 months of age or only adults were excluded. Systematic reviews addressing 
the questions of interest were also considered. 
 
Algorithm construction  
ALMANACH, an electronic algorithm derived from IMCI, was used as a starting point for 
construction of the new algorithm. We used the evidence retrieved from the literature search 
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to propose modifications when relevant. Diagnostic criteria to be included should not only 
have adequate accuracy at primary care level but also be assessable by health workers in 
resource-poor settings. A new decision tree, e-POCT was constructed including a detailed 
reference paper version that was used to program the algorithm onto an android-based 
electronic support tool using the Mangologic software  (http://www.mangologic.com/). Each 
branch of the electronic algorithm was validated against a standardized set of theoretical 
patient scenarios. A final version was piloted during a pilot phase in primary care facilities in 
Dar es Salaam, Tanzania, that included 100 pediatric consultations, which were directly 
supervised by a medical doctor or pediatrician. The final algorithm was evaluated later in a 
clinical trial which is described elsewhere (Chapter 7).  
Development of e-POCT algorithm 28
5.4. Results 
Figure 10 displays the retrieved and included publications.  
 
 
 
 
 
 
 
 
 
 
 
 
5.4.1. Identification of children with severe infections: how can current referral 
criteria be improved? 
 
What is the evidence for currently employed IMCI danger signs? 
The 2014 IMCI algorithm recommends immediate hospital transfer in the presence of any 
one of the general or disease specific danger signs (Table 6). 
Records identified through 
database searching 
(n=12,124) 
Additional records identified 
through other sources 
(n=21) 
Records after duplicates removed (n=11,059) 
Records screened 
(n=11,059) 
Full-text articles 
assessed for eligibility 
(n=546) 
Studies included 
(n=171) 
Records excluded 
(n=10,513) 
Full text articles 
excluded (n=375), 
Topic =171, Patient 
population=36, 
Design=168 
Figure 4 Flowchart of literature search results and included publications 
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Table 6 Summary of the main differences between e-POCT, ALMANACH, and the 2014 IMCI version. 
  e-POCT 
 
ALMANACH (Rambaud-Althaus, Shao, et al., 2015) IMCI (World Health Organization, 2014) 
 Classification Clinical 
signs/symptoms 
Vital sign POCT Clinical signs/symptoms Vital sign POCT 
 
Clinical 
signs/symptoms 
Vital sign POCT 
 
S
e
v
e
r
e
 
d
i
s
e
a
s
e
 
CNS infection - Severe lethargy 
- Stiff neck 
- ≥2 convulsions 
  - Severe lethargy,  
- Stiff neck  
-  ≥1 convulsions 
  - Severe lethargy,  
- Stiff neck 
 ≥1 convulsions 
  
Severe 
pneumonia 
- Severe 
respiratory 
distress1  
- Severe 
tachypnea2 
SaO2 <90% 
 
- Chest indrawing 
- Cyanosis 
- Stridor 
 
  - Stridor  
- Chest indrawing and 
HIV positive 
 
 
 
HIV 
positive 
Severe anemia 
  Hb <6g/dl - Severe palmar pallor   - Severe palmar pallor   
Severe 
dehydration 
- Not tolerating oral 
liquids 
 Severe 
tachycardia3 
- Vomits everything or two 
of: Lethargic/ 
unconscious; Sunken eyes; 
Not able to drink/drinks 
poorly; Skin pinch very 
slow 
  - Vomits everything or 
two of:  
Lethargic/ 
unconscious; Sunken 
eyes; Not able to 
drink/drinks poorly; 
Skin pinch very slow 
  
Severe 
malnutrition 
 - Very low 
WFA and/or 
MUAC4 
 - Severe wasting 
- Edema of both feet 
  - Edema of both feet or 
- Very low WFH/MUAC 
combined with 
complications6 
  
Other severe 
disease 
None   - Jaundice 
- Tender swelling behind ear 
- Infected skin lesion or lump 
larger than 4 cm or with red 
streaks or with tender 
nodes or multiple 
abscesses 
 
  - Tender swelling behind 
ear 
 
  
Severe malaria Any severe 
classification and 
 Positive mRDT Not considered   Not considered   
C
N
o
n
-
s
e
v
e
r
e
 
d
i
s
e
a
s
e
 
Clinical 
pneumonia 
- Not considered   - Cough and  Very fast 
breathing7 
 - Cough and  -Fast 
breathing7 
- Chest 
indrawing 
 
Bacterial LRTI - Cough and - Tachypnea6 
and 
-  
CRP≥80 mg/L - Not considered   Not considered   
Viral LRTI/ 
bronchiolitis 
- Cough and - Tachypnea6 
and 
 
CRP<80mg/L - Not considered   Not considered   
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Upper 
respiratory 
infection 
 
- Cough and - No 
tachypnea6 
 
 - Cough and  No very fast 
breathing7 
 Cough and  No fast 
breathing8 
 
Gastrointestinal 
infection with 
dehydration 
- Significant 
diarrhea and /or 
vomiting9 
  - Two of: Restless irritable; 
Sunken eyes; Drinks 
eagerly, thirsty; Skin pinch 
slow 
 
  - Two of: Restless 
irritable; Sunken eyes; 
Drinks eagerly, thirsty; 
Skin pinch slow 
 
  
Skin infection Skin infection 
without additional 
severe diagnosis10 
  - Infected skin lesion smaller 
than 4 cm and without red 
streaks and without tender 
nodes or single abscesses 
 
  Not considered in main 
algorithm 
  
Fever without 
source, likely 
bacterial 
infection 
 
 
 
 CRP≥80mg/L  
and/or 
PCT≥4 µg/L 
 
- Purulent ear discharge  Positive urine 
dipstick (<2 
years only) 
or positive 
typhoid test (≥2 
years only) 
 
Not considered   
Fever without 
source, likely 
viral infection 
  CRP<80mg/L 
and 
PCT<4 µg/L 
 
  Negative urine 
dipstick (<2 
years only) and 
negative 
typhoid test (≥2 
years only) 
 
Not considered   
 
Uncomplicated 
malaria 
  Positive mRDT   Positive mRDT   Positive 
mRDT 
Abbreviations: Central nervous system (CNS), oxygen saturation (SaO2), human immunodeficiency virus (HIV), weight-for-age (WFA), mid-upper arm circumference 
(MUAC), point-of-care test (POCT), respiratory rate (RR), heart rate (HR), rapid test for malaria (mRDT), C-reactive protein (CRP), procalcitonin (PCT), lower respiratory 
tract infections (LRTI). 
1: Severe respiratory distress: Speaks only single words or grunts or speaks short phrases only or short cries and lower chest wall indrawing  
2: Severe tachypnea: RR ≥97th %ile for age and temperature (Nijman et al., 2012). 
3: Severe tachycardia: Heart rate ≥90th %ile for age and temperature (Thompson, Harnden, et al., 2009).  
4: Weight for age <-3 z-score and/ or MUAC <11.5cm and age >6 months 
5: Weight for length/height <-3 z-score and/ or MUAC <11.5cm and age >6 months; complications defined as: feeding problem or medical problem 
6: Tachypnea: Respiratory rate (RR) ≥75th %ile for age and temperature  
7: Very fast breathing: RR≥50/min, regardless of age 
8: Fast breathing: RR≥40/min and age <12 months or RR≥50/min and age≥ 12 months. 
9: >5 loose stools/over past 24hrs or ≥3 loose stools/over past 24hrs and emesis or >3 emesis/over past 24hrs 
10: algorithm provides diagnoses and specific treatment recommendations for 13 common skin diseases (abscess, cellulitis, impetigo/pyoderma, tinea corporis, pityriasis 
versicolor, candidiasis, tinea capitis, scabies, chicken pox, herpes, larva migrans, eczema, urticarial) 
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These danger signs were chosen based on expert opinion and refined during the initial IMCI 
development studies (Gove, 1997; Perkins et al., 1997; Weber et al., 1997). They were then 
evaluated in two studies conducted in hospital outpatient departments in Kenya and 
Bangladesh between 1993 and 1995 (Paxton et al., 1996; Kalter, Schillinger, et al., 1997). 
These studies determined the accuracy of the IMCI danger signs to predict hospitalization 
when compared to clinical judgment of a medical doctor or clinical officer. The Kenyan (2799 
children, 779 admissions) study found a sensitivity and specificity of 46% and 80%, 
respectively.—a similar range compared to what was observed in the initial development 
studies (Perkins et al., 1997; Weber et al., 1997). Stiff neck, stridor, corneal ulceration, and 
tender swelling behind the ear were detected in none of the children. The Bangladeshi study 
(668 children, 226 admissions) reported a sensitivity of 86% and a specificity of 64% (Kalter, 
Schillinger, et al., 1997). The heterogeneity of reported accuracy is probably related to 
differences in the studied population and in the outcome assessment. Since the overall 
performance of IMCI severity criteria was low, we sought to identify additional studies that 
evaluated and complemented single criteria. In order to identify criteria with higher 
performance that would be implementable in primary care facilities in low resources settings, 
we looked at pediatric triage tools, severity scores predicting mortality, and diagnostic tools 
to identify serious infections. 
 
Should additional signs from pediatric triage tools be considered? 
Several triage tools exist that are design to help prioritize treatment of sick children at 
hospital level. Two scales have been tailored to low resource environments: the WHO 
Emergency Triage and Treatment Tool (ETAT, World Health Organization, 2016a), and the 
Pediatric South African Triage Scale (PSATS, Twomey et al., 2013). However, only ETAT 
has been evaluated in a low-income country (Malawi, Robertson and Molyneux, 2001). The 
ETAT guidelines rely on clinical discriminators using an ABCD concept (Airway, Breathing, 
Circulation/Coma/Convulsion, Dehydration, World Health Organization, 2013).  
 
Should we include criteria from available pediatric severity scores? 
In well-resourced countries, a number of pediatric severity scores have been developed 
such as the Pediatric Risk of Mortality (PRISM) score (Pollack, Patel and Ruttimann, 1996; 
Gerardin et al., 2006), the Pediatric Index of Mortality (PIM, Shann et al., 1997), the Pediatric 
Early Warning System (PEWS, Duncan, Hutchison and Parshuram, 2006), Bedside PEWS 
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(Parshuram, Hutchison and Middaugh, 2009), and Pediatric Advanced Warning Score 
(PAWS, Egdell, Finlay and Pedley, 2008). Besides PAWS, these scores are neither 
designed for use in outpatient nor resource-poor settings and rely on complex clinical 
assessments and laboratory data. Rather, the scores were designed to predict inpatient 
death. The PAWS score uses a full set of vital signs (respiratory rate [RR], heart rate [HR], 
oxygen saturation [SaO2], blood pressure [BP], body temperature [T]) and work of breathing, 
inspirated O2, CRT, and the Alert, Voice, Pain, Unresponsive (AVPU) scale. When validated 
among 49 pediatric patients admitted from the emergency department of a tertiary care 
hospital to the intensive care unit versus 46 controls admitted to the regular pediatric floor, 
it’s accuracy was moderate: the sensitivity and specificity were 83% and 65% for of a score 
≥2 and 70% and 90% for a score ≥3 (Egdell, Finlay and Pedley, 2008). For comparison, a 
child with fever and chest indrawing and no other criteria would have a PAWS score of at 
least 4. 
Similarly, general and disease-specific risk scores have been developed in resource-limited 
settings that aim at predicting death among hospitalized patients (Shann, Barker and Poore, 
1989; Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, 
Winstanley P, Warn P, Peshu N, 1995; Berkley, 2003; Helbok et al., 2006). The Signs of 
Inflammation in Children that Kill (SICK), a score to predict in-hospital mortality, was derived 
from 1,099 (44 deaths) children in a tertiary care setting and validated among 125 children in 
the same setting (23 deaths), as well as 3,895 (58 deaths) children in another Indian hospital 
and 1,473 children (5 deaths) in a UK hospital (Kumar et al., 2003; Bhal et al., 2006; Gupta 
et al., 2010). Second, the Lambaréné Organ Dysfunction Score (LODS), a tool to predict 
death among children hospitalized with malaria, was developed based on data from 23,809 
hospitalized children in Africa (1,004 deaths, Helbok et al., 2009). A study among 8,091 (436 
deaths) hospitalized children in Kenya identified predictors for immediate, early, and late 
death (PEDIA, Berkley, 2003; Kotloff et al., 2013). We did not identify additional signs that 
could be assessed by health workers at primary care level from these scores. One sign of 
PEDIA, jaundice, was also included in ALMANACH as an additional danger sign. This was 
because jaundice was a good predictor for documented bacterial disease (positive likelihood 
ratio [LR+] 2.9), in particular typhoid (LR+ 6.2), and against documented viral disease (LR+ 
0.11) in a study on fever etiologies in 1005 children in Tanzania (D’Acremont et al., 2014; De 
Santis and D’Acremont, 2017) and, because it was hypothesized that primary health care 
workers could detect clinical jaundice (Rambaud-Althaus, Shao, et al., 2015). Jaundice was, 
however, detected in none of the children in the ALMANACH arm during the initial evaluation 
studies (Shao, personal communication).  
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What evidence exists from studies on clinical signs to identify children with serious 
infections? 
The body of evidence has been growing for the use of clinical signs to identify children with 
serious infections (essentially infections that require hospital-based treatment) in outpatient 
high-resource settings. A systematic review of 30 studies assessed the performance of 
clinical signs in predicting serious infections (Van den Bruel et al., 2010; Thompson et al., 
2012). Likelihood ratios (LRs) were constructed to represent the ability of single predictors to 
rule in (LR+ >5) and rule-out (negative likelihood ratio [LR-]<0.2) serious infections. The 
following predictors of signs that would be measurable by low-level health workers had rule-
in value in settings with low-prevalence of serious infections: cyanosis (LR+ 52.2), poor 
peripheral perfusion (LR + 38.8), shortness of breath (LR+ 9.3), rapid breathing (LR+ 9.78), 
meningeal irritation (LR +25.7), seizures (LR+ 20.7), and unconsciousness (LR+ 19.8). 
These findings are in line with findings from studies on predictors of mortality in low-resource 
settings (Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, 
Winstanley P, Warn P, Peshu N, 1995; Berkley, 2003; Berkley, Maitland, et al., 2005; Bhal et 
al., 2006; Helbok et al., 2009; von Seidlein et al., 2012). Most of these estimates were based 
on a prospective derivation study conducted among 3981 children (31 admissions for 
serious infection) in Belgium (Van den Bruel et al., 2007). From this study a multivariable 
triage instrument to predict serious infections requiring hospitalization was constructed using 
classification and regression tree (CART) analyses. The tool consisted of the clinician’s 
feeling “that something is wrong”, dyspnea, temperature, age, and presence of diarrhea. It 
had a sensitivity of 96.8% at a specificity of 88.5%. The triage tool was assessed in another 
study including 8962 acute illness episodes (283 serious infections, Van den Bruel et al., 
2007). Sensitivity was 100% at a specificity of 83.6% in the general practitioner setting with 
17% of children testing positive. Thompson et al. assessed the diagnostic performance of 
vital signs in distinguishing 313 children with serious infections from 339 patients mild 
infections and 48 children with no infections in one outpatient department in England 
(Thompson, Coad, et al., 2009). The LR+ and LR- were as follows: temperature ≥39°C 2.1 
and 0.8, tachypnea 1.3 and 0.8, tachycardia 1.5 and 0.7, prolonged CRT 17.7 and 0.9, 
SaO2≤94% 2.7 and 0.9. Advanced Pediatric Life Support (APLS) cut-offs were used for 
definition of tachypnea and tachycardia. Having a derangement in any of the vital categories 
had a LR+ of 1.3 at a LR- of 0.5.  
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Criteria from triage-, severity- and serious infection-scores integrated into e-POCT  
All current general IMCI danger signs were kept in the e-POCT algorithm. This was because 
all have high LR+. i.e. value as “red flags” (Thompson, Coad, et al., 2009). However, they 
lack sensitivity and we hence added additional criteria. From ETAT, we included oximetry, 
and severe respiratory distress into the e-POCT algorithm (see severe pneumonia section 
below). The circulatory signs were not included since the reliability of CRT and ‘weak pulse’, 
when measured by low-level health workers at primary care level, have not been assessed 
sufficiently (Fleming et al., 2015). Cyanosis, which was added into ALMANACH, was not 
included into the e-POCT algorithm since we integrated oximetry. From the single criteria of 
the PAWS score and the diagnostic accuracy studies for detection of serious infections, 
severe tachycardia was added to the e-POCT algorithm to represent “poor peripheral 
perfusion”. Tachycardia is indeed a well-recognized criterion for septic shock in children 
(Biban et al., 2012). Given that an oximeter was included into e-POCT (see below), the HR 
could be fed into the algorithm without requiring additional measurements by the health 
worker. Like for RR cutoffs (see below), we chose age-and temperature-based percentiles 
for HR as opposed to APLS-based cutoffs. The electronic algorithm format allowed 
integration of these more complex calculations. As shown above, APLS thresholds for HR 
had clinically irrelevant diagnostic accuracy (Thompson, Coad, et al., 2009). HR and RR 
vary with age but also with temperature (Simoes et al., 1991; Campbell, Byass and 
O’Dempsey, 1992; O’Dempsey et al., 1993; Thompson, Harnden, et al., 2009; Fleming et 
al., 2011; Nijman et al., 2012). Recently compiled age centile charts were in large 
disagreement with previously publishes reference ranges, including APLS (Fleming et al., 
2011). In the study by Thompson et al., the diagnostic performance for severe tachycardia 
improved drastically if age-and temperature-based percentiles were used: a HR exceeding 
the 90th centile was highly specific (88%), though not sensitive (24%), for serious infection 
compared to minor infection (Thompson, Coad, et al., 2009). Again, CRT and cyanosis were 
not included from the severity- and serious infection-scores for the reasons stated above. 
Dyspnea and tachypnea were addressed in the pneumonia-section of the algorithm (see 
below). We did not consider the Belgian triage tool since the physician’s statement that 
“something is wrong” was paramount for the tree (Van den Bruel et al., 2007). The 
physician’s general impression is likely strongly correlated to the degree of training. 
Consequently, we hypothesized that it would not be useful to integrate the Belgian triage tool 
into the assessment of general danger signs for low-level health workers.  
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Should hemoglobin screening be included?  
Systematic hemoglobin screening was integrated for all children into e-POCT based on the 
following rationale: First, severe anemia is an important cause of mortality. In a systematic 
review, Brabin et al. estimated the relative risk of in-hospital mortality for children with severe 
anemia at around twice that of less anemic children (Brabin, Premji and Verhoeff, 2001). 
Subsequent studies have confirmed that anemia is an important predictor for inpatient death 
(Djelantik et al., 2003; Helbok et al., 2009). Second, severe anemia is associated with 
bacteremia in febrile children (Calis et al., 2008; De Santis and D’Acremont, 2017). Third, 
anemia cannot be detected based on clinical signs and at-risk groups cannot be clearly 
defined. In a meta-analysis, Chalco et al. found a low sensitivity for conjunctival and palmar 
pallor in detecting severe anemia (Chalco et al., 2005). The pooled sensitivity and specificity 
of conjunctival pallor and palmar pallor were 43.6 (95% CI 41.7–45.6) and 81.4 (95% CI 
78.6–83.9), respectively, and 39.2 (95% CI 37.4–41.1) and 86.7 (95% CI 84.6–88.5, Chalco 
et al., 2005). Two studies identified since the meta-analysis confirmed these findings (Butt et 
al., 2010; Aggarwal et al., 2014). On the other hand, receiving transfusion early improves 
survival in children with severe anemia (Lackritz et al., 1992). Children with severe anemia 
should be referred to higher-level facilities for monitoring of signs that indicate the immediate 
need for blood transfusion, Lackritz et al., 1992; English et al., 2002). POC 
hemoglobinometer are already in us for other indications in peripheral, resource-limited 
settings.  
 
5.4.2. How can the management of children with respiratory illness be 
improved? 
 
Based on the results from a recent modeling effort, our priority was to integrate a diagnostic 
test for bacterial pneumonia and a test for severe pneumonia. In this model, the benefits of 
these test would also largely depend on the infrastructure required and the resulting level of 
access to the test, i.e. the test should be performable at peripheral care level and results 
should be obtainable within one hour. The targeted sensitivity and specificity of the tests 
from the model was 95% and 85%, respectively, for the bacterial pneumonia test and 85% 
and 90% for the severe pneumonia test (Lim et al., 2006). 
Severe pneumonia 
IMCI Severe Pneumonia classification is given in the presence of any danger signs or stridor 
in a calm child (World Health Organization, 2014). Before 2014, children with a cough and 
lower chest indrawing were also classified as severe pneumonia (World Health 
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Organization, 2008). This sign was removed subsequently, as a result of a series of clinical 
studies (Addo-Yobo et al., 2004, 2011; Hazir et al., 2008; Bari et al., 2011; Soofi et al., 2012; 
Das and Singh, 2013; Agweyu et al., 2015; Patel et al., 2015), referred to henceforth as 
“severe pneumonia trials”.  In these studies, intravenous antibiotic treatment and/or hospital-
based treatment were not found to be beneficial in children with severe pneumonia based on 
chest indrawing alone. However, they have several limitations raising the question whether 
chest indrawing should truly be disregarded as a sign for severe pneumonia. First, like in the 
early IMCI pneumonia studies, prevalence of chest indrawing was considerably higher in 
children in the South Asian studies compared to African studies (Paxton et al., 1996; Kalter, 
Schillinger, et al., 1997). Whether this reflects differences in diagnosis or epidemiology is not 
clear. Second, case-fatality rate for children included was low (<1%) though the case-fatality 
rate for severe pneumonia globally has been estimated at 7.2% and others have reported 
18% (Pépin et al.; Nair et al., 2013). Third, the presence of hypoxemia was not reported. 
Fourth, it is unclear whether hospital-based supportive interventions, such as provision of 
oxygen or rehydration, were provided adequately in the control arms. For respiratory 
infections especially, the need for antibiotic treatment does not necessarily overlap with the 
need for hospital-based supportive care. Children with bronchiolitis, for example, do not 
require antibiotic treatment at all but may require respiratory support or rehydration therapy. 
It is hence essential to identify children in need for hospital-based supportive care, 
regardless of the microbiological etiology. This was reflected in results from a hospital-based 
cohort study in Kenya that included 2803 children with respiratory infections. The prevalence 
of invasive bacterial infection with severe pneumonia syndrome was similar to that with mild 
pneumonia syndrome, but case fatality was greater among children with severe pneumonia 
syndrome (Berkley, Maitland, et al., 2005). Among 310 children with pneumonia (cough and 
chest indrawing), two viruses causing bronchiolitis (Respiratory Syncytial Virus and human 
Metapneumovirus) were associated with treatment failure for pneumonia (Kelly et al., 2015).   
Since the introduction of IMCI, several severity scores for bronchiolitis (Voets, van Berlaer 
and Hachimi-Idrissi, 2006; Duarte-Dorado et al., 2013) and asthma (Hurwitz et al., 1984; 
Conway and Littlewood, 1985; Chalut, Ducharme and Davis, 2000; Arnold et al., 2011) have 
been developed in high-resource settings with varying degrees of quality and validation 
(Bekhof, Reimink and Brand, 2014). The Respiratory Index of Severity in Children (RISC) 
score and its modified versions were developed to predict in-hospital death in South Africa 
(Reed et al., 2012), Kenya (Emukule et al., 2014) and Malawi (Hooli et al., 2016). From the 
highest quality asthma and bronchiolitis scores, as well as studies in low-income settings 
that aimed at identifying children with hypoxemia and those at risk for adverse outcome from 
respiratory infections (Pépin et al.; Shann, Barker and Poore, 1989; Demers et al., 2000; 
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Kelly et al., 2000; Djelantik et al., 2003; Berkley, Maitland, et al., 2005; Mamtani et al., 2009; 
Reed et al., 2012; Corrard et al., 2013; Jain, Sarathi and Jawalekar, 2013; Wandeler et al., 
2015), we identified the following clinical criteria that could be used by low-level health 
workers: respiratory rate (RR), accessory breathing muscle use (lower chest indrawing), 
vocalization (short phrases/weak cry, unable to speak/cry), grunting, HR, inability to drink,  
malnutrition, severe anemia, and level of consciousness (Bekhof, Reimink and Brand, 2014). 
Inability to drink, level of consciousness, malnutrition, severe anemia, and HR were 
integrated into the general danger signs (see above). We then constructed the  “severe 
respiratory distress” classification as presence of a cough and two of the following signs: 
severe tachypnea (very fast breathing), chest indrawing, decreased vocalization (speaks in 
short sentences or unable to speak/cry), or grunting. We used a combination of two signs to 
increase the specificity of detecting children that may require hospital-based supportive care, 
as suggested in previous studies (Pépin et al.). For example, children with chest indrawing 
alone could be safely managed with home-based treatment as in “severe pneumonia 
trials“(see above). Fast breathing alone was not found to be related to asthma severity 
(Roofe et al., 2014). However, fast breathing in addition to chest indrawing has been 
identified as a predictor for treatment failure among children with WHO severe pneumonia in 
the “severe pneumonia trials” and other observational studies (Addo-Yobo et al., 2011; Fox 
et al., 2013; Jain, Sarathi and Jawalekar, 2013; McCollum et al., 2015). Similarly lower chest 
indrawing in combination with grunting was suggested as a criterion for hospitalization for 
children with WHO severe pneumonia (Pépin et al.). RR is known to vary with age and also 
with temperature in pediatric patients. Consequently, like for HR, we used age and 
temperature-corrected respiratory centile cutoffs to define tachypnea and severe tachypnea 
(Nijman et al., 2012), Table 6. The 97th %ile provided the best cutoff for severe tachypnea in 
terms of sensitivity and specificity when applying it to the “fever study dataset” (D’Acremont 
et al., 2014). We also included hypoxemia as a criterion for severe pneumonia. Hypoxemia 
was proposed in the 2014 IMCI chart booklet but has not been implemented (World Health 
Organization, 2014). Though it is still unclear at what level of care oximeters are most useful 
(health center versus hospital-based triage), we did include oximetry into e-POCT to be able 
to assess its utility at peripheral health care level.  
In the era of Haemophilus influenza type B (Hib) vaccine, bacterial epiglottitis causing stridor 
has become very rare.  For croup, a viral upper respiratory infection, stridor alone is not 
sufficient for severe classifications (Taussig et al., 1975; Westley, Cotton and Brooks, 1978). 
Most children with stridor and severe disease also have other signs of respiratory distress, 
such as lower chest indrawing (Pépin et al.). Finally, stridor is difficult to recognize for low-
level health workers (Simoes and McGrath, no date; Perkins et al., 1997) and rare (Pépin et 
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al.; Shao, 2015). Stridor was therefore omitted in the ePOCT algorithm as a sign for severe 
pneumonia. 
 
Non-severe pneumonia 
For the “bacterial pneumonia” test, i.e. a test that would identify children in need for antibiotic 
treatment among children with non-severe respiratory symptoms, we developed a two-step 
approach of a clinical ‘rule-out-step’ with high sensitivity (fast breathing and/ or chest 
indrawing) and a subsequent biomarker ‘rule-in-step’ with high specificity. This two-step 
approach was chosen due to the low prevalence of bacterial pneumonia at peripheral health 
care level, and the high frequency of respiratory complaints. Using a sensitive, clinical 
criterion as a first step would select children with a relevant probability of having bacterial 
pneumonia and therefore i) increase the positive predictive value of the biomarker and ii) 
avoid unnecessary testing of children at very low risk of having bacterial pneumonia.  
Rambaud-Alhaus et al. recently reviewed clinical predictors for radiographic pneumonia and 
found that they all had very low accuracy, including age-related fast breathing (pooled 
positive and negative likelihood ratio 1,55 and 0,63, Rambaud-Althaus, Althaus, et al., 
2015). However, age-related fast breathing was the most sensitive predictor among all 
studied. Some of the lack in diagnostic accuracy of RR may be related to its variation over 
time (in the order of 10 counts within one hour, Simoes et al., 1991; Muro et al., 2015) and 
between observers (English et al., 1995). RR decreases with age until adolescence with the 
steepest decline apparent in infants during the first 2 years of life (Fleming et al., 2011). It 
also increases with body temperature (Campbell, Byass and O’Dempsey, 1992; O’Dempsey 
et al., 1993; Nijman et al., 2012). Using arbitrary simple binary cutoffs probably 
oversimplifies the complex relationship between RR and pneumonia (Spruijt et al., 2013). 
We thus used the 75th percentile of RR for age and temperature derived by Nijman et el. as 
a cutoff for tachypnea (fast breathing, Nijman et al., 2012). We added lower chest indrawing 
as another criterion to further increase sensitivity. This identified 94% (29/31) of children with 
radiographic pneumonia in the ‘Fever Study’ dataset (D’Acremont et al., 2014). 
We found evidence that CRP would be helpful in identifying children with bacterial 
pneumonia. First, there is evidence from pneumococcal vaccine trials that a CRP cutoff of 
140 mg/L was shown to identify pneumococcal pneumonia in children with changes seen on 
chest radiograph (Madhi and Klugman, 2007). Moreover, in a study among hospitalized 
children in Mozambique CRP values were significantly higher in 89 children with bacterial 
pneumonia (positive blood culture) compared to 87 children with viral pneumonia (Díez-
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Padrisa et al., 2010). In a systematic review that included 8 studies the diagnostic accuracy 
of CRP for pneumonia was moderate overall, with sensitivities ranging from 35%-100% at 
specificities from 40-100% [100]. CRP concentrations exceeding 35–60 mg/L occurred 
significantly more often in children with bacterial pneumonia. However, the outcome 
definitions for pneumonia were very heterogeneous, including clinical, radiological, and 
microbiological feature. This reflects an overall major limitation of studies assessing the 
accuracy of biomarkers for pneumonia: an acceptable gold standard remains yet to be 
developed (Lynch et al., 2010). Lynch et al. reviewed systematically the diagnosis of 
pneumonia and found that authors used 11 different gold standards for 25 of the studies 
included (Lynch et al., 2010).  Radiographically defined pneumonia is often used as a proxy 
for bacterial pneumonia since it is known that they are correlated: Hib and pneumococcal 
conjugate vaccines (PCV) reduced radiographic pneumonia by circa 20% in vaccine trials 
(Mulholland et al., 1997; Levine et al., 1999; Cutts et al., 2005). However, reliable data is 
missing on the true proportion of bacterial pneumonia among cases with chest X-ray (CXR) 
consolidation (Lynch et al., 2010). Furthermore, studies included into the systematic review 
contained different populations, including populations with a high prevalence of malnutrition 
(Babu et al., 1989), Malnourished children have distinct inflammatory responses to infection 
(Page et al., 2013). The review by Flood et al. was further limited by different CRP cutoffs 
used (ranging from 35-60mg/L, Flood, Badik and Aronoff, 2008).  
Since these reviews, Koster et al. published data on the accuracy of CRP in predicting CXR 
consolidation in 286 children in a Dutch emergency department. Cutoffs of 20, 50, 75, and 
100 mg/L yielded sensitivities of 81%, 55%, 51%, and 32%, respectively, at specificities of 
53%, 78%, 87%, and 93% (Koster et al., 2013). In the Tanzanian ‘Fever Study’, using CART 
analysis, a combination of CRP and Chitinase 3-like-1 discriminated between end-point 
pneumonia (n=30) and non-end-point pneumonia (n=125) among children with a cough and 
fast breathing with 93% sensitivity and 81% specificity (Erdman et al., 2015). A CRP cutoff 
point of >44 mg/L had a LR+ of 3.8 and a LR- of 0.25 and had the strongest association with 
end-point pneumonia among all biomarkers studied. Galetto-Lacour et al. found that CRP 
(≥100 mg/L) had a LR+ of  2.33 and a LR- of 0.13 in differentiating 37 patients with 
presumed pneumococcal pneumonia from 38 patients with non-pneumococcal pneumonia 
(Galetto-Lacour et al., 2013). In a hospital-based study in 119 children in Italy, CRP values 
above 49 mg/L were correlated with CXR consolidation and pleural effusion (Agnello et al., 
2016). In another hospital-based study that aimed at establishing a prediction model to 
differentiate bacterial pneumonia (CXR consolidation and positive microbiological testing for 
typical and/or atypical bacteria) from viral pneumonia (CXR consolidation and positive viral 
PCR), CRP>80mg/L was the most significant predictor for bacterial pneumonia (Elemraid et 
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al., 2014). An analysis among 124 children with clinical signs of pneumonia and radiographic 
changes found that a CRP >80mg/L and >40mg/L had a LR+ of 6.4 and 5.1, and a LR- of 
0.38 and 0.32 in detecting 50 children with endpoint pneumonia (Alcoba et al., 2017). For 
identifying 24 children with complicated pneumonia (pleural effusion and/or bacteremia), the 
LR+ and LR- for a CRP >80mg/L and >40mg/L were 2.67 and 1.69, and 0.11 and 0.17, 
respectively. In a multicenter study in the United States including children with pneumonia, 
bacteremic patients had higher median CRP values (200mg/L, interquartile range 90-320), 
compared to those with negative blood culture (median 67mg/L, interquartile range 24-190, 
Myers et al., 2013). A study in a tertiary care center in India found that a CRP cutoff of 
60mg/L 93% sensitive and 64% specific in differentiating 28 patients with WHO very severe 
pneumonia from 22 with WHO severe pneumonia-all had CXR endpoint consolidation 
(Yadav et al., 2015).  
Several studies have addressed the accuracy of PCT differentiating bacterial and viral 
pneumonia in children(Heiskanen-Kosma and Korppi, 2000; Toikka et al., 2000; Korppi and 
Remes, 2001; Moulin et al., 2001; Korppi, Remes and Heiskanen-Kosma, 2003; Prat et al., 
2003; Leroy et al., 2007; Nascimento-Carvalho et al., 2010; Cohen et al., 2012; Galetto-
Lacour et al., 2013). Results are conflicting: some report an advantage over CRP (Moulin et 
al., 2001; Prat et al., 2003) and others don’t (Toikka et al., 2000; Galetto-Lacour et al., 
2013). CRP outperformed PCT in predicting end-point pneumonia in the ‘Tanzanian fever 
study’ (Erdman et al., 2015). No added value was found in a study that combined the two 
biomarkers over using them alone (Toikka et al., 2000). Given that i) there is no clear benefit 
in terms of diagnostic accuracy of using PCT over CRP, ii) the availability of a semi-
quantitative lateral-flow rapid test and iii) the lower blood volume required to perform CRP 
versus PCT testing, we decided to use CRP alone as a second step for the diagnosis of 
bacterial pneumonia, using a relatively high cutoff in the 60-100mg/L range to ensure high 
specificity. Given the semi-quantitative cutoffs provided by the manufacturer of the test used 
for the evaluation of e-POCT in a clinical trial (Bionexia, Biomerieux), we chose 80mg/L as 
a cut-off.  
In sum, children with a cough and tachypnea (RR above or equal to the 75th percentile age 
and temperature) and/or chest indrawing underwent CRP-testing. Children with CRP values 
equal or above 80mg/L were classified as bacterial pneumonia and antibiotic treatment was 
recommended, except for children with malaria since malaria alone raises CRP values 
(Díez-Padrisa et al., 2010). The relatively high cutoff of 80mg/L was chosen to guarantee 
high rule-in value at the primary care level and to avoid unnecessary antibiotic treatment.  
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5.4.3. How can we improve diagnosis of serious bacterial infections among 
children with fever without source? 
 
When the probable cause of a febrile illness cannot be determined by history or physical 
examination, the illness is labeled as fever without source (FWS, alternatively fever without 
localizing signs, fever without a focus or undifferentiated fever).  Though the majority of 
children with FWS have self-limiting viral diseases, a small proportion will have bacterial 
infections; the most common are urinary tract infection (UTI), occult bacteremia, and occult 
pneumonia. Before the introduction of Hib and PCV, 3-4% of children aged 3-24 months with 
FWS had occult bacteremia in outpatients studies in the United States, the majority due to 
Hib and Pneumococcus (MCGowan et al., 1973; Baron et al., 1980). In studies conducted in 
Europe and United States, the overall bacteremia rate for children 3-36 months dropped to 
<0.5% in settings with high PCV coverage (Bressan et al., 2012; Hernandez-Bou et al., 
2015). UTIs occur in approximately 7% of children with FWS (Shaikh et al., 2008; Roberts, 
2011). To address UTI, urinary dipstick testing was introduced into ALMANACH (Rambaud-
Althaus, Shao, et al., 2015). A meta-analysis reported a pooled LR+ of 6.1 (4.3, 8.6) and LR- 
of 0.20 (0.16, 0.26) for a positive urine dipstick in diagnosing a positive urine culture (Whiting 
et al., 2005). The test accuracy in children younger than 2 years is lower compared to older 
children (Mori et al., 2010). Obtaining clean urinary samples is however challenging in small 
children, i.e. those at highest risk for urinary tract infection (Roberts, 2011). In the tropics, 
malaria is an important cause of FWS, which can be readily diagnosed by mRDT 
(D’Acremont et al., 2014). For bacterial infections, typhoid fever, rickettsial diseases, scrub 
typhus, and Leptospirosis cause FWS, with seasonal and geographic variation. ALMANACH 
included abdominal tenderness as a predictor for typhoid disease (Rambaud-Althaus, Shao, 
et al., 2015). However, assessment of abdominal tenderness requires advanced pediatric 
clinical skills. It was detected in none of the 842 patients assessed in the ALMANACH study 
(Shao, 2015). In studies using methodologies without gold standard diagnosis, available 
pathogen-specific POCTs for typhoid have low accuracy with sensitivities of approximately 
60% and specificities of approximately 80% (Islam et al., 2016).  
In order to improve identification of children in need for antibiotic treatment among those with 
FWS, we first evaluated clinical signs. Van den Bruel et al. systematically reviewed clinical 
signs for identifying children with serious bacterial infections (Van den Bruel et al., 2010). No 
additional clinical signs could be identified from this review. More recently, De Santis et al. 
evaluated clinical predictors of bacterial disease in the Tanzanian fever study. In addition to 
the signs that were already included in the severe disease classification (see above), low 
weight (weight for age [WFA] <2 standard deviations (World Health Organization, 2006), 
adjusted LR+ 4.6], cervical, axillary or inguinal lymphadenopathy (adjusted LR+ 3.5) and 
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fever duration of >3 days (adjusted LR+ 1.6) were identified (De Santis and D’Acremont, 
2017). Abdominal tenderness was a predictor of typhoid (adjusted LR+ 7.0). However, we 
did not keep “abdominal tenderness” due to its unproven reliability (see above).  
Next, we assessed whether CRP or PCT (which are available as POCT), or a combination of 
both biomarkers would be helpful in detecting children in need for antibiotic prescription 
among children with FWS. Van den Bruel et al. summarized the diagnostic value of 
laboratory tests in identifying serious infections in children (including children with FWS) in a 
systematic review (Van den Bruel et al., 2011). The best performing biomarkers were PCT 
(LR+ 1.75 to 3.11; LR- 0.08 to 0.35) and CRP (LR+ 2.40 to 3.79; LR- 0.25 to 0.61). An 
earlier review focusing on CRP only found similar results (Sanders et al., 2008). For UTI 
specifically, we identified 6 and 13 studies that addressed the diagnostic accuracy of PCT 
and CRP respectively for the diagnosis of pyelonephritis (confirmed by DMSA scan) in 
children. All studies were summarized in a recent systematic Cochrane review (Shaikh et al., 
2015): PCT, at a cutoff of 0.5 ng/mL, and CRP, at a cutoff of 20mg/L had a sensitivity of 86% 
and 94% and a specificity of 74% and 39% respectively. Test accuracies for higher cutoffs 
were not reported. We found two relevant studies that assessed the diagnostic accuracy of 
CRP in detecting invasive Salmonella infection. In the first study, a CRP cutoff of 35mg/L 
was found to be 55% sensitive at a specificity of 88% (Meloni et al., 1999). The accuracy 
was lower when clinical and/or microbiological confirmation were used in other studies 
(Choo et al., 2001; Cooper et al., 2014). We could not identify relevant studies on the 
diagnostic accuracy of CRP or PCT for leptospirosis, rickettsial disease nor scrub typhus.  
The overall evidence of retrieved studies was not sufficient to inform on cutoffs of CRP and 
PCT to be used in patients with FWS in resource-poor settings. In general, there was little 
benefit in combining two tests in the study by van den Bruel et al (Van den Bruel et al., 
2011). However, we postulated a theoretical benefit since PCT and CRP are positive at 
different time-points of the disease. Currently, IMCI does not recommend antibiotic 
prescription for children without severe symptoms but with FWS. In order to avoid over-
prescription of antibiotics in such children with a low pre-test probability of having a serious 
bacterial infection, we chose cutoff values with strong rule-in value, i.e. PCT 4ng/mL and 
CRP 80mg/L.  
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5.4.4. How should severe malnutrition be measured? Should it be included as 
a danger sign? 
 
Severe malnutrition is recognized as an important risk factor for severe outcome from 
infections (Reed et al., 2012; Jain, Sarathi and Jawalekar, 2013; Gowraiah et al., 2014). In a 
study among 10,580 pediatric admissions in Kenya severe malnutrition accounted for 21% 
(141/659) of invasive bacterial infections and 38% (200/533) of deaths. Eighty-one percent 
(959/1183) of these admissions did not meet criteria for antibiotic treatment based on other 
symptoms, making anthropometry or kwashiorkor the sole basis for antibiotic treatments 
(Berkley, Maitland, et al., 2005). This justifies systematic antibiotic treatment for children with 
fever and severe malnutrition, and possibly hospital referral.  
IMCI defines severe malnutrition as severe wasting (weight for height [standing] or weight for 
length [lying flat] less than -3 z-scores), or mid-upper arm circumference (MUAC) less than 
115 mm, or visible clinical signs of severe malnutrition (World Health Organization, 2014). 
The use of several signs is out of the recognition that all signs are very specific for acute 
severe malnutrition and that they are not necessarily overlapping. For example, in a study 
among 8190 hospitalized children in Kenya (359 deaths), sensitivity and specificity for 
subsequent inpatient death were, respectively, 46% and 91% for MUAC less than or equal 
to 11.5 cm, 42% and 92% for wasting, and 47% and 93% for visible severe wasting (Berkley, 
Mwangi, et al., 2005). The three indices identified different subgroups of children and were 
independently associated with mortality.  
Myatt et al. reviewed the performance of different methods for detection of severe 
malnutrition at community level (Myatt, Khara and Collins, 2006). The review concluded that 
weight for height/length (WFH)-based case-detection perform worse, in terms of precision, 
accuracy, sensitivity, and specificity than any alternative anthropometry-based method. WFH 
was neither found to be simple, cheap, or acceptable. MUAC in turn was found to be the 
best performing method, followed by WFA. One concern with using WFA is that, in 
populations with a high prevalence of chronic stunting, low WFA will lack specificity, as it will 
misclassify children with chronic stunting as having severe acute malnutrition. Interestingly, 
chronic stunting has increasingly been recognized as an independent risk factor for 
infectious complications and mortality (Smedman et al., 1987; Pelletier et al., 1995; 
Kossmann et al., 2000; Black et al., 2008; Olofin et al., 2013; Prendergast and Humphrey, 
2014). Accordingly, WFA was found to be a better predictor for mortality than WFH in 
several studies. However, MUAC, as a measure for acute malnutrition remained the best 
predictor in most studies (Chen, Chowdhury and Huffman, 1980; Briend and Zimicki, 1986; 
Alam, Wojtyniak and Rahaman, 1989; Vella et al., 1994). An important practical restraint of 
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length measurements at peripheral level is that they likely not feasible given the short time 
available for consultation and the challenges involved when children are irritable and sick 
(Myatt, Khara and Collins, 2006). For example, in a survey of IMCI implementation in 
Bangladesh, weight measurement was done in 20% of 842 eligible children but length 
measurement in only 0.6% (Saha et al., 2015). Precision of measurement by trained 
community health workers was found to be lowest for WFL and highest for WFA (Velzeboer 
et al., 1983). Based on the evidence summarized above, we included MUAC measurement 
into e-POCT for all children above 6 months and, because there is currently not enough data 
to recommend it as sole measurement (Roberfroid et al., 2013), we replaced WFH with WFA 
using a cutoff of <-3 z-score (Center for Disease Control and World Food Programme, 
2005). Clinical signs for severe malnutrition (wasting, edema) were not included since there 
is conflicting and little data regarding the accuracy of detection of such signs by low-level 
health workers (Hamer et al., 2004; Mogeni et al., 2011). However, the inclusion of edema in 
areas with significant risk of severe protein energy malnutrition may be considered in the 
future, as only MUAC, and not WFA, is able to detect children with Kwashiorkor given the 
fluid retention associated with this condition (Myatt, Khara and Collins, 2006).  
5.4.5. How can the diagnosis of severe dehydration be improved? 
 
The WHO dehydration scale currently used in IMCI has never been formally derived nor 
validated. In the initial IMCI evaluation studies, all signs of the WHO dehydration scale 
showed low sensitivity when compared to physician diagnosis (overall sensitivity 51%, 
ranging from 27% for general condition and 64% for thirst, Perkins et al., 1997). The clinical 
signs also had low reliability when assessed by IMCI-trained low-level health workers 
compared to medical doctors (Simoes et al., 1997). Two small hospital-based validation 
studies have been carried out in Rwanda since then. In the first study including 50 patients 
(29 with severe dehydration), the WHO scale had an area under the curve (AUC) for 
moderate and severe dehydration of 0.58 for both (Pringle et al., 2011). In the second study 
including 127 children (17 with severe dehydration), the AUC was 0.72. The optimal cutoff of 
≥2 points had a sensitivity of 68% at a specificity of 67% (Levine et al., 2013). Several 
dehydration scales have been developed in high-resource-settings which include clinical and 
laboratory features (Mackenzie, Barnes and Shann, 1989; Duggan et al., 1996; Gorelick, 
Shaw and Murphy, 1997; Vega and Avner, 1997; Friedman et al., 2004; Steiner, DeWalt and 
Byerley, 2004; Falszewska, Dziechciarz and Szajewska, 2014). Only one, the Clinical 
Dehydration Scale (CDS) was developed using formal measurement methodology, including 
the evaluation against several outcome measures (Friedman et al., 2004). The assessment 
of several outcomes is of importance since most studies only have used post-illness weight 
gain to estimate weight loss (Mackenzie, Barnes and Shann, 1989; Duggan et al., 1996; 
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Gorelick, Shaw and Murphy, 1997; Vega and Avner, 1997; Friedman et al., 2004; Steiner, 
DeWalt and Byerley, 2004), which is not a sufficiently validated gold-standard (Gorelick, 
Shaw and Murphy, 1997). CDS contains 4 clinical items: general appearance, eyes, mucous 
membranes, and tears. In emergency department populations in high-resource settings the 
CDS was found to be useful in predicting weight gain (Gravel et al., 2010; Kinlin and 
Freedman, 2012), the need for intravenous rehydration (Goldman, Friedman and Parkin, 
2008; Gravel et al., 2010; Kinlin and Freedman, 2012), need for hospitalization (Gravel et al., 
2010; Kinlin and Freedman, 2012), and hospital length of stay (Goldman, Friedman and 
Parkin, 2008; Bailey et al., 2010; Kinlin and Freedman, 2012). However, it only had a 
moderate inter-observer reliability (k= 0.52, Kinlin and Freedman, 2012). For resource-poor 
settings, the accuracy of the CDS has been assessed in 2 hospital-based studies in Rwanda 
(Pringle et al., 2011; Levine et al., 2013). In the first study its sensitivity was 68% and its 
specificity 45% for predicting 5% body weight gain (moderate dehydration) in 48 children 
(Pringle et al., 2011). The second study used a composite outcome of 10% body weight or 
death present in 8% of patients (11/140 patients). In this study the scale had an area under 
the curve of 0.80 (Levine et al., 2013). No studies have assessed the feasibility and 
usefulness of using the CDS in outpatient resource-poor settings.  
Given that the evidence for the WHO scale was poor and that for the CDS limited in terms of 
reliability and use in low-resource outpatient settings, we decided to use a practical “at-risk 
approach” using variables of the modified Vesikari severity scale (Ruuska and Vesikari, 
1990) for gastroenteritis. This scale was validated in a multicenter study and is used to 
classify severity of diarrhea in clinical trials and epidemiological studies (Freedman, Eltorky 
and Gorelick, 2010; Schnadower et al., 2013). Based on the Vesikari scale we considered 
that children with ≥5 loose stools/over past 24hrs OR ≥3 loose stools/over past 24hrs and 
emesis OR ≥3 emesis/over past 24hrs were at risk for dehydration and offered oral fluids. If 
these children would be unable to drink or would experience persistent vomiting, they would 
be referred for further hospital-based hydration treatment.  
 
5.4.6. Algorithm design 
 
We designed a novel algorithm (e-POCT) that integrated the modifications and additional 
elements developed based on the structured literature searches described above. We 
developed a paper flowchart that summarizes e-POCT’s logic (Figure 11). 
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Figure 11a (left, previous page) 
Example of input- and output screens, sensor input, and background algorithm calculations 
Point-of-care test (POCT), oxygen saturation (SaO2), rapid test for malaria (mRDT), C-reactive protein 
(CRP), procalcitonin (PCT), human immunodeficiency virus (HIV), respiratory rate (RR) 
Figure 11a (right, previous page) Content of e-POCT algorithm 
1: Heart rate ≥90th %ile for age and temperature (Thompson, Harnden, et al., 2009); 2: <3.3mmol/l; 3: 
Respiratory rate ≥97th %ile for age, temperature(Nijman et al., 2012); 4: Children ≥6 months only; 5: Weight 
for age <3z-score per WHO 2006 growth charts AND/OR mid-upper arm circumference <11.5cm and 
age>6months; 6: Clouding of cornea OR severe mouth ulcers OR cough and tachypnea (respiratory rate 
≥75th %ile for age and temperature, Nijman et al., 2012); 7: Hb (g/dL): 2-6 months<9, 7-24months<10, 25-
59months<11; 8: measured for patients with negative mRDT only; 9: Respiratory rate ≥75th %ile for age, 
temperature (Nijman et al., 2012); 10:>5 loose stools/over past 24hrs or ≥3 loose stools/over past 24hrs and 
emesis or >3 emesis/over past 24hrs; Abbreviations: central nervous system (CNS), intramuscular (IM), per 
os (PO), intrarectal (IR), inhaled (INH), oral rehydration solution (ORS), prevention of mother-to-child 
transmission (PMTCT), respiratory (resp), Hemoglobin (Hb) 
For each patient, the algorithm asks for 5 main symptoms, follow-up with additional 
questions if needed based on the initial input screen, recommends laboratory testing, 
and gives a classification and treatment recommendation (Fig2). All medication dosages 
are weight-based. Like in ALMANACH, all danger signs are evaluated at the start of the 
algorithm, including the disease-specific danger signs. This allows rapid assessment and 
referral of severe patients. Since children with severe disease and positive malaria tests 
are at high risk of bacterial infections (Berkley, Maitland, et al., 2005), both antibiotic and 
anti-malaria treatment are recommended. Whenever possible oral antibiotics were 
recommended for increased patient safety (Li et al., 2015). We also added a section on 
common skin diseases, including picture examples of common tropical skin infections. 
Skin diseases have indeed been under-addressed within IMCI since its start (Perkins et 
al., 1997).  
The electronic support tool allowed for the automated steps (Figure 11A). First, since we 
managed to connect the oximeter probe directly to the android support tool, the 
measurements of SaO2 and HR could be fed directly into the algorithm without further 
manual input. Second, the software calculated automatically weight-based medication 
dosages and reference values (HR and RR percentiles based on age and temperature, 
WHO growth chart percentiles). When necessary, the software allowed entering several 
sub-branches simultaneously. If an antibiotic was needed for two different infections, the 
algorithm was able to integrate the information and to recommend one antibiotic that 
would work for both infections, instead of one for each disease. Third, the software 
recommended laboratory tests based on the signs and symptoms entered on a single 
screen (instead of a separate screen for each suspected disease classification). Forth, 
the electronic algorithm integrated all clinical signs and symptoms, as well as results of 
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all laboratory tests performed. It then provided disease classifications and treatments 
based on this integrated data. Overall, the use of software allowed integration of more 
complex data while maintaining simple input and output screens. This allowed inclusion 
of additional clinical and laboratory parameters that could not be handled during a 
routine, “manual” consultation.  
 
5.5. Discussion 
 
We here provide a detailed rationale for the construction of e-POCT, a novel electronic 
algorithm that integrates POCTs for management of febrile illnesses in under-fives in low 
resource settings. The algorithm is built on an IMCI backbone and maintains IMCI’s 
integrative approach to the management of childhood infections.  In the construction of 
e-POCT, we sought to address IMCI’s major challenges through a structured review of 
key IMCI elements, and the integration of POCTs. To our knowledge, this was the most 
comprehensive effort to “revisit” the IMCI case management chart considering a broad 
range of literature that has been published since development of IMCI, including host 
biomarkers. This effort was further strengthened by the experience acquired through the 
development and evaluation of the ALMANACH algorithm (Rambaud-Althaus, Shao, et 
al., 2015; Shao et al., 2015; Rambaud-Althaus et al., 2017).  
The evidence retrieved allowed us to perform major useful modifications: for the 
identification of patients with severe illness, pulse oximetry was integrated to identify 
patients with hypoxemia and severe tachycardia. Cutoffs for HR and RR were updated 
based on recent epidemiological studies and are corrected automatically for age and 
temperature by the algorithm. Systematic Hb screening was added to identify children 
with severe anemia. e-POCT uses MUAC and WFA to improve detection of children with 
severe malnutrition. For the management of children with respiratory infections, we 
constructed a ‘severe respiratory distress’ category and added a two-step diagnostic 
approach for bacterial pneumonia using RR and a CRP POCTs. Bacterial infections in 
children with FWS were addressed through CRP and PCT POCTs. The low-evidence 
and complex WHO dehydration scale was replaced with a simple ‘at-risk’ approach 
based on 24hr parental recall. We aimed at increasing the user-friendliness through the 
use of an electronic format, the reduction of clinical elements, and a simple user-
interface.  
Overall, the design of the algorithm was limited by the scarcity of evidence of some of 
the key areas that required revision. This was especially true for evidence from low-
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resource settings. Prospective studies on the accuracy of danger signs (especially the 
sensitivity) are lacking. All studies that assess IMCI danger signs were hospital-based 
(Paxton et al., 1996; Kalter, Schillinger, et al., 1997). Hence, they can only give 
estimates on the specificity of danger signs. Some additional clinical signs, such as CRT 
or jaundice have been shown to be valid in predicting severe illness. However, their 
reliability when measured by low-level health workers has not been demonstrated. Since 
development of e-POCT, some of the pediatric severity scores have been further 
validated (Conroy et al., 2015). Two additional score have been developed (George et 
al., 2015; Mpimbaza et al., 2015). However, the reliability and usefulness of the scores at 
peripheral health care level remains to be determined. Unfortunately, there is no clinical 
discriminator for anemia, requiring systematic Hb screening of all children. Given the 
high mortality from anemia, such an approach may be justified. However, this will likely 
lead to higher referral of patients and has to be met with improved hospital-based blood 
transfusion capacity. Furthermore, the majority of severe anemia used to occur in 
children with malaria (Biemba et al., 2000; Koram et al., 2000; Owusu-Agyei et al., 
2002). With declining malaria transmission this proportion has decreased (Pedro et al., 
2010) and the usefulness of systematic Hb screening has to be assessed in low malaria 
transmission areas. Alternative approaches to Hb screening, such as the Hemoglobin 
scale may be a future option, though its accuracy had to be improved (Marn and 
Critchley, 2016). Identification of children with severe respiratory infections is limited by 
low-level evidence of discriminatory signs. Lower chest indrawing has been omitted as a 
sign for severe pneumonia since it has been demonstrated that children with severe 
pneumonia do not benefit from intravenous antibiotic treatment. This is, however, not 
surprising since a great proportion of children with severe pneumonia suffer from viral 
infections (Ali et al., 2013). Further studies should evaluate predictive signs for the need 
of hospital-based supportive care, regardless of the microbiological etiology. For the 
diagnosis of bacterial pneumonia, the role of RR as a marker for pneumonia is unclear. It 
was constructed as a very sensitive diagnostic criterion, but more recent evidence 
suggests that the current WHO cutoffs are neither sensitive nor specific (Rambaud-
Althaus, Althaus, et al., 2015). The validity of using RR as an initial rule-in criterion for 
the diagnosis of bacterial pneumonia has to be evaluated further. One reason may be 
that binary cutoffs over-simplify correlation of RR with pneumonia. This is why we used 
updated RR cutoffs, corrected for age and temperature. A prospect may be the utilization 
of ‘digital stethoscopes’ that can detect children with bronchiolitis who do not require 
CRP testing (Simoes et al., 1991). Overall, the evidence for the use of CRP to diagnose 
bacterial pneumonia in children was moderate. Outcome studies are lacking. A recent 
study in Vietnam demonstrated that CRP could reduce antibiotic prescription for 
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respiratory infections in children (Do et al., 2016). However, the trial was not powered to 
assess clinical outcome. Newer studies have assessed the accuracy of PCT in 
diagnosing childhood pneumonia (Bivona et al., 2015; Agnello et al., 2016). PCT is 
indeed a useful marker for bacterial pneumonia in adults (Shaddock, 2016). Using PCT 
for detecting bacterial pneumonia in children could be considered. As for FWS, little 
evidence could be retrieved on the most useful cutoff for diagnosing bacterial infections 
in a low prevalence setting. We used higher cutoffs for both biomarkers to avoid over-
treating children at low risk for bacterial infections with antibiotics. The accuracy of 
biomarkers depends on the time point of measurement within the course of an illness 
(Melbye et al., 2004). Previous efforts to improve management of children with FWS 
have included urine dipstick testing to detect children with UTI (World Health 
Organization, 2005; Rambaud-Althaus, Shao, et al., 2015). The high CRP and PCT 
cutoffs may miss children with UTI raising the concern for the development of renal 
scarring. However, recently, specialists have proposed that less aggressive testing 
strategies UTI, such as testing of children with several days of fever only, may be just as 
adequate (Salleeh et al., 2010; Newman, Shreves and Runde, 2013). Overall, obtaining 
clean urine samples in children in resource-limited setting is challenging. This could be 
considered when more detailed evidence is available. Overall, all studies on predictors 
reviewed were limited by the fact that they were mostly conducted in emergency 
department settings. This may limit the applicability of the findings for the settings 
targeted by e-POCT with a lower prevalence of bacterial infections. Finally, the 
involvement of parental judgment, which has shown to be useful in studies in high-
resource-settings has not been explored for the IMCI setting (Van den Bruel et al., 2007).  
e-POCT has the potential to improve management of the febrile child in low-resource 
settings through integration of recent evidence of fever management, novel, POCTs, and 
electronic technology. This new tool should be validated in real conditions of primary 
care in resource-poor settings. 
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6. Validation of prediction rules for serious bacterial infections in 
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What’s Known on This Subject  
Clinical algorithms designed developing countries (e.g. IMCI) have not been validated for 
their performance in detecting serious bacterial infections (SBI) using stringent criteria. 
Prediction rules and guidelines for SBI from well-resourced countries showed moderate 
performance in a European validation study.  
 
What This Study Adds  
In the Tanzanian outpatient setting, all prediction rules and guidelines examined had 
insufficient accuracy for ruling SBI in or out. IMCI had a low sensitivity. Rules using a 
combination of clinical and laboratory criteria (instead of either one) performed better.  
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6.1. Abstract 
 
Background and Objectives 
Health-workers in developing countries rely on clinical algorithms, such as the Integrated 
Management of Childhood Illnesses (IMCI), for the management of patients, including 
diagnosis of serious bacterial infections (SBI). The diagnostic accuracy of IMCI in detecting 
children with SBI is unknown. Prediction rules and guidelines for SBI from well-resourced 
countries have not been evaluated in resource-limited countries at outpatient level. The aim 
of this study was to estimate the diagnostic accuracy of existing prediction rules and clinical 
guidelines in identifying children with SBI in a cohort of febrile children attending outpatient 
health facilities in Tanzania. 
Methods 
Structured literature review to identify available prediction rules and guidelines aimed at 
detecting SBI and retrospective, external validation on a dataset containing 1,005 febrile 
Tanzanian children with acute infections. The reference standard, SBI, was established 
based on rigorous clinical and microbiological criteria.  
Results 
Four prediction rules and five guidelines, including IMCI, could be validated. All examined 
rules and guidelines had insufficient diagnostic accuracy for ruling-in or ruling-out SBI with 
positive and negative likelihood ratios ranging from 1.04-1.87 to 0.47-0.92, respectively. 
IMCI had a sensitivity of 36.7% (95% CI 29.4-44.6%) at a specificity of 70.3% (67.1-73.4%).  
Conclusions 
Revised clinical algorithms including simple point-of-care tests with improved accuracy for 
detecting SBI targeting in tropical resource-poor settings are needed. They should undergo 
careful external validation against clinical outcome before implementation, given the inherent 
limitations of gold standards for SBI. 
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6.2. Introduction 
 
Acute febrile illnesses are the most common presentation of young children attending 
outpatient settings worldwide (Burton et al., 2011). Serious bacterial infections (SBI) are 
infections that may results in life-threatening complications without antibiotic treatment, such 
as bacteremia, meningitis, pneumonia, osteomyelitis, and febrile urinary tract infections 
(UTI). Children with these infections often present with non-specific clinical signs and several 
concomitant symptoms (Horwood et al., 2011). Like in well-resourced settings, SBI in 
resource-poor settings have become increasingly rare with improving vaccination coverage 
and hygiene (D’Acremont et al., 2014). This combined makes the assessment of children 
with acute infections challenging—especially in developing countries where health care 
workers lack diagnostic tools and resources. Sub-standard management of children with 
infections has resulted in persistent high mortality from common childhood infections(Liu et 
al., 2014) and high-volume over-prescription of antibiotics (Risk et al., 2013).  
The World Health Organization (WHO) developed the Integrated Management of Childhood 
Illnesses (IMCI) strategy in the 1990s. The cornerstone of the IMCI strategy is a set of 
algorithms that recommends presumptive treatment based on clinical signs and symptoms 
(besides the rapid diagnostic test for malaria that was introduced in the 2014 version, World 
Health Organization, 2014). The Integrated Community Case Management guidelines 
(iCCM) is a simplified version of IMCI, geared towards community health workers (UNICEF 
and World Health Organization, 2011). More recently, an improved version of IMCI was 
developed and validated, ALMANACH, that includes urinary dipstick testing (Rambaud-
Althaus, Shao, et al., 2015). Due to the lack of available evidence when IMCI was initially 
developed, the algorithm was based mainly on expert opinion in addition to small derivation 
studies. Though IMCI and iCCM have been implemented globally, their performance in 
detecting children with SBI has not been validated to date using stringent microbiological, 
instead of expert clinical diagnosis (and chest radiograph [CXR] in some studies, USAID, 
1998). In a 1995 outpatient department study in Bangladesh, Factor et al. included blood 
culture in the outcome definition for SBI, the remaining SBI definition were, however, based 
on pediatrician’s clinical diagnosis and CXR only (Factor et al., 2001). In economically 
developed countries a series of clinical and laboratory prediction rules and clinical 
guidelines, with different degrees of validation, have been designed for the management of 
febrile children in the ambulatory setting (American College of Emergency Physicians 
Clinical Policies Committee, 2003; Thayyil et al., 2005; Van den Bruel et al., 2007; Bleeker et 
al., 2007; Lacour, Zamora and Gervaix, 2008; Bilkis et al., 2010; Craig et al., 2010; Brent et 
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al., 2011; Neuman et al., 2011; Thompson et al., 2012; National Institute of Health and Care 
Excellence, 2013; Nijman et al., 2013). There is a growing body of evidence that the causes 
of acute febrile illnesses in children in low- and high resource settings are in fact quite similar 
(D’Acremont et al., 2014). Such clinical prediction rules and guidelines may thus be an 
attractive prospect for improving case management in low-resource settings. However, 
external validation to support their use in resource-poor settings is lacking.  
The aim of this study was to estimate the diagnostic accuracy of existing prediction rules and 
clinical guidelines, including IMCI and iCCM, in identifying children with SBI in a resource-
poor setting, using retrospective external validation on dataset collected prospectively in 
Tanzania(D’Acremont et al., 2014). 
 
6.3. Patients and Methods  
 
We used the Standard for Reporting of Diagnostic Accuracy (STARD) guidelines for study 
reporting(Bossuyt et al., 2003). The protocol of the validation dataset was approved by the 
regional ethics committee in Basel, Switzerland, and by the national ethics committee in 
Tanzania (D’Acremont et al., 2014).  
Participants 
The study population comprised 1005 children from a study on causes of fever in rural and 
urban Tanzania, the 'Tanzanian Fever Study'(D’Acremont et al., 2014).Details of the study 
are reported elsewhere(D’Acremont et al., 2014). Briefly, children aged two months to 10 
years with fever (axillary temperature of ≥38°C) were enrolled consecutively. Children with 
severe malnutrition and/or those requiring immediate live-saving procedures were excluded. 
Recruitment in Tanzania took place at the outpatient clinic of Amana District Hospital in Dar 
es Salaam (urban setting) from April to August 2008, and at the outpatient clinic of the St-
Francis Designated-District Hospital in Ifakara, Kilombero District (rural setting) from June to 
December 2008.  
Outcome definition 
The outcome, SBI, i.e. a bacterial infection requiring antibiotic treatment, was defined as 
presence of one of the following: bacteremia (positive blood culture for a known pathogen), 
Salmonella typhi infection (positive blood-or stool culture, or positive specific IgM rapid 
diagnostic test), radiographic pneumonia, urinary tract infection (positive urine dipstick and 
urine culture), meningitis, bacterial gastroenteritis (positive stool culture), significant skin/soft 
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tissue infections and other systemic bacterial infections (Rickettsiosis, Coxiellosis, and 
Leptospirosis). Definitions were based on the methodology used in the 'Tanzania Fever 
Study': for each patient, the final diagnosis (or diagnoses) was established with a computer-
generated algorithm based on pre-defined clinical and microbiological criteria(D’Acremont et 
al., 2014). These criteria were derived from international guidelines as well as systematic 
reviews.  
Clinical and laboratory assessment  
Investigators used standardized case report forms to record clinical findings. The form 
included 23 symptoms and their respective duration, potential travel history and/or sick 
contacts, known chronic conditions, and 49 clinical signs. At the initial visit a systematic set 
of investigations was performed according to predefined algorithm (D’Acremont et al., 2014). 
If a clinical or laboratory diagnosis could not be made at the initial visit, a follow-up visit was 
scheduled for day 7 when an identical, full clinical and laboratory assessment was 
performed again for those with persistent fever or those who experienced new symptoms. In 
all cases, blood samples and pooled nasal and throat swabs were taken for microbiologic 
testing (cultures and rapid tests) on site and further serologic and molecular work-up in 
Switzerland and the USA. CXR were performed on site in the subgroup of cases fulfilling the 
WHO clinical definition of pneumonia (World Health Organization, 2013). Images were 
reviewed by a pediatric radiologist in Switzerland who was blinded to the presumed 
diagnosis and who classified the radiographic findings according to WHO’s Pneumococcal 
Trialist Ad Hoc Committee recommendations (Cherian et al., 2005). The diagnosis of 
radiological pneumonia was made in cases where CXR showed 'primary endpoint 
consolidation'. If the IMCI clinical criteria for a suspected human immunodeficiency virus 
(HIV) infection were present, voluntary HIV testing was recommended to the child’s 
guardian.  
Selection of prediction rules and guidelines 
All available prediction rules (laboratory and clinical) for identifying any SBI in children in the 
outpatient settings were identified through a structured literature review in Medline and 
Embase as part of the development of a novel disease management algorithm (Chapter 
5.3). The search was modified based on previously published systematic review and a 
European validation study (Thompson et al., 2012; Verbakel et al., 2013). Prediction rules 
and guidelines that target the neonatal period, i.e. < 3 months, were excluded. We also did 
not include prediction rules that primarily aim at predicting death (such as the PEDIA 
[Berkley, 2003], LODS [Helbok et al., 2009], and SICK [Bhal et al., 2006] scores), or the 
need for referral to the pediatric intensive care unit at in-patient level. Scores aimed at 
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identifying dehydration for patients with gastroenteritis, or at detecting children with 
meningitis (there were only 2 patients with meningitis in the dataset) were also not included. 
When variables of the dataset were not entirely matching the variables of the original rule or 
guideline, we identified proxies where possible. For instance, the variable 'ill-appearance' of 
the Rotterdam Fever Model was not recorded in the dataset. We therefore used 'lethargic' or 
'drowsy' as proxies. When more than 20 percent of the required variables were not recorded 
in the dataset, the rule/guideline was not included in the validation. This was based on the 
assumption that missing more than 20% of predictor variables was not clinically sensible. 
Missing data on variables used in the validation were not imputed because the necessary 
missing-at-random assumption was likely to be incorrect given that all data was collected 
based on a predefined algorithm. For example, urine testing was obtained in children per 
pre-defined criteria and not randomly. We report the number of observations available for 
analysis of each prediction rule after application of the above assumptions. Where rules 
generated sum scores, previously published cut-offs were applied.  
Statistical analysis 
The accuracy of the included prediction rules and guidelines was estimated retrospectively 
in the prospectively collected 'Tanzania Fever Study' dataset by calculating sensitivity, 
specificity, and likelihood ratio (LR). To assess the influence of the age range, we performed 
several sensitivity analyses by comparing the 95% confidence intervals (CIs) of the 
diagnostic accuracy results in the target age group of the rules/ guidelines with that in the 
entire age range of validation dataset, Since some predictors (fast breathing in IMCI, iCCM, 
and ALMANACH, and a positive CXR in the American Academy of Emergency Physicians 
[AAEP] guideline) was part of the diagnostic criterion for pneumonia in the validation 
dataset, we also did sensitivity analyses by comparing the full dataset with a dataset 
excluding pneumonia cases for these 4 guidelines. The same was done for UTI for 
prediction scales and guidelines that use urinary dipstick (Bleeker Score, Lab Score, 
ALMANACH and AAEP). Malaria is known to raise C-reactive protein (CRP) values(Naik 
and Voller, 1984). We hence performed a sensitivity analysis comparing malaria negative 
patients with the full dataset for prediction rules that contain C-reactive protein. All analyses 
were performed with Stata version 13.1. We used a web-based tool to generate Venn 
diagrams (http://jura.wi.mit.edu/bioc/tools/venn.php).  
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6.4. Results 
 
Prediction rules and guidelines  
Through the structured literature review (Chapter 5.4), we identified 34 prediction 
rules/guidelines for the use in febrile children. Sixteen were designed to predict SBI at the 
outpatient level (Figure 12).  
 
 
Figure 12 Flowchart of scores identified and considered for validation. Adapted from Figure 10, Pediatric 
Intensive Care Unit (PICU) 
The NICE guideline is intended to predict  ‘serious disease’ among children with acute 
febrile illness, and not to indicate antibiotic treatment. However, given that it was the only 
guideline designed for the use by healthcare professionals in primary care with various 
levels of training, we decided to include it in the validation exercise. The prediction rules and 
Records identified through database 
searching 
(n =12,124) 
Additional records identified through 
other sources 
(n =21) 
Records after duplicates removed (n =11,059) 
Records screened 
(n =11,059) 
Records excluded 
(n =10,513) 
Full-text articles assessed for 
eligibility 
(n =546) 
Full-text articles excluded 
(n =375)   
Topic=171 
Patient population=36 
Design=168 
171 full-text articles reviewed, 
34 scores for the use in 
febrile children identified Scores excluded (n =18)   
Neonatal=5 
Death=5 
Transfer to PICU=2 
Dehydration=4 
Meningitis=2 
16 scores considered for 
validation 
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guidelines identified are summarized in Table 7. In addition to the prediction rules and 
guidelines from the systematic review and European validation study (Thompson et al., 
2012; Verbakel et al., 2013), we found one additional prediction rule for diagnosis of SBI 
(Craig et al., 2010), and two prediction rules for pneumonia(Bilkis et al., 2010; Neuman et 
al., 2011). We also identified one additional clinical guideline (AAEP, American College of 
Emergency Physicians Clinical Policies Committee, 2003) in addition to IMCI, iCCM, and 
ALMANACH (UNICEF and World Health Organization, 2011; World Health Organization, 
2014; Rambaud-Althaus, Shao, et al., 2015). Appendix 1 displays which rules and guidelines 
could be used for retrospective validation. For the prediction rules, validation was possible 
for the Bleeker Score, Thavyil Score, Lab Score and the Rotterdam Fever Model. More than 
20% of predictors were missing for other prediction rules, including 3 pneumonia rules. All 
clinical guidelines identified could be used for validation. The proxy variables used for certain 
predictors are also shown in Appendix 1.  
 
Validation dataset 
The median age of children included in the validation dataset was 18 months (interquartile 
range 10-34), 33% of children were younger than 12 months. The full details on the 
demographic and clinical characteristics of the study population are provided in the original 
study report (D’Acremont et al., 2014). A SBI was identified in 16% (162/1005) of patients in 
the validation dataset. Table 8 shows the prevalence and overlap of the different SBI 
categories.  
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Table 7A Clinical and laboratory prediction rules for management of acute febrile illnesses in children* 
Name of Prediction 
Rule 
Age Group Predictors Derivation study 
All serious infections 
Yale Observation Scale <24m 
 
Quality of Cry Reaction to parents’ stimulation State Variation Color Hydration Response to social 
overtures 
Mccarthy et al., 1982  
 Strong OR not 
crying(1) 
Whimpering (3) 
Weak (5) 
Cries briefly (1) 
Cries on/off (3) 
Continual cry (5) 
Stays awake (1) 
Awakes with stimulation 
(3) 
Falls to sleep (5) 
Pink (1) 
Pale extremities (3) 
Pale OR cyanotic (5) 
Skin normal (1) 
Dry mouth (3) 
Skin doughy (5) 
Smiles OR Alert (1)  
Brief smile OR alerts 
briefly (3) 
No smile OR face 
anxious (5) 
 
 Sum of all six feature values (cut-offs used in literature: 8, 9 or 10) 
Five Stage Decision Tree 0-16 y Clinician instinct that something is 
wrong 
Dyspnea Temperature > 39.95°C Diarrhea Age 15-25m Van den Bruel et al., 
2007  
 No                               0 
Yes or unknown         1 
No or unknown          
0 
Yes                            
1 
No                              0 
Yes                            1 
No or unknown          0 
Yes                            1 
No or unknown        0 
Yes                          1 
 
 If yes to any of these five features 
Bleeker <36m Duration fever 
Days (points) 
H/o vomiting Ill 
appearance 
Chest wall retractions+ 
tachypnea 
Poor peripheral 
circulation 
WBC CRP (mg/l) Urine WBC Bleeker et al., 2007 
 0.5 (0), 1(2), 1.5 (4),2-
2.5(5), 3-3.5(6), 4-
4.5(7), 5-6(8), 6.5-
8.5(9), ≥ 9(10) 
Y=5  Y=4 Y=12 Y=7 <10(0), 10-19(2), 
20-29(4), 30-
39(6), ≥ 40(8) 
Divide value by 10 
and round to lower 
integer, max.=16 
points 
≥ 70 WBC/µl =9  
 Total points, described cutoffs: clinical: 10, lab: 8  
Thayyil 1-36m PCT (ng/ml) CRP (mg/l) WBC Thayyil et al., 2005 
  >2 >50 >15  
  Cutoff: All positive  
Lab Score 7d-36m PCT (ng/ml) CRP (mg/l) Urine Dipstick Lacour, Zamora and 
Gervaix, 2008 
  <0.5 (0), ≥0.5 (2), ≥2 (4) <40 (0), 40-99 (2), ≥100 (4) Positive leucocyte or nitrite  
  Cutoff: 3 
 
 
AUS fever model 0-5 y General appearance, cough, temperature, breathing difficulty, abnormal chest sounds, chronic disease, capillary refill time, urinary symptoms, 
respiratory rate, chest crackles, pneumococcal vaccine, heart rate, felt hot, meningococcal vaccine, infectious contacts, crying, fluid intake, respiratory 
symptoms, diarrhea, bulging fontanelle, male, focal bacterial infection, abnormal ear, nose, and throat signs, age rash, stridor, wheeze 
Craig et al., 2010  
  Model risk estimate  
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Name of Prediction 
Rule 
Age Group Predictors Derivation study 
SBI risk score 1m-15y Developme
ntal delay 
Infection 
risk factor 
State variation T (°C) CRT Hydration Tachypnea* Hypoxia (Brent et al., 2011) 
  No (0) 
Yes (4) 
No  (0),  
Yes (2) 
Eyes open (0) 
Eyes close briefly (1) 
Falls asleep (2) 
<37.5 (0), 
37.5 – 38.3 (1)  
≥38.4 (2) 
<2 (0) 
≥2 (2) 
Well hydrated (0) 
Dry mucous membranes (2) 
Reduced skin turgor (4) 
No   (0) 
Yes  (1) 
No (0) 
Mild (1) 
Severe (2) 
 
Rotterdam Fever model 1m-16y Age<1, Sex, Duration of Fever, Height of Fever, Tachypnea, Tachycardia, SaO2<94%, CRT >3sec, Chest Wall retraction, Ill-appearance, CRP (Nijman et al., 2013) 
  Model risk estimate  
Pneumonia 
   
Pneumonia Rule n°1 0-16 y Parental concern illness is different Shortness of breath (Van den Bruel et al., 
2007)  
Values  If yes to any of these two features  
Pneumonia Rule n°2 0-21y SaO2 Triage T Wheeze Decreased breath sounds Focal rales Chest pain History of 
fever 
(Neuman et al., 2011) 
Values  Classification of Regression Tree/ clinical model  
Pneumonia Rule n°3 1-16y Grunting Cough Rales Decreased breath sound Vomiting (Bilkis et al., 2010) 
  Model risk estimate  
 
 
Table 7B:  Guidelines for management of acute febrile illnesses in children* 
Name of guideline Age Group Clinical and laboratory features Publication 
IMCI 2m-5y CNS Hydration/ nutrition Respiratory Other  
Danger signs  - Lethargic or unconscious 
-h/o convulsions or currently 
seizing  
-stiff neck 
- Vomits everything 
-Unable to drink/ breastfeed 
-Severe malnutrition AND medical 
complications OR feeding issue 
-Severe dehydration (Two of the following) 
--Lethargic or unconcious 
--Sunken eyes 
--Not able to drink or drinking poorly 
--Reduced skin turgor 
 
- Stridor in a calm child 
-SaO2 <90% on RA (if available) 
-Chest indrawing and HIV positive 
 
-Tender swelling behind ear 
-Severe palmar pallor 
-Severe complicated measles 
(World Health 
Organization, 2014) 
Indications for antibiotic 
treatment 
 
  -Uncomplicated severe malnutrition 
 
-Cough and tachypnea and/or chest 
indrawing after trial of bronchodilator 
(2-12m: RR >50/min; ≥12m: RR> 
40/min)  
-Ear pain or ear discharge 
<14 days 
-Blood in stool 
 
 
 If yes to any of the danger signs: referral and IM antibiotics 
If yes to any of the antibiotic signs: oral antibiotic treatment 
 
iCCM 2m-5y CNS Hydration/ nutrition Respiratory Other  
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Danger signs  - Lethargic or unconscious 
-h/o convulsions or currently 
seizing 
 
-Vomits everything 
-Unable to drink/ breastfeed 
-Severe malnutrition (low MUAC or bilateral 
edema) 
 
  
-Chest indrawing  -HIV positive 
-Blood in stool 
(World Health 
Organization, 2014) 
Indications for antibiotic 
treatment 
 
   -Cough and tachypnea  
(2-12m: RR>50/min; ≥12m: >40/min) 
  
  If yes to any of the antibiotic signs; oral antibiotic treatment 
If yes to any of the danger signs: referral and oral  antibiotics 
 
Name of guideline Age Group Clinical and laboratory features   Publication 
ALMANACH 2m-5y CNS Hydration/ nutrition Respiratory Other  
Danger signs  - Lethargic or unconscious 
-h/o convulsions or currently 
seizing 
-stiff neck 
-Vomits everything 
-Unable to drink/ breastfeed 
-Severe wasting 
-Severe dehydration (Two of the following) 
--Lethargic or unconscious 
--Sunken eyes 
--Not able to drink or drinking poorly 
--Reduced skin turgor 
-Chest indrawing 
-Stridor in a calm child 
-Cyanosis 
-Tender swelling behind ear 
-Severe pallor 
-Jaundice 
-Severe soft tissue infection 
(Rambaud-Althaus, Shao, 
et al., 2015) 
Indications for antibiotic 
treatment 
 
   Cough and RR > 50/min Acute ear discharge  
Blood in stool 
Urine dipstick ( Positive 
leucocyte or nitrite)  
Abdominal tenderness 
 
  If yes to any of the antibiotic signs; oral antibiotic treatment 
If yes to any of the danger signs: referral and IM antibiotics 
 
NICE traffic light system <5y Colour Activity Respiratory Circulation and Hydration Other (National Institute of 
Health and Care 
Excellence, 2013) 
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*Modified and appended from Verbakel et al., 2013, ** Advanced pediatric life support cutoff, beats per minute (bpm), capillary refill time (CRT), C-reactive protein (CRP), history of (h/o), 
months (m), oxygen saturation (SaO2), procalcitonin (PCT), respiratory rate (RR), body temperature (T), yes (Y), years (y), white blood cell count (WBC) 
Red- high risk  - 
Pale/mottled/ 
  Ashen/blue 
-No response to social cues 
-Appears ill to healthcare 
professional 
-Does not wake or if roused does 
not stay awake 
-Weak high-pitched or continuous 
cry 
- Grunting 
- RR>60/min 
- Moderate/severe chest 
indrawing 
 
- Reduced skin turgor - Age 0-3m & T≥38°C 
- Non-blanching rash 
- Bulging fontanelle 
- Neck stiffness 
- Status epilepticus 
- Focal neurological signs 
- Focal seizures 
 
Amber- intermediate risk  - Pallor 
 
- Not responding normally to social 
cues 
- Wakes only with prolonged 
stimulation 
- Decreased activity 
- No smile 
 
 
- Nasal flaring 
- Tachypnea  
  (6-12m: RR>50/min; >12m: 
> 40/min) 
- SaO2≤ 95% 
- Crackles 
 
 
-Tachycardia(<12m: >160bpm; 
12-24m: >150bpm; 2-5y: 
>140bpm)- Dry mucous 
membranes 
- Poor feeding in infants 
- CRT≥ 3 seconds 
- Reduced urine output 
 
- fever ≥5 days 
- swelling of a limb or joint 
- non-weight bearing limb/not using  
  extremity 
- age 3-6m, T≥39°C 
 
 
 
Values  If yes to any of these 5 categories, each scoring 2 to 13 features  
American Academy of 
Emergency Physicians 
Guidelines 
3-36 m Ill appearing Positive chest radiography (to be obtained 
if:T≥39°Cand WBC >20K/mm3 or “clinical 
evidence of lower respiratory infection” 
Positive urine leucocyte + nitrite (to be 
obtained in male <1 year and female <2 
year) 
T≥39°C 
And WBC>15K/mm3 
(American College of 
Emergency Physicians 
Clinical Policies 
Committee, 2003) 
Values  If yes to any of these features  
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Table 8 Cross table of serious bacterial infection (SBI) categories 
 
 
SBI categories, % (n), N=1005 
 Meningitis Pneumonia Bacteremia UTI Typhoid Cellulitis/ Abscess 
Bacterial 
gastroenteritis Leptospirosis 
Intracellula
r bacteria 
Meningitis 2 (0.2) 0 0 0 0 0 0 0 0 
Pneumonia  3.1 (31) 0 0 0.4 (4) 0 0 0 0 
Bacteremia*   1.7 (18) 0.4 (4) 0.4 (4) 0 1 (0.1) 0 0 
UTI    5.9  (59) 0.1 (1) 0 0 0 0 
Typhoid     3.7 (37) 0 0.2 (2) 0 0 
Cellulitis/ Abscess      0.5 (5) 0 0 0 
Bacterial 
gastroenteritis 
 
     
1.4 (14) 0 0 
Leptospirosis        0.4 (4) 0 
Intracellular bacteria         1.1 (11) 
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Validation results  
The diagnostic accuracy for all included prediction rules and guidelines was low to 
moderate (Table 9). The Bleeker rule, Rotterdam Fever Model (2.5% risk cutoff), and 
NICE guidelines had the highest sensitivity, ranging from 77.3% to 83.7%. However, the 
specificity of the Bleeker score was only 40.8% (95% CI 36.9%-44.9%), and those of the 
Rotterdam Fever Model (2.5% risk cutoff), and NICE guidelines even lower: 35.6% (95% 
CI 32.4%-39.0%) and 25.2% (95% CI 22.6%-28.6%), respectively. IMCI (like iCCM) had 
a very low sensitivity of 37.0% (95% CI 29.4%-44.6%) and a moderate specificity of 
70.3% (95% CI 67.1%-73.4%). Compared to IMCI, ALMANACH had a higher sensitivity 
of 63.3% (55.4%-70.6%). However, ALMANACH’s specificity was lower compared to 
IMCI (63.2%, 95% CI 59.8%-66.4%). None of the scores had LRs that would be 
considered helpful for ruling in or ruling-out SBI in low-prevalence settings (LR+ greater 
5 or LR- lower than 0.2, Oostenbrink et al., 2012).  
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Table 9 results of external validation of prediction rules and guidelines to rule-in and rule-out serious bacterial infection 
  
%test positive % sensitivity (95% CI) % specificity    (95% CI) Likelihood ratio (95% CI) 
Prediction 
rule/guideline n/N* positive negative 
Bleeker 126/731 62.9% 81.0 (73.0-87.4) 40.8 (36.9-44.9) 1.37 (1.23-1.52) 0.47 (0.32-0.68) 
Thayyil 162/1001 5.2% 31.7 (24.7-39.4) 74.4 (71.3-77.4) 1.24 (0.96-1.60) 0.92 (0.82-1.03) 
Lab Score 126/731 68.3% 70.6 (61.9-78.4) 32.2 (28.5-36.1) 1.04 (0.92-1.18) 0.91 (0.68-1.22) 
Rotterdam fever model 
    
 
2.5% risk 161/985 66.50% 77.3 (70.1-83.5) 35.6 (32.4-39.0) 1.21 (1.10-1.32) 0.64 (0.47-0.86) 
 5% risk 161/985 55.53% 69.9 (62.3-76.9) 47.3 (43.9-50.8) 1.33 (1.18-1.50) 0.64 (0.50-0.81) 
 15% risk 161/985 36.24% 49.7 (41.8-57.6) 66.4 (63.1-69.6) 1.48 (1.23-1.78) 0.76 (0.65-0.89) 
IMCI 164/1005 30.8% 36.7 (29.4-44.6) 70.3 (67.1-73.4) 1.22 (0.97-1.55) 0.90 (0.79-1.02) 
iCCM 164/1005 30.5% 36.7 (29.4-44.6) 70.7 (67.5-73.7) 1.25 (1.00-1.57) 0.89 (0.79-1.01) 
ALMANACH 164/1005 44.3% 63.3 (55.4-70.6) 63.2 (59.8-66.4) 1.72 (1.48-1.99) 0.58 (0.47-0.71) 
NICE 164/1005 76.0% 83.7 (77.2-89.0) 25.5 (22.6-28.6) 1.12 (1.04-1.22) 0.64 (0.44-0.92) 
AAEP 164/1005 41.7% 68.1 (60.4-75.1) 63.5 (60.2-66.8) 1.87 (1.63-2.14) 0.50 (0.40-0.63) 
*Number of children with SBI out of all children included into validation.
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Figure 13 illustrates the overlap between SBI classification (reference) and antibiotic 
treatment classifications by the algorithm or rule. The Bleeker score and NICE guideline 
achieved the highest proportion of correct classifications (14% of the total population) but at 
the expense of many unnecessary antibiotic prescriptions: 49% and 69% of patients, 
respectively. IMCI, iCCM and the Thavyil score resulted in the lowest proportion of correct 
classifications (6% of patients).  
 
Figure 13 Overlap of serious bacterial infection classification (blue) and antibiotic treatment 
classification per rule or guideline (pink). 
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Figure 14 shows the missed cases of SBI according to different classifications. Not 
surprisingly, IMCI , iCCM, and AAEP missed very few pneumonia cases since the 
classifications used by these guidelines were part of the outcome definition (see sensitivity 
analysis). Similarly, missed UTI cases were fewer in scores that use urine laboratory testing. 
All rules and guidelines, besides the Rotterdam model at low cutoff and the NICE guideline, 
missed a large amount of patients with bacteremia (50%-75% of bacteremia cases). 
 
 
Figure 14 Missed cases of serious bacterial infections (SBI) 
Sensitivity analysis 
Applying the rule only to the age group for which it was originally designed, resulted in a 
significantly higher specificity for the Bleeker rule, Thavyil score, Lab Score and AAEP 
guideline (Appendix 2). The sensitivity of the Thavyil score was reduced.  We found similar 
results for relevant scores when including patients without pneumonia or without malaria 
only, when compared to the full validation dataset (Appendix 2). The specificity of 
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ALMANACH was increased when applying to patients without UTI only otherwise we noted 
no significant differences in diagnostic accuracy. 
 
6.5. Discussion 
 
In the outpatient setting in Tanzania, none of the prediction rules and guidelines examined 
had sufficient diagnostic accuracy to detect children with SBI. IMCI and iCCM, which were 
designed to be sensitive for detecting SBI in these settings, actually had very low 
sensitivities when applied to our validation dataset. The Bleeker score, NICE guidelines, and 
Rotterdam Model at low cutoff showed the highest, though moderate, sensitivity, indicating a 
value in ruling-out children for SBI in low-prevalence, peripheral health care settings. 
However, at the same time, they classified many children as having a SBI, i.e. requiring 
antibiotic treatment. The use of such rules or guidelines would hence require further 
confirmatory testing to avoid antibiotic over-prescription. Rules that use a combination of 
clinical and laboratory testing, the Bleeker score, Rotterdam Model, ALMANACH, and AAEP 
guideline had better performance compared to rules and guidelines using only clinical and or 
laboratory elements.  
This study has several limitations. Only a single dataset from one country was available for 
validation, which limits the generalizability of our findings. There are multiple sources of 
heterogeneity. The most obvious one is the difference in setting for all prediction rules and 
two out of the four guidelines.  Difference in bacterial pathogens, such as typhoid and 
rickettsial diseases, substantially limits the applicability of “Northern” guidelines to tropical 
settings. In addition, the presence of co-factors affecting the overall inflammatory state, such 
as malaria and sickle cell disease, may lead to different clinical presentation and laboratory 
values. Variation in recorded values is another major limitation for this analysis. Other 
sources of heterogeneity include differences in inclusion criteria and immunization coverage. 
Though this study used robust, predefined reference criteria with extensive microbiological 
testing, the gold standards for SBI certainly remain imperfect. For pneumonia end-point 
consolidation on CXR has been used though it is known that only an (unknown) percentage 
of consolidations are of bacterial origin (Lynch et al., 2010). The diagnostic accuracy of all 
available tests for typhoid is poor (Crump et al., 2015) and hence the typhoid classification in 
this cohort, even if based on a combination of rapid test and blood and stool cultures, was 
certainly suboptimal. Bag urine collection was used in the validation cohort, which certainly 
resulted in a number of false positive UTI diagnoses (Roberts, 2011). Despite the 
comprehensive collection of clinical and laboratory predictors in the validation dataset, we 
were able to validate only four of the nine prediction rules plus all guidelines. We had to use 
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proxies for several predictors. For the Bleeker score, for example, “ill-appearance” was likely 
underestimated in our validation dataset since the variables “lethargy, and very sick child” 
refer to a sicker child. On the other hand, using the urine leucocyte dipstick test instead of 
the urine WBC likely overestimated the presence of UTI.  
To our knowledge, this was the first comprehensive attempt to examine the accuracy of IMCI 
and other prediction rules and guidelines in diagnosing SBI in a tropical, low-resource 
outpatient setting against a robust gold standard. Besides one 1995 study in Bangladesh 
that performed blood cultures and CXR (Factor et al., 2001), guidelines developed for low-
resource-settings (IMCI, iCCM, ALMANACH) have never been validated against carefully 
established gold standards (contrary to expert opinion). During its development, IMCI was 
validated against pediatrician’s diagnosis among 440 children in the Gambia(Weber et al., 
1997). Pneumonia was the only SBI included; the reported sensitivity and specificity were 
81% and 89%. Similarly to our study, the higher diagnostic accuracy for this subgroup of 
patients may have resulted from the fact that similar criteria (respiratory rate) were used both 
as predictors and to establish the reference standard. Investigations for other SBI, such as 
bacteremia and UTI were not performed in the Gambian validation study. Overall guidance 
for SBI other than pneumonia and dysentery are lacking in the current IMCI guidelines, 
which specifies only “to give antibiotic treatment if a bacterial source of infection is 
identified”. But identifying such bacterial infections without guidance is challenging for low-
level health workers. Alarmingly, the sensitivity of IMCI was very low—IMCI was originally 
designed to be very sensitive at the expense of being specific for detection of infections 
requiring antibiotic treatment. The diagnostic accuracy of ALMANACH sought to address 
these challenges through adding urinary dipstick testing and a clinical predictor for typhoid 
(Rambaud-Althaus, Shao, et al., 2015). Indeed, sensitivity was improved but at the cost of a 
lower specificity in our dataset. Generally, very few studies have validated outpatient 
prediction rules and clinical guidelines for SBI systematically. One recent study validated 
systematically four clinical prediction rules and two national guidelines retrospectively across 
datasets from primary care and emergency departments in Europe (Verbakel et al., 2013). 
The diagnostic accuracy of the prediction rules and guidelines also validated in our study 
were generally higher. This may be due to the fact that the original derivation population was 
more similar to the validation datasets of the European validation study. Other studies in the 
African setting have evaluated scores for SBI and death at the inpatient level. Nadjm et al. 
evaluated prospectively the accuracy of WHO hospital-level clinical criteria for presumptive 
antibiotic treatment in detecting SBI (positive blood and/or cerebrospinal fluid culture) among 
3,639 admitted children in Tanzania (Nadjm et al., 2010). The sensitivity was higher when 
compared to IMCI in our study (67.4%, 95% CI 65.9%-69.0%), at a lower specificity of 
51.5% (95% CI 49.9% -53.1%). Reported sensitivities of a similar study by Berkley at al. 
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were even higher (Berkley, Maitland, et al., 2005). However, the comparison of results from 
these studies with the present analysis is extremely limited by the difference in prevalence of 
SBI in the inpatient versus outpatient setting, and the restricted number of investigations for 
SBI performed (blood and cerebrospinal fluid culture only). Conroy et al. validated three 
scores to predict in-hospital (and not outpatient) mortality among Ugandan children with 
fever (Conroy et al., 2015). Through mortality is a relevant and robust outcome, its use at the 
outpatient level, where death is a rare event, is difficult.  
Our findings have several implications for clinical practice and research in low-resource 
settings. First, the efforts should be made to increase the sensitivity of current screening 
tools for SBI. With the increasing availability of vaccines, the overall prevalence of SBI will 
likely decrease further. Simple but sensitive clinical criteria will be needed to quickly rule-out 
children with SBI. Such an approach would have to be complemented with second-stage 
laboratory testing, such as point-of-care biomarkers, in order to avoid unnecessary antibiotic 
treatment. Second, in resource-poor settings with high-volume of patients and limited clinical 
skills and diagnostics, clinicians will continue to rely on case management algorithms. No 
algorithm will have perfect diagnostic accuracy making safety netting (follow-up) an 
important component of clinical care. Third, disease management algorithms should 
undergo careful external validation before implementation. Ideally, such validation studies 
should be performed against clinical outcome, and not against a microbiological gold 
standard only. Validation studies are limited by the imperfect gold standards for SBI. In 
addition, viral infections, such as bronchiolitis, may cause severe disease. The guidance on 
supportive measures for viral infections by a clinical algorithm designed for the low-resource 
outpatient setting may be become equally important with declining prevalence of SBI. 
ALMANACH, for example, achieved better clinical outcome in a validation study against 
routine care in Tanzania (Shao et al., 2015).  
6.6. Conclusions 
 
None of the examined prediction rules and guidelines had sufficient diagnostic accuracy to 
detect children with SBI in a tropical, low-resource setting. IMCI and iCCM, which were 
designed to be sensitive for detecting SBI in these settings, actually had very low 
sensitivities when applied to our validation dataset. Some prediction rules and guidelines 
had higher sensitivity and hence showed promise to rule-out SBI in our dataset. However, 
they also classified a larger number of patients as having a SBI, calling for additional 
second-stage testing, such as point-of care inflammatory markers, and tests for severity 
such as oximetry and hemoglobin. New clinical algorithms should undergo careful external 
validation studies against clinical outcome before implementation in routine care. 
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7.1. Abstract  
 
Background 
The management of childhood infections remains inadequate in resource-limited countries, 
resulting in high mortality and irrational use of antimicrobials. Current disease management 
tools, such as the Integrated Management of Childhood Illness (IMCI) algorithm, rely solely on 
clinical signs and have not made use of available point-of-care tests that can help to identify 
children with severe infections and children in need for antibiotic treatment. e-POCT is a novel 
electronic algorithm based on current evidence of pediatric febrile illness management. It 
guides through the entire consultation and recommends treatment based on a few clinical signs 
and point-of-care test results (C-reactive protein, procalcitonin, hemoglobin, oximeter, 
glucometer, malaria rapid diagnostic test). The objective was to determine whether the clinical 
outcome of febrile children managed by the e-POCT tool was non-inferior to a validated 
electronic algorithm derived from IMCI (ALMANACH) while reducing the proportion of antibiotic 
prescription. 
 
Methods and Findings 
We performed a randomized (at patient level), controlled non-inferiority study among children 
aged 2-59 months presenting with acute febrile illness to 9 outpatient clinics in Dar es Salaam, 
Tanzania. The primary outcome was the proportion of clinical failure by day 7 of follow-up. The 
secondary outcomes were the proportion of antibiotics prescribed on day 0 and severe adverse 
events by day 30 (secondary hospitalizations and deaths). We enrolled 3192 patients between 
December 2014 and February 2016. 3169 patients (e-POCT: 1586; control: 1583) completed 
the intervention and day 7 follow-up. Using e-POCT, the absolute proportion of clinical failure 
by day 7 was reduced from 4.1% to 2.3% compared to the control arm (risk ratio [RR] 0.57, 
95% confidence interval [CI] 0.38-0.85), and the proportion of severe adverse events from 1.5% 
to 0.6% (RR 0.42, 95% CI 0.20, 0.87). The proportion of antibiotic prescription was substantially 
lowered from 29.7% to 11.5% (RR 0.39, 95% CI 0.33, 0.45). Using e-POCT, the most common 
indication for antibiotic prescription were severe diseases (57%, 103/182 prescriptions); with 
the control algorithm non-severe respiratory infections (70%, 330/470 prescriptions).  
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Conclusions 
e-POCT, an innovative electronic algorithm using host biomarker point-of-care tests, including 
C-reactive protein and procalcitonin, has the potential to improve the clinical outcome of 
children with febrile illnesses while reducing antibiotic use through improved identification of 
children with severe infections, and better targeting of children in need for antibiotic 
prescription. Future implementation studies should evaluate whether this effect can be 
sustained in routine settings.  
7.2. Introduction 
 
Febrile illnesses comprise the vast majority of pediatric outpatient consultations in resource-
poor settings (Burton et al., 2011). Only a small percentage of these children require antibiotic 
treatment or referral for hospital-based supportive care, such as oxygen therapy (Shao et al., 
2015). However, correct identification of this minority of children is pivotal; sub-standard 
management of children with infections has led to two major public health challenges. First, 
persistent high mortality from common childhood infections (Liu et al., 2014); second, the 
tremendous over-prescription of antibiotics at peripheral health care level (Risk et al., 2013), 
which contributes to spreading antimicrobial resistance (Okeke et al., 2005).  
Though common, the management of childhood infections requires integration of a multitude of 
information such as epidemiological, demographic, clinical, and laboratory data. It also 
necessitates the consideration of multiple diagnoses at once, as children will often present with 
several concurrent complaints and symptoms (Horwood et al., 2011). Such an integrated 
approach for the classification and treatment of childhood infections is reflected in the current 
World Health Organization (WHO) strategy, Integrated Management of Childhood Illnesses 
(IMCI, World Health Organization, 2014). Though a positive impact on child mortality could be 
shown (Gera et al., 2016), its implementation has faced major challenges through a spectrum 
of obstacles within the health system, from the macro (policy) to the micro (patient-provider 
interaction) level. At the micro level the cornerstone of the IMCI strategy remains a set of 
paper-based algorithms that recommends presumptive treatment based on clinical signs and 
symptoms (besides the rapid diagnostic test for malaria [mRDT] that was introduced in the 
2014 version, World Health Organization, 2014). Adherence to the IMCI guidelines is low 
across geographical settings (Arifeen et al., 2005; Horwood et al., 2009; Baiden et al., 2011). 
Electronic IMCI versions (e-IMCI) provide a user-friendlier format and may thereby increase 
algorithm adherence and the consistency of clinical assessments (Mitchell et al., 2013; Shao et 
al., 2015). Beyond e-IMCI, electronic algorithms also have the potential to integrate more 
complex information while maintaining a simple user interface.  
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In addition to format-related barriers, IMCI implementation also faces content-related 
challenges. First, the algorithm lacks guidance for a significant proportion of febrile children, 
such as children without localizing symptoms (fever without source [FWS]). For such children, 
IMCI instructs to “give appropriate antibiotic treatment for an identified bacterial cause of fever” 
but provides no guidance on how to identify a bacterial cause of fever (World Health 
Organization, 2014). Before introduction of mRDT-based treatment, IMCI classified all children 
with fever presumptively as having malaria. Now that mRDTs are used, and lacking adequate 
diagnostics for bacterial infections, clinicians have practically exchanged antimalarial against 
non-selective antibiotic treatment for patients with negative mRDTs (D’Acremont et al., 2011). 
This has led to a tremendous overuse of antibiotics at the peripheral level (Risk et al., 2013). To 
address this challenge of diagnosing bacterial infections in children with FWS, a revised, IMCI-
based algorithm was developed (ALMANACH). It includes urine dipstick testing and a clinical 
predictor or rapid test for typhoid (Rambaud-Althaus, Shao, et al., 2015). However, these two 
diseases only represent a fraction of bacterial infections that would need to be considered 
(D’Acremont et al., 2014). Second, the IMCI algorithm relies on clinical symptoms alone which 
inherently lack diagnostic accuracy in detecting children in need for antibiotic treatment or 
referral for hospital-based supportive care (Thompson et al., 2012, Chapter 5). Host 
biomarkers, that can help identify children with bacterial infections, such as C-reactive protein 
(CRP) and procalcitonin (PCT), have not been considered within the IMCI strategy (Van den 
Bruel et al., 2011). The safety of using CRP or PCT cutoffs to decide on antibiotic prescription 
in children has never been evaluated. Besides the one trial in Vietnam that evaluated CRP for 
the use of CRP without provision of clinical guidance to guide antibiotic prescription in mild 
respiratory infections (Do et al., 2016), all studies of CRP and PCT in children have focused on 
analytical performance; none have assessed whether using these tests would change patient 
outcome. Furthermore, some point-of-care tests (POCTs) may help detect children with severe 
symptoms where clinical signs lack diagnostics accuracy: for example hemoglobin (Hb) testing 
can detect children with severe anemia in need of blood transfusions. Lastly, the diagnostic 
value of clinical signs that were included into IMCI (based on expert opinion and small 
derivation studies) has changed. The epidemiology context of infections has indeed shifted 
away from bacterial and parasitic infections towards viral infections (D’Acremont et al., 2014). 
Additionally, since development of IMCI 30 years ago, a considerable amount of novel 
evidence on such clinical signs has emerged, which has not been integrated into IMCI thus far 
(Thompson et al., 2012).  
Based on the challenges and opportunities identified we constructed a novel electronic patient 
management algorithm, e-POCT, onto the IMCI backbone. e-POCT is derived from the latest 
evidence of pediatric fever management based on studies both from low-and high-income 
e-POCT main randomized non-inferiority trial 76
settings (Chapter 5). It is built into an android application, which guides the clinician through the 
entire consultation and recommends management based on a few clinical elements, as well as 
POCTs. The POCTs used aim at triaging children with severe disease who require referral to a 
higher level of care (oxygen saturation [SaO2], heart rate, Hb), detecting malaria infection 
(mRDT) and distinguishing between bacterial and viral diseases (CRP, PCT). Given the 
innovative approach of the algorithm, we first sought to assess its safety when applied to 
children presenting with febrile illnesses in a low-resource-setting. Hence, the objectives of this 
study were to determine whether e-POCT was non-inferior in terms of clinical outcome to a 
validated electronic algorithm derived from IMCI (ALMANACH) when managing febrile illness in 
under-fives and to compare the proportion of antibiotic prescription and severe adverse events 
(deaths and secondary hospitalizations) between the two arms.  
 
7.3. Methods  
 
Study design 
This was a randomized (at patient level), open, controlled trial to investigate whether a novel, 
electronic algorithm using point-of-care testing (e-POCT) was not inferior in terms of clinical 
outcome to a validated electronic algorithm derived from IMCI (ALMANACH) when treating 
febrile infections in children under-five. The protocol for this trial and supporting CONSORT 
checklist are available as supporting information (S1 Appendix, S2 Appendix).  
Ethics 
The study protocol and related documents were approved by the Institutional Review Board of 
the Ifakara Health Institute and the National Institute for Medical Research Review Board in 
Tanzania, by the Ethikkommission beider Basel in Switzerland, and the Boston Children’s 
Hospital Ethical Review Board. An independent Data Monitoring Committee oversaw the study. 
The trial was registered in ClinicalTrials.gov, identifier NCT02225769.  
Participants 
This study was conducted in the city of Dar es Salaam, Tanzania. Malaria endemicity in this 
region is relatively low with about 10% of fever positive for malaria; transmission is perennial 
with a peak in the post-rainy season [15]. Consecutive patients presenting for acute care during 
normal business hours at the outpatient departments of 3 district hospitals and 6 health centers 
in Dar es Salaam were screened for eligibility. Recruitment sites were chosen to represent the 
pediatric outpatient population in Dar es Salaam. Inclusion criteria were: age 2 to 59 months, 
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history of fever for 7 days or less and axillary temperature ≥37.5 °C at presentation. Exclusion 
criteria were: weight less than 2.5kg, main complaint being an injury or acute poisoning, or 
previous medical care for the present illness. Children satisfying the inclusion and exclusion 
criteria were enrolled if the parent or guardian had received full information on the study and 
signed written informed consent.  
Randomization 
Patients were enrolled by the study clinicians and then randomized to one of the two 
management arms. They were individually randomized in blocks of four according to a 
computer-generated randomization list provided by an independent, off site researcher. Sealed, 
opaque forms were used for allocation concealment and opened only after the patient's 
enrollment. 
Interventions and Study Procedures  
The intervention consisted in having study clinicians using the e-POCT algorithm during the 
consultation to manage the patient. Children enrolled in the intervention arm were assigned to 
study clinicians using ePOCT during 2 weeks while children enrolled in the control arm were 
managed by other study clinicians using ALMANACH. In order to minimize a cluster effect at 
clinician level, clinicians then switched arms and thus algorithms every 2 weeks. Based on their 
assignment enrolled children were directed either to the e-POCT or ALMANACH clinician. 
The development and content of e-POCT are described elsewhere (Chapter 5). Compared 
to the IMCI-based algorithm (ALMANACH) used by study clinicians in the control arm, e-
POCT uses fewer clinical symptoms and signs. It rather relies on signs that can be 
measured objectively, hypoxemia and severe tachycardia, (oximeter), severe anemia (POC 
hemoglobinometer), hypoglycemia (POC glucometer), as well as host biomarkers of 
inflammation predictive of bacterial infection (elevated CRP using a rapid semi-quantitative 
lateral-flow test and elevated PCT using a POC immunoassay system). The main 
differences between the intervention and control algorithm, as well as IMCI, are summarized 
in Table 6.  
We chose ALMANACH, instead of the paper IMCI, as a control group, since ALMANACH is 
also built into an android support tool: we were interested in comparing the impact related to 
the content of the algorithms rather than the format and technological features. In addition, 
since our goal was to reduce antibiotic prescription while ensuring optimal clinical patient 
outcome, and since a reduction in both antibiotic prescription and clinical failures using 
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ALMANACH versus routine care has already been demonstrated, we regarded ALMANACH as 
the current gold standard in terms of antibiotic prescription and used it for the control arm [2].  
POCTs were performed on site as recommended by the algorithms. mRDT testing was done 
for all patients using either the SD BIOLINE Malaria Ag P.f/Pan™ (Standard Diagnostics Inc.) 
or CareStart Malaria HRP2™ (Access Bio, Inc.) assays. According to Tanzanian national 
guidelines, voluntary screening for human immunodeficiency virus (HIV) antibodies using the 
Determine™ HIV-1/2 (Alere Inc.) was offered to all patients when HIV test kits were available at 
the health facilities. In the e-POCT arm, Hb measurement (HemoCue 201+™ photometer) and 
oximetry (NONIN XPod™ with pediatric probe) was done in all patients. Children with clinical 
signs of lower respiratory tract infection (LRTI, Table 6) underwent CRP testing to decide on 
antibiotic prescription for pneumonia. For children with FWS, the e-POCT algorithm uses 
combined CRP and PCT testing (Table 6). For CRP testing we used a POC semi-quantitative 
assay (bioNexia CRPplus™, Biomérieux). PCT values were determined on site using the 
B.R.A.H.M.S PCT™ assay on the miniVIDAS™ platform (Biomérieux, Thermo Scientific). Using 
ALMANACH, children less than 2 years with FWS underwent urine dipstick testing, as well as 
older children with dysuria (Table 6). Children 2 years or older with FWS were tested for 
typhoid using the Typhidot assay™ (Reszon Diagnostics International Sdn. Bhd. Malaysia).  
 
Figure 15 Lab Manager performing POCTs at Rangi Tatu Health Center 
Follow-up 
All caregivers were asked to return with the child for scheduled visits on days 3 and 7, or at any 
time if the parent was concerned about the child’s condition. Patients cured at day 3 were 
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followed-up by phone only on day 7. Field workers traced patients missing the day 7 follow-up. 
For admitted patients, the scheduled visits were done in the hospital. Patients not cured before 
day 7 were treated again per the assigned algorithm, i.e the ePOCT algorithm if they were part 
of the intervention arm or ALMANACH if in the control arm. Patients not cured at day 7 were 
treated per the clinician’s judgment and another follow-up visit was performed at day 14 to 
assure that the child was cured. All patients were called by phone at day 30. When the 
algorithm recommended referral, a field worker escorted the patient to the nearest referral 
hospital. Patients were then admitted (or discharged home) and managed at the discretion of 
the responsible medical doctor in the referral hospital.  
Outcomes 
The primary outcome measure was the risk of clinical failure (Table 10) by day 7.  
Table 10 Defintion of clinical failure by day 7 (primary outcome measure) 
At any time between initial 
assessment and day 7: 
At day 3: At day 7: 
• Severe disease: 
- Coma 
- More than 2 convulsions 
within 24hr 
- Inability to drink or 
breastfeed 
- Hypoxemia 
- Severe tachypnea 
- Severe tachycardia 
 
• Clinical pneumonia: 
- History of cough and 
tachypnea 
- History of cough and lower 
chest indrawing 
• Significant dehydration 
 
• Fever or temperature ≥38°C 
• Clinical pneumonia: 
- History of cough and tachypnea 
- History of cough and lower 
chest indrawing 
• Diarrhea  
• Significant dehydration 
• Serious skin infection 
• A new significant symptom or 
sign related to the acute episode 
but not present at day 0. 
 
Clinicians were unaware of these criteria that were not used for patient management. To 
guarantee equal assessments of the primary outcome in both arms, the following additional 
measures were taken: Patients were considered “not cured” and treated again using the 
respective algorithms either i) if the caregiver considered that the child was still ill or ii) still had 
fever when assessed by trained field workers who did not know the content of the algorithms 
nor the criteria for clinical failure. The secondary outcome measures were the risk in antibiotic 
prescription at day 0 and by day 7, the risk of primary referrals at day 0, as well as of severe 
adverse events (secondary hospitalizations and death) by day 30. 
Sample Size and Statistical Analyses 
The sample size was computed for the primary analysis based on a 97.5% (one-sided) 
confidence interval (CI). To prove non-inferiority the lower limit of this CI was to be within 3%. 
This non-inferiority margin was considered as a clinically meaningful difference in clinical failure 
by day 7. The proportion of clinical failures by day 7 was estimated to be 10% in both arms 
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based on prior studies using ALMANACH in the same area (Shao et al., 2015). Assuming 80% 
statistical power, 3,140 patients were needed to show that the difference in clinical failure by 
day 7 between e-POCT and ALMANACH arm was within 3%.  
Interim analyses of the clinical failure rates were performed after inclusion of the first 200 and 
1,000 patients. A stopping rule was predefined as the absolute difference in clinical failure by 
day 7 of more than 5%. Both intention-to-treat (ITT) and per-protocol (PP) study populations 
were defined. The ITT population comprised all randomized patients (and per definition, 
patients who were lost for follow-up were treated as clinical failures). The PP population 
included all randomized patients who received the intervention and completed the day 7 
assessment (Figure 16).  
 
 
Figure 16 Patient flowchart 
Since this was a non-inferiority trial, and bias towards the null would tend to favor non-
inferiority, we used a PP analysis as our primary analysis. Accordingly, all results are displayed 
according to PP analyses if not stated otherwise. Risk difference (RD) and relative risks (RR) 
4729 assessed for 
1391 not eligible   
3192 randomized 
1586 analysed  1583 analysed   
1596 allocated to 
Per protocol 
1591 received control 
8 lost to follow-up by 
D7 
5 did not 
receive 
5 lost to follow-up by 
D7  
1591 received intervention 
1596 allocated to e-POCT 
Intention to Treat 
5 did not receive 
intervention 
e-POCT main randomized non-inferiority trial 81
with 95% CI were calculated to estimate the intervention effects on the main study outcomes. 
Stratified analyses with Mantel–Haenszel estimates for RR were performed to explore 
statistical heterogeneity of effect between health centers and clinicians (Joseph Newton et al., 
2009). For the primary outcome, mixed effects logistic regression was used to adjust for 
possible confounding covariates. Changes in odds ratio (OR) were used as approximated 
changes in RR since the primary outcome was rare. Kaplan-Meier survival analysis was used 
to compare the duration of fever between the two study arms.  
7.4. Results 
 
Recruitment and follow-up 
Overall, between December 2014 to February 2016, 4729 patients were screened, and 3192 
randomized (ITT population, Fig 1). Eight hundred fifty eight (27%) patients were recruited in 
the rainy season, 736 (23%) in the post-rainy season and the remaining 1598 (50%) in the dry 
season. The PP population consisted of 3169 patients (1598 in the intervention, and 1583 in 
the control arm): four patients in the intervention and 5 in the control group, respectively, 
withdrew consent after randomization. There was only one algorithm deviation in the e-POCT 
and none in the ALMANACH group. Five and 8 patients were lost to follow-up for the day 7 
outcome assessment in the e-POCT and control arm, respectively. The day 30-phone follow-up 
could not be completed in 20/1586 patients (1.3%) in the e-POCT arm and 25/1583 patients 
(1.6%) in the control arm. In both arms follow-up intervals for the day 3 and day 7 outcome 
assessments were 3 (IQR 3-3, range 2-5) and 7 (IQR 7-7, range 6-12) days, respectively. 
Baseline characteristics did not differ between the two groups (Table 11).  
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Table 11 Baseline Characteristics 
Characteristic 
 
N 
ePOCT  
n (%) 
ALMANACH  
n (%) 
Demographic 
   
Male Sex 3192 891 (56) 875 (55) 
Age group 3192   
 2 – 11 months  686 (43) 721 (45) 
 12 – 23 months  553 (35) 501 (32) 
 ≥24 months  357 (22) 374 (23) 
Primary caregiver other than mother 3113 64 (4) 66 (4) 
Mother’s highest grade of education 3106   
 None  137 (9) 152 (10) 
 Primary  1060 (68) 1015 (65) 
 Post-primary  354 (23) 388 (25) 
Number of children in household** 3100 2 (1-3) 2 (1-3) 
Medical History 
   
Main reasons for consultation 3192   
 Fever only  214 (13) 216 (14) 
 Cough  917 (57) 890 (56) 
 Rhinorrhea/nasal congestion  669 (42) 696 (44) 
 Diarrhea  313 (20) 328 (21) 
 Vomiting  312 (20) 286 (18) 
Duration of fever 3180   
 1 day or less  1004 (63) 982 (62) 
 2-4 days  569 (36) 591 (37) 
 5 days or more  16 (1) 18 (1) 
Duration of cough 1827   
 2 days or less  629 (68) 606 (67) 
 3-6 days  282 (31) 292 (32) 
 7 days or more  12 (1) 6 (1) 
Clinical signs 
   
WFA z-score$  3189 -0.8 (1.3) -0.7 (1.3) 
WFA z-score <-3z or MUAC<11.5cm and age >6 months$ 3189 64 (4) 50 (3) 
Respiratory rate** 3180 41 (36-49) 41 (36-51) 
Heart rate* 3142 145 (17) 143 (16) 
Tachypnea per IMCI $$ 3180 419 (26) 416 (26) 
Severe symptom per IMCI $$$ 3192 22 (1) 23 (1) 
Numbers are displayed as % (n) if not marked otherwise: *mean (SD); **median (IQR); $ WHO 2006 growth curve 
[22];   
$$ 
<12 months and RR≥50/min, ≥12 months and RR≥40/min; $$$ positive meningeal signs, convulsion or history of 
convulsion, lethargy, severe anemia, HIV positive with chest indrawing, severe malnutrition$ with complications 
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Clinical Failure and Severe Advert Events 
Table 12 shows the primary and secondary study outcomes.  
Table 12 Primary and secondary study outcomes 
 
e-POCT  
% (n/N) 
ALMANACH 
 % (n/N) 
Risk Difference 
(95% CI) 
Risk Ratio  
(95% CI) 
Primary Outcome     
Clinical Failure by day 7 (PP) 2.3 (37/1586) 4.1 (65/1583) -1.7 (-3.0, -0.5) 0.57 (0.38-0.85) 
Clinical Failure by day 7 (ITT) 2.9 (47/1596) 4.9 (78/1596) -1.9 (-3.3, -0.6) 0.60 (0.42-0.86) 
Secondary Outcomes (PP) 
    
Primary referrals 6.6 (104/1586) 2.9 (46/1583) 3.6 (2.2, 5.1) 2.26 (1.61, 3.17) 
Antibiotic prescription at day 0 11.5 (182/1586) 29.7 (470/1583) 
-18.2 (-21.0, -
15.5) 0.39 (0.33, 0.45) 
Severe adverse events by day 
30 0.6 (10/1586) 1.5 (24/1583) -0.9 (-1.6, -0.2) 0.42 (0.20, 0.87) 
 Secondary admissions 0.4 (7/1586) 1.2 (19/1583) -0.8 (-1.4, -0.1) 0.37 (0.15, 0.87) 
 Deaths  0.2 (3/1586) 0.4 (6/1583) -0.2 (-0.6, 0.2) 0.50 (0.12, 2.0) 
 
In the PP population, 2.3 % (37/1586) of patients experienced clinical failure by day 7 using e-
POCT group versus 4.1% (65/1583) of patients treated with the control algorithm (RD -1.7, 95% 
CI -3.0, -0.5, RR 0.57 95% CI 0.38-0.85). There was a 43% reduction in relative risk for clinical 
failure in the e-POCT arm compared to the control arm. The non-inferiority plot of clinical failure 
in the ITT and PP populations is displayed in Figure 17.  
 
Figure 17 Non-inferiority plot comparing clinical outcome by day 7 in the intervention and control arm. 
-4 -3 -2 -1 0 1 2 3 4
ITT
PP
e-POCT better ALMANACH better 
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As depicted in Table 13, the main reduction in clinical failure between the two algorithms 
occurred by day 3 (RR 0.39, 95% CI 0.22, 0.67)—there was no significant difference in clinical 
failure from days 4-7 (RR 0.93, 95% CI 0.51, 1.72).  
Table 13 Details of clinical failure by day 7 
 e-POCT  ALMANACH 
Criteria for clinical failure Clinical Failure 
Secondary 
Admission Death  
Clinical 
Failure 
Secondary 
Admission Death 
Day 0-3: 
       
Coma/convulsion 1 - -  5 1 5 
Hypoxemia/severe tachypnea 1 1 -  7 2 1 
Other severe symptom 5 4 1  9 6 - 
Cough and tachypnea/ chest 
indrawing 10 2 1  23 3 - 
Total at day 0-3 % (n/N) 1.1 (17/1586) 0.4  (7/1586) 
0.1 
(2/1586)  
2.8 
(44/1583) 
0.8 
(12/1583) 
0.4 
(6/1583) 
Day 4-7: 
       
Hypoxemia/severe tachypnea 1 - 1  - - - 
Severe anemia - - -  1 1 - 
Persistent fever 13 - -  16 5 - 
Cough and tachypnea/ chest 
indrawing 3 - -  2 - - 
Diarrhea/vomiting 2 - -  1 - - 
Significant skin infection 1 - -  1 1 - 
Total at day 4-7 % (n/N) 1.3 (20/1569) 0 (0/1579) 
0.1 
(1/1584)  
1.4 
(21/1539) 
0.4 
(7/1571) 
0 
(0/1577) 
 
The crude OR (0.56, 95% CI 0.37-0.84) for clinical failure by day 7 was similar to the adjusted 
OR (0.55, 95% CI 0.36-0.84) when adjusting for significant covariates and random effects (age, 
axillary temperature, weight for age z-score (World Health Organization, 2006), respiratory rate, 
clinician, and health center). We did not note statistical heterogeneity between health centers or 
clinicians for both primary and secondary outcome measures. There was a 68% reduction in 
relative risk of severe adverse events (secondary hospitalizations and deaths) in the e-POCT 
arm (0.6%, 10/1586) compared to the control arm (1.5%, 24/1583), (RR 0.42, 95% CI 0.20, 
0.87). 0.5% (8/1586) of patients in the e-POCT arm versus 1.4% (22/1583) of children in the 
ALMANACH arm developed severe symptoms during follow-up (RR 0.36, 95% CI 0.16, 0.81), 
Table 13. Within both algorithms, having a severe classification at D0 was associated with a 
higher, and having a likely viral infection classification with a lower risk of clinical failure, 
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respectively (Table 14). Within the ALMANACH algorithm, patients with a clinical pneumonia 
classification also had a higher risk of clinical failure (Table 14).  
Table 14 Association between clinical failure and disease classification. 
 e-POCT ALMANACH 
Algorithm classification Clinical failure 
by day 7 % 
(n/N) 
RR (95% CI) 
Clinical failure 
by day             7 
% (n/N) 
RR (95% CI) 
Severe disease 5.8 (6/103) 2.79 (1.19, 6.53) 23.6 (13/55) 6.9 (4.03, 11.98) 
Clinical pneumonia -  6.4 (21/330) 1.81 (1.09. 3.00) 
Bacterial, respiratory 
infection 0 (0/10) NA -  
Viral, respiratory infection 3.0 (13/429) 1.46 (0.75, 2.84) -  
Upper respiratory infection 3.1 (12/391) 1.47 (0.05, 2.89) 3.7 (20/542) 0.85 (0.51, 1.43) 
Gastrointestinal disease with 
dehydration 2.4 (4/169) 1.02 (0.36, 2.83) 4.7 (14/296) 1.19 (0.67, 2.13) 
Skin infection 2.7 (2/75) 1.13 (0.28, 4.61) 1.4 (1/69) 0.34 (0.05, 2.44) 
FWS, likely bacterial 
infection 1.9 (1/52) 0.82 (0.11, 5.86) 4.3 (3/70) 1.05 (0.34, 3.25) 
FWS, likely viral infection 0.6 (2/349) 0.20 (0.05, 0.84) 1.1 (4/357) 0.23 (0.08, 0.62) 
Uncomplicated malaria 0 (0/166) NA 2.8 (5/180) 0.65 (0.27, 1.61) 
Antibiotic treatment 
recommended (non-severe 
disease) 
1.3 (1/79) 0.59 (0.08, 4.29) 5.8 (24/415) 2.30 (1.35, 3.92) 
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Days to resolution of fever was not different between the two arms (Figure 18).  
 
Figure 18 Days to resolution of fever 
 
Identification of patients with severe disease at inclusion 
The results of the POCTs are summarized in Table 15 and the algorithm classifications in Fig 4.  
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Table 15 Results of point-of-care tests (POCTs) 
Characteristic 
 
N 
e-POCT  
% (n/N) 
ALMANACH  
% (n/N) 
POCTs for identification of patients with 
severe disease 
 
  
SaO2 <90% 1591 0.3 (4/1591) - 
Severe tachycardia 1591 0.4 (6/1591)  
Hemoglobin (g/dL)* 1591 9.7 (1.5) - 
Hemoglobin <6 g/dL 1591 1.3 (20/1591) - 
POCTs for Identification of patients in 
need for antibiotic treatment 
 
  
CRP (mg/L) 823   
 0-9  63.4 (522/823) - 
 10-39  28.4 (234/823) - 
 40-79  5.8 (48/823) - 
 ≥80  2.3 (19/823) - 
PCT (µg/L) 407   
 <0.5  70.3 (286/407) - 
 0.5-0.9  8.6 (35/407) - 
 1.0-1.9  5.2 (21/407) - 
 2.0-3.9  3.9 (16/407) - 
 ≥4.0  12.0 (49/407) - 
CRP ≥80 mg/L and PCT ≥4.0 µg/L 406 0.7 (3/406)   
Positive Typhidot, D0 152 - 0.7 (1/153) 
Positive urine dipstick** 370  13.5 (50/370) 
Other POCTs 
   
Malaria RDT positive 3182 12.0 (191/1591) 11.6 (186/1591) 
HIV-1/2 antibody positive 2917 1.4 (21/1466) 1.1 (16/1451) 
Numbers are displayed as % (n) if not marked otherwise: *mean (SD 
Figure 19 (next page): Algorithm classifications and reasons for antibiotic prescription at day 0. A: Non-
severe classifications, e-POCT; B: Non-severe classifications, ALMANACH; C: Severe classifications, e-
POCT; D: Severe classifications, ALMANACH; E: Percent of patients with antibiotic prescription at day 0 
with reasons. Please note that one patient may have several disease classification
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A  e-POCT 1483 patients, 1628 diagnoses B  ALMANACH 1528 patients, 1829 diagnoses 
C  e-POCT 103 patients, 128 diagnoses D  ALMANACH 55 patients, 55 diagnoses 
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Compared to the control algorithm e-POCT categorized around twice as many patients as 
having severe disease (and recommended referral) at day 0: 6% (103/1586) versus 3% 
(55/1583, Figure 19).  A large proportion of this difference was attributable to the severe 
malnutrition and severe anemia classifications: e-POCT identified 3.5% (55/1586) of patients 
with severe malnutrition, ALMANACH 0.1% (1/1583), p<0.001. With e-POCT 1.3% (20/1586) 
were classified as severe anemia using Hb testing versus 0.3% (5/1583) based on clinical 
symptoms in the ALMANACH arm (p<0.003).  
Antibiotic prescription 
In the intervention arm, 11.5% (182/1586) participants were prescribed an antibiotic treatment 
at day 0 versus 29.7% (470/1583) in the control arm (RR 0.39, 95% CI 0.33, 0.45, Table 12). 
An additional 4% (53/1404) and 4% (49/1113) of patients who had not been prescribed an 
antibiotic at day 0, received antibiotics between day 1 and day 6 in the e-POCT and control 
arms, respectively. Out of these antibiotic prescriptions after the initial consultation, 47% 
(25/53) e-POCT and 65% (32/49) of ALMANACH patients received antibiotics through 
consultation with non-study physicians. The majority (57%, 103/182) of antibiotic prescriptions 
in the e-POCT arm resulted from severe classification (Figure 19). In the control arm, (non-
severe) clinical pneumonia was the leading cause for antibiotic treatment (70%, 330/470) while 
a severe classification was the reason for 12% (55/470) of these prescriptions (Figure 19). In 
contrast to that, non-severe respiratory infections were the reason for only 6% (10/182) of 
antibiotic prescriptions in the e-POCT arm (Figure 19). Importantly, among patients with non-
severe classification, antibiotic prescription was associated with clinical failure in the 
ALMANACH arm, but not in the e-POCT arm (Table 14).  
Use of POCTs in the e-POCT arm 
0.3% (4/1591) of children were detected as having hypoxemia, 0.4% (6/1591) severe 
tachycardia and 1.3% (20/1591) severe anemia (Table 15). Among children with non-severe 
signs and symptoms, 2.3% (19/1591) met the CRP cutoff criterion (≥80mg/L) for antibiotic 
treatment: out of the 19 children with high CRP (≥80mg/L), 53% (10) presented with respiratory 
symptoms and 47% (9/19) had fever without localizing signs. Another 2.9% (46/1591) of 
patients with fever without localizing symptoms and low CRP values had PCT values of ≥4.0 
µg/L, hence met the criterion for antibiotic treatment. In sum, a total of 13% (52/401) of children 
with fever without localizing symptoms were classified as having a likely bacterial infection 
using PCT and CRP testing in e-POCT, compared to 17% (70/424) in the ALMANACH arm 
using clinical signs, urine dipstick testing, and a rapid typhoid diagnostic test (Figure 19). There 
was no statistically significant difference in the risk of clinical failure in patients without 
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localizing symptoms between the two arms: 0.7% (3/401) for e-POCT versus 1.4% (6/415) for 
ALMANACH (RR 0.52, 95% CI 0.13, 2.05).  
 
7.5. Discussion  
 
In this multicenter non-inferiority, randomized controlled trial including 3192 children with febrile 
illnesses in Dar es Salam Tanzania, we showed that e-POCT, a novel patient management 
algorithm using host biomarker POCTs, was non-inferior to a reference electronic IMCI-based 
algorithm (ALMANACH) in terms of clinical outcome. e-POCT actually achieved a reduction of 
43% in the proportion of clinical failure by day 7 and of 58% in the proportion of severe adverse 
events compared to ALMANACH while substantially lowering the proportion of antibiotic 
prescription from 30% to 11%. e-POCT categorized more patients as having severe disease on 
day 0. Using e-POCT, the pattern of antibiotic prescription was shifted away from non-severe 
respiratory infections towards patients with severe disease when compared to the IMCI-based 
control algorithm.  
Though the study was designed as a non-inferiority trial, the very low attrition rate makes a 
type-I error unlikely when interpreting the results towards superiority. One could argue that a 
superiority trial would have been more adequate from the start. However we rather opted for a 
non-inferiority design, since it was already been demonstrated that ALMANACH was superior in 
terms of clinical outcome when compared to routine care (Shao et al., 2015). We hence did not 
expect an additional benefit in terms of clinical outcome. Rather, given the innovative features 
of e-POCT, we wanted to assess its safety and evaluate whether e-POCT would provide 
additional benefits in terms of detection of children with severe illness and reduction of 
antibiotic prescription compared to ALMANACH. We used an individual randomization scheme, 
instead of cluster randomization, since the available clusters in the study region were limited. 
We were concerned about bias from a strong inter-cluster correlation. Given that study 
clinicians swapped algorithms every two weeks, and given that the electronic format 
guaranteed full algorithm adherence, the overall concern about a bias towards the null, was 
low. The criteria used to define clinical failure was based on previous pneumonia management 
trials (Hazir et al., 2011; Fox et al., 2013). The validity of some of the criteria used for non-
severe disease classifications should certainly be re-evaluated for future trials. For example 
one could argue that having persistent “clinical pneumonia” on day 3 actually does not 
represent clinical failure but may rather be the natural course of illness of a viral respiratory 
tract infection (Thompson et al., 2013). Similarly, patients with persistent fever after several 
days have in fact a high likelihood of having a viral infection, such as Epstein-Barr virus or 
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Cytomegalovirus infection (Begovac, Soldo and Presecki, 1988). We included febrile children 
only, instead of all children presenting with acute medical complaints, since children without 
fever have a very low risk of having an infection that requires antibiotics (Shao et al., 2015). 
Consequently, the results should be generalizable even more to non-febrile children.  
In terms of using host biomarkers of inflammation for the management of febrile illness, this 
was the first trial that assessed the safety of using CRP and/or PCT testing to decide on 
antibiotic prescription in children in a resource-limited country. CRP and PCT testing in our 
study even improved clinical outcome. One recent open, randomized trial evaluated the impact 
of using a CRP POC testing in Vietnam among patients with respiratory symptoms, including 
287 children less than 6 years of age (Do et al., 2016). This trial was underpowered to detect 
differences in clinical outcome as sample size calculations were done based on reduction of 
antibiotic prescription. Several randomized trials have assessed CRP and PCT for deciding on 
antibiotic prescription in respiratory infections in adults (Burkhardt et al., 2010; Schuetz, Briel 
and Mueller, 2013; Aabenhus et al., 2014). A series of studies assessed the accuracy of CRP 
and PCT in diagnosing bacterial infections in children in outpatient setting in well-resourced 
settings (Van den Bruel et al., 2011; Lubell et al., 2015). These studies found moderate 
diagnostic accuracy of both CRP and PCT. However, one has to bear in mind that diagnostic 
gold standards are often imperfect. For example, for pneumonia, the most recognized current 
gold-standard is “WHO endpoint pneumonia”, i.e. consolidation on chest radiograph (Erdman et 
al., 2015). However, only a (undefined) proportion of WHO endpoint pneumonia is bacterial in 
origin. Besides the one trial in Vietnam that included both children and adults, all studies of 
CRP and PCT in children have focused on analytical performance; none have assessed 
whether using these tests would change patient outcome.  
In terms of impact on antibiotic prescription when using host biomarkers POCTs, a much 
smaller effect in terms of reduction in antibiotic prescription can be expected when these 
POCTs are provided without guidance (i.e. performed on all patients). For example, in the 
Vietnam trial, the reduction of antibiotic prescription observed was from 74% to 68% by day 14 
(Do et al., 2016). Such small reductions in prescription rates could be achieved on clinical 
grounds alone: in our study 43% (392/920) of patients in the intervention arm with cough did 
not meet clinical criteria for CRP testing and were categorized as having an upper respiratory 
infection. This was also demonstrated in a cluster-randomized trial assessing the use of 
ALMANACH (Shao et al., 2015). To make best use of CRP and PCT testing we decided to 
include them in a patient management tool. It guided clinicians on which patient to select for 
testing and how to use the result in the clinical context. We also employed higher cut-offs 
(80mg/L for CRP and 4ug/L for PCT) to rule-in patients that likely require antibiotic treatment 
(instead of ruling out patients with a very low probability of having a bacterial infection using 
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lower CRP cutoffs, such 10mg/L in the Vietnam trial, Do et al., 2016). This was based on the 
analyses of host biomarkers results in the Tanzanian etiology of fever study (Erdman et al., 
2015) and on the fact that patients in outpatient settings have a very low pre-test probability of 
having a bacterial infection (D’Acremont et al., 2014). We indeed selected few patients that 
required antibiotic treatment with this strategy: 1.2% (10/833) of patients with non-severe 
respiratory classifications, and 13% (53/402) of patients with fever without localizing symptoms.  
e-POCT also uses POCTs for detecting children with severe disease: an oximeter to detect 
hypoxemia and severe tachycardia, and a POC hemoglobinometer to identify children with 
severe anemia. e-POCT indeed classified around twice as many children as having severe 
disease than the control algorithm. However, this was only partially due to the POCTs 
employed: only very few children with hypoxemia and/or severe tachycardia were identified. 
The use of oximeters as part of IMCI has been advocated. However, their utility at peripheral 
health care level should be assessed further (Enoch, English and Shepperd, 2015). e-POCT 
diagnosed 4 times as many patients with severe anemia than the IMCI-based control algorithm 
(and only 1/5 patients in the control algorithm with severe anemia diagnosis actually had a low 
Hb value). This confirms findings from previous studies that severe anemia cannot be detected 
using clinical signs (Chalco et al., 2005). However, severe anemia, in turn, is an important risk 
factor of death from severe infections and associated with severe infections (Brabin, Premji and 
Verhoeff, 2001; Calis et al., 2008). Given that children cannot be preselected for Hb testing 
based on clinical elements, all children would have to undergo Hb testing to detect the few 
children with severe anemia. This strategy will only become feasible once low-cost Hb tests can 
be deployed to the peripheral health care level, if possible that can be directly connected to 
tablets. e-POCT also detected and referred more than twenty times as many children with a 
severe malnutrition classification using combined weight-for-age (WFA) and mid-upper arm 
circumference (MUAC) testing (compared to clinical signs in the control arm). Severe 
malnutrition is recognized as an important risk factor for severe outcome from infections (Reed 
et al., 2012; Jain, Sarathi and Jawalekar, 2013; Gowraiah et al., 2014). Overall, the adequacy 
of the referral criteria could not be assessed in this study, which is certainly a limitation. This is 
because the hospital-based care is often low in quality and non-standardized. As a result 
neither admission decisions nor admission diagnoses could hence be used as a diagnostic gold 
standard (English et al., 2004).  
Overall, our data provides evidence that e-POCT not only reduced the proportion of antibiotic 
prescription but also increased the targeting of children in need for antibiotic treatment. 
Antibiotic treatment was indeed shifted away from non-severe respiratory infections towards 
severe disease classifications. Furthermore, in addition to the overall improved clinical outcome 
using e-POCT, antibiotic prescription was associated with clinical failure in the control arm, but 
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not in the e-POCT arm. This may be because children who received unnecessary antibiotic 
prescription in the control arm suffered from antibiotic side effects, or the neglect of other 
important supportive treatments for viral infection (such as bronchodilator treatment or 
rehydration).  
Our study has several limitations that need to be addressed in further study. First, this was a 
multi-center but single region study, which limits the generalizability of our findings. Given the 
innovative character of e-POCT we opted for a study setting where good oversight and 
pediatric back up could be guaranteed. Key algorithm components should be re-assessed in 
different geographical settings and populations with higher HIV- and malnutrition rates. Second, 
there are concerns of using CRP testing to detect bacterial infections in patients with malaria 
(malaria infection in itself will lead to high levels of CRP and PCT, Naik and Voller, 1984; Lubell 
et al., 2015). However, antibiotic prescription is generally not indicated in patients with 
uncomplicated malaria. Bacterial co-infections are nevertheless common in patients with 
severe malaria (Church and Maitland, 2014). Using enhanced severity criteria, such as Hb 
testing, may actually improve detection of patients with severe malaria and may thus help to 
identify children in need for concomitant anti-malarial and antibiotic treatment. Third, 
equipment-based treatment, rather than treatment based on clinical grounds alone, are faced 
with challenges in terms of supply chain, and possibly cost. However, antibiotic over-
prescription is also associated with costs on an individual and societal level (Lim et al., 2006). 
Finally, the true utility of e-POCT can only be evaluated through open implementation studies 
since adherence to the algorithm will be an important factor to make use of its advantages in 
terms of clinical outcome and antibiotic prescription.  
 
7.6. Conclusion 
 
e-POCT, an innovative electronic algorithm using host biomarker point-of-care tests has the 
potential to improve the clinical outcome of children with febrile illnesses in low-resource 
settings while reducing antibiotic use through improved identification of children with severe 
infections and increased targeting of children in need for antibiotic prescriptions. Using CRP 
and PCT cutoffs, integrated into an overall disease management algorithm, for the 
management of children with respiratory infections and FWS was safe in terms of clinical 
outcome. Notwithstanding the need for replication of these findings in other geographical 
settings and further implementation studies, our results provide first evidence that such an 
innovative patient management approach is beneficial. Electronic algorithms in general are an 
important prospect to increase compliance to IMCI—the integration of POCTs would make 
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even better use of such technologies. A key advantage of using host biomarkers tests, as 
compared with a series of disease etiology tests, is that such an approach is likely more robust 
to seasonal and geographic variations in disease etiology. POCTs should include both tests for 
identification of patients with severe disease (for example with severe anemia) and for 
detection of children with bacterial infections (such as CRP and PCT). To make best use of 
these POCTs, they should be integrated into a patient management tool that will help not only 
to select patient subgroups for which testing is useful, but also to help interpret results within an 
overall patient assessment. This will also allow the continuation of an integrated approach to 
the treatment of childhood infections as it has been implemented through IMCI.  
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8.1. Summary 
 
Background 
The safety and efficacy of C-reactive protein (CRP)-based antibiotic prescription in febrile 
children at risk for pneumonia has not been assessed.  
Methods 
This was a multi-center, open-label randomized controlled trial in nine primary health care 
centers in Dar es Salaam, Tanzania. Children aged 2-59 months with fever and cough and 
without severe disease requiring hospital referral were enrolled as part of a larger non-
inferiority trial evaluating a novel electronic algorithm (e-POCT). Patients were randomized 
1:1 to either a CRP-based strategy or the World Health Organization strategy for 
classification of bacterial pneumonia. In the intervention arm antibiotic was given in case of 
tachypnea and a CRP of greater than 80mg/L. The primary outcome was clinical failure by 
day 7. Secondary outcomes were antibiotic use, and severe adverse events (secondary 
hospitalization or death). All analyses were per-protocol. ClinicalTrials.gov, identifier 
NCT02225769 
Findings 
From December 2014 to February 2016, 3192 children were randomized into the main 
study; 1727 non-severe respiratory disease (intervention: 868, control: 859). 0·4% (7/1727) 
were lost to follow-up by day 7. The proportion of clinical failure by day 7 was 2·9% (25/865) 
in the intervention versus 4·9% (42/855) in the control algorithm (RR 0·59, 95% CI 0·36, 
0·96, RD……). 2·3% (20/865) of children in the intervention versus 40·6% (347/855) in the 
control arm received antibiotics at day 0 (RR 0·06, 95% CI 0·04, 0·09). There were fewer 
severe adverse events using the C-reactive protein based strategy; 0·5 % (4/865) versus 
1·5% (13/855, RR 0·30, 95% CI: 0·10, 0·93).  
Interpretation 
CRP testing, integrated into a clinical decision algorithm, has the potential to improve 
outcome in febrile children with respiratory infections while substantially reducing antibiotic 
prescription. Future implementation studies should assess this strategy in routine care.   
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8.2. Research in context 
 
Evidence before this study 
Respiratory infections are the most important drivers for antibiotic over-prescription in 
children, especially in low-resource setting. In a 2014 Cochrane review, Aabenhus et al. 
systematically reviewed randomized controlled trials (RCTs) on the use of C-reactive protein 
(CRP) to decide on antibiotic prescription. Studies in children were lacking. We searched 
MEDLINE, Embase with a combination of “respiratory tract infection”, “antibiotic”, “C-reactive 
protein”, and “child/pediatric”. We found one additional RCT in Vietnam that included 287 
children less than six years of age. C-reactive protein testing resulted in a moderate 
reduction in antibiotic prescription in children at low risk for pneumonia (without tachypnea).  
Added value of this study 
This is the first RCT, both in low-and high-resource settings, designed to assess the clinical 
outcome of children with respiratory tract infections when treated based on an antibiotic 
prescription strategy using point-of-care CRP. It is also the first trial that included children 
with significant risk of having bacterial pneumonia (children with tachypnea). Point-of-care 
CRP testing included into a clinical algorithm improved clinical outcome in children 
presenting with febrile respiratory infections in low-resource setting, while substantially 
reducing the amount of antibiotic prescription, when compared to the World Health 
Organization-based strategy.  
Implication of all the available evidence 
This C-reactive protein based strategy has the potential to improve clinical outcome in 
children with febrile respiratory infections and to increase rational use of antibiotics. 
Evaluating of such strategies in routine care, and outcome-based studies in high-resource 
settings should be the objective of future research. 
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8.3. Introduction 
 
Respiratory tract infections, including upper respiratory tract infections (URTI), pneumonia, 
and viral lower respiratory tract infections (LRTI) are the most important drivers for antibiotic 
over-use in children, contributing to the increasing rate of antibiotic resistance. Over-
prescription is in particular an issue in low-resource settings where antibiotics are now 
increasingly available. Here, health workers lack adequate diagnostic support and prescribe 
antibiotics indiscriminately to the vast majority of children—to be ‘on the safe side’ (Risk et 
al., 2013). Despite this non-differential approach to antibiotic prescription, childhood mortality 
from respiratory infections remains high(Liu et al., 2014). Over-relying on antibiotic treatment 
has resulted in the neglect of the correct management of viral respiratory infections, such as 
reactive airway disease (Nantanda et al., 2013).  
The majority of respiratory infections are of viral etiology (D’Acremont et al., 2014), with 
introduction Haemophilus influenzae type B (HiB) and pneumococcal conjugate vaccines 
(PCV) the proportion of bacterial pneumonia has decreased further (Lucero et al., 2009). 
Accordingly, in the outpatient setting, very few children require antibiotic treatment(Hazir et 
al., 2011; Shao et al., 2015). The diagnosis of bacterial pneumonia relies principally on 
clinical criteria (e.g., cough, dyspnea, fever) and chest radiography to document lung 
infiltrates (McIntosh, 2002). In low-resource settings, since radiography is not readily 
available, the diagnosis of bacterial pneumonia is based clinical features only (fast 
breathing, chest indrawing and auditory wheezing), as recommended by the World Health 
Organization (WHO, World Health Organization, 2014). However, data on the usefulness of 
these tools has been contradictory: other than wheezing, clinical features, including 
respiratory rate (RR), were largely uniform across the spectrum of microbiological etiology in 
a series of studies (McIntosh, 2002; Rambaud-Althaus, Althaus, et al., 2015). Similarly, 
though it has been shown through vaccines trials that radiographic lung infiltrates are 
correlated with bacterial pneumonia (Klugman, Madhi and Albrich, 2008), several studies 
have shown that radiographic infiltrate cannot be used to distinguish between bacterial and 
viral etiology (McIntosh, 2002).  
C-reactive protein (CRP), available at point-of-care (POC), has been proposed as a non-
microbiological test to diagnose childhood bacterial pneumonia. The reported diagnostic 
accuracy varied widely across studies with sensitivities of 35%-100% at specificities of 40-
100%, depending on the cut-off and gold standard used (Flood, Badik and Aronoff, 2008; 
Erdman et al., 2015). These diagnostic accuracy studies were generally limited by the lack 
CRP-guided antibiotic therapy for respiratory infections 99
of an acceptable gold standard for bacterial pneumonia (Lynch et al., 2010). Clinical 
outcome studies are lacking. In adults, as reviewed in a 2014 systematic review, CRP has 
been shown to reduce antibiotic prescription for respiratory infections in primary care, 
without differences in clinical recovery (Aabenhus et al., 2014). Its use has started to be 
explored in children (Do et al., 2016) but neither controlled studies sufficiently powered to 
detect differences in clinical outcome, nor studies in children with clinical signs suggestive of 
pneumonia have been performed.  
We developed a two-step approach for diagnosis of bacterial pneumonia at outpatient level 
using cough, fever, and refined RR-cutoffs as an initial ‘rule-out’ step, followed by POC CRP 
testing as a ‘rule-in’ step. This was part of a larger effort to improve management of febrile 
illnesses in children in low-resource settings through the development and evaluation of a 
novel electronic algorithm (e-POCT), that uses POC testing (Chapter 3). Within the 
algorithm, CRP testing was not used to decide on antibiotic treatment in children with severe 
disease or severe malnutrition requiring hospital referral. This was because, first, children 
with severe disease likely benefit from antibiotic treatment and are rare in primary care 
(Shao et al., 2015). Second, children with severe malnutrition have distinct inflammatory 
responses that have not been adequately characterized (Page et al., 2013). We hence 
concluded that the risk of missing bacterial infections outweighed the possible benefit in 
terms of reduction of inappropriate antibiotic prescription.  
The aim of this analysis were to determine whether using POC CRP-testing, integrated into 
a clinical algorithm, to decide on antibiotic prescription in under-fives presenting with febrile 
respiratory symptoms, can reduce unnecessary antibiotic prescription, while being non-
inferior in terms of clinical outcome, compared to the WHO-recommend diagnostic and 
treatment approach.  
 
8.4. Methods 
 
Study design 
This was a subgroup analysis of an individually randomized, open, controlled trial to 
investigate whether a novel, electronic algorithm using POCTs (e-POCT) was not inferior in 
terms of health outcomes to a validated electronic algorithm derived from IMCI 
(ALMANACH) when treating febrile infections in under-fives. The study was conducted at 
nine public outpatients clinics in Dar es Salaam, Tanzania, from December 2014 to March 
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2016. Recruitment sites were chosen to represent the pediatric outpatient population in Dar 
es Salaam. The overall methods and results of this trial are reported elsewhere (Chapter 7).  
The study protocol and related documents were approved by the Institutional Review Board 
of the Ifakara Health Institute and by the National Institute for Medical Research Review 
Board in Tanzania, by the Ethikkommission beider Basel in Switzerland, and by the Boston 
Children’s Hospital Ethical Review Board.  
Participants 
Consecutive patients presenting for care during normal business hours were screened for 
eligibility. Inclusion criteria were: age two to 59 months, history of fever for more seven days 
or less, and axillary temperature ≥37·5°centigrade at presentation. Exclusion criteria were: 
weight less than 2·5kg, main complaint injury or acute poisoning, and previous medical care 
for the present illness. Children satisfying the inclusion/exclusion criteria were enrolled if the 
guardian signed a detailed written informed consent. For this subgroup analysis, we included 
all children with febrile non-severe respiratory symptoms. This comprises all children 
presenting with cough but without severe symptoms (convulsion or positive meningeal signs, 
hypoxemia, cyanosis, severe respiratory distress, unable to tolerate oral liquids, severe 
dehydration, severe anemia, severe acute malnutrition, Figure 20). 
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Figure 20 Trial profile 
Randomization 
Patients were enrolled by the study clinicians and then randomized to one of the 
management arms. Patients were individually randomized in blocks of four by the study 
clinicians according to a computer-generated randomization list provided by an independent, 
off site researcher. Sealed, opaque forms were used for allocation concealment and opened 
only after the patient's enrollment.  
Procedures 
The intervention consisted in having study clinicians using the e-POCT algorithm during the 
consultation to manage the patient. Children enrolled in the intervention arm were assigned 
to two study clinicians using e-POCT while two other study clinicians using ALMANACH 
managed children enrolled in the control arm. In order to minimize a possible type I error 
4729 patients 
assessed for eligibility 
3192 enrolled 
1391 ineligible 
146 not 
recruited 
3192 randomised 
1596 assigned e-POCT 1596 assigned 
 
859 included in 
modified intention-to-
treat analysis 
 
 
 
 
868 with non-severe 
respiratory symptoms 
868 included in 
modified intention-to-
treat analysis 
5 were not treated per e-
POCT 
5 were not treated per 
ALMANACH 
723 with severe 
symptoms or without 
732 with severe 
symptoms or without 
859 with non-severe 
respiratory symptoms 
865 completed day 
seven follow-up (per 
protocol analysis) 
855 completed day 
seven follow-up (per 
protocol analysis) 
3 lost to follow-up 4 lost to follow-up 
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through differences in the care between clinicians, clinicians switched arms and thus 
algorithms every two weeks. The development and content of e-POCT are described 
elsewhere (Chapter 5).  For children with cough (and without severe symptoms) e-POCT 
makes a diagnosis of LRTI in patients with RR equal or above the 75th %ile for age and 
temperature according to a European derivation study(Nijman et al., 2012). The algorithm 
asks for CRP testing for all children with LRTI. Antibiotic prescription was recommended for 
children with CRP-values of 80mg/L or above (presumed bacterial LRTI). Children with 
CRP-values less than 80mg/L were not treated with antibiotics (presumed viral LRTI), except 
if a concomitant bacterial infection from another source was documented. Children with 
positive mRDT were not given with antibiotics since malaria infection is associated with 
elevated CRP values (Díez-Padrisa et al., 2010). Inhaled salbutamol treatment was given to 
all children greater than six months of age with LRTI. If the clinician observed an 
improvement in respiratory symptoms, salbutamol was prescribed for home treatment. The 
control group was treated using a WHO IMCI-based electronic algorithm (ALMANACH, 
Rambaud-Althaus, Shao, et al., 2015). We chose an electronic IMCI algorithm-based as a 
control since were interested in comparing the content of the algorithms, rather than the 
format. ALMANACH is the only validated electronic IMCI-based algorithm and hence the 
current gold standard (Shao et al., 2015). In addition, ALMANACH recommends antibiotic 
treatment for all children with RR equal or greater than 50/min, instead of the more 
conservative WHO IMCI cutoff of 50/min for children less than 12 month and 40/min for 
children aged 12 month to five years. Using a slightly higher cutoff already results in a 
reduction in antibiotic prescription. Using ALMANACH, inhaled salbutamol treatment was 
given and prescribed for patients with auditory wheezing. All children from the intervention 
and control arm were prescribed amoxicillin at 80-100mg/kg/day for five days unless another 
concomitant infection (e.g. skin infection) required broadening of antibiotic coverage.  
Laboratory POCTs were performed on site as recommended by the algorithms. mRDT 
testing was done for all patients in both arms using either the SD BIOLINE Malaria Ag 
P.f/Pan™ (Standard Diagnostics Inc.) or CareStart Malaria HRP2™ (Access Bio, Inc.) 
assays. According to Tanzanian national guidelines, voluntary screening for HIV antibodies 
using the Determine™ HIV-1/2 (Alere Inc.) was offered to all patients in both arms when HIV 
test kits were available at the health facilities. For CRP testing in the intervention arm we 
used a POC semi-quantitative assay (bioNexia CRPplus™, Biomérieux). 
All caregivers were asked to return with the child for scheduled visits on days three and 
seven post randomization (day 0), or if the parent was concerned about the child’s condition. 
Patients cured at day three were followed-up by phone only on day seven. Field workers 
traced patients missing the day seven visit. Patients not cured at day three were managed 
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per the assigned algorithm and attended again at day seven; patients not cured at day 
seven were treated per the clinician’s judgment and another follow-up visit was performed at 
day 14 to assure that the child was cured. All patients were called by phone at day 30 to 
inquire about interim hospitalizations or deaths.   
Outcomes 
The primary outcome measure was the proportion of clinical failure (see definition in Table 
10) by day seven. Clinicians were unaware of the clinical failure criteria and these criteria 
were thus not used for clinical management of the patient. In addition, to guarantee equal 
assessments of the primary outcome in both arms, the following additional measures were 
taken: Patients were considered “not cured” and treated again using the respective 
algorithms either i) if the caregiver considered that the child was still ill or ii) still had fever 
when assessed by trained field workers who did not know the content of the algorithms nor 
the criteria for clinical failure. The secondary outcome measures were the risk in antibiotic 
prescription at day 0 and by day seven, the risk of primary referrals at day 0, as well as of 
severe adverse events (secondary hospitalizations and death) by day 30. 
Statistical Analysis 
For the larger trial, the sample size for the overall study was computed for the primary 
analysis based on a 97·5% (one-sided) confidence interval (CI). To prove non-inferiority the 
lower limit of this CI was to be within 3%. This non-inferiority margin was established based 
on what was considered a clinically meaningful difference in clinical failure by day seven 
(see main publication for details on sample size calculation including stopping rules). In this 
subgroup analysis, for the observed clinical failure rate of 5·0% in the control arm and total 
sample size of 1727 subjects, the attainable power was 81%.  
Both modified intention-to-treat (mITT) and per-protocol (PP) study populations were 
defined. The mITT population comprised all randomized patients for which the inclusion 
criteria for this subgroup analysis could be assessed (all patients who received the day 0 
intervention). Per definition, patients who were lost for follow-up were treated as clinical 
failures. The PP population included all randomized patients who received the intervention 
and completed the day seven assessment (Figure 20). The primary outcome was calculated 
for both the mITT and PP populations.  Because of the very small, and equal, proportion of 
loss to follow-up in both arms, all results are displayed according to PP analyses if not stated 
otherwise. Risk difference (RD) and relative risks (RR) with 95% CI were calculated to 
estimate the intervention effects on the main study outcomes. Stratified analyses with 
Mantel–Haenszel estimates for RR were performed to explore statistical heterogeneity of the 
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effect between clinicians(Joseph Newton et al., 2009). For the primary outcome, mixed 
effects logistic regression was used to adjust for possible confounding covariates. Changes 
in odds ratio (OR) were used as approximated changes in RR since the primary outcome 
was rare. Kaplan-Meier survival curves were generated to compare the time to fever 
clearance between the two groups. An independent Data Monitoring Committee oversaw the 
study. The trial was registered prior to the enrolment of the first patient in ClinicalTrials.gov, 
identifier NCT02225769. We used Stata version 13·1 for the analysis.  
Role of funding source 
Neither the funders of the study nor Biomérieux (who provided the CRP test kits) had no role 
in study design, data collection, data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in the study and had final responsibility 
for the decision to submit for publication.  
 
8.5. Results 
 
Recruitment took place from December 10, 2014 to February 10, 2016. Overall, 4729 febrile 
patients aged two to 59 months were screened, and 3192 randomized into the main study 
(Figure 20). Five patients in each arm did not receive the intervention. The mITT population 
of patients with non-severe respiratory symptoms included 1728 patients: 868 (50%) in the 
e-POCT and 859 (50%) in the control arm. Three and four patients were lost to follow-up for 
the day seven outcome assessment in the e-POCT and control arms, respectively.  The day 
30 phone follow-up could be completed in 99% (852/865) of patients in the e-POCT arm and 
99% (844/855) in the control arm. In both arms follow-up intervals for the day three and day 
seven outcome assessments were three (interquartile range [IQR] three to three, range two 
to five) and seven (IQR seven to seven, range six to 12) days, respectively. 
Baseline characteristics did not differ between the two groups (Table 16).  
Table 16 Baseline characteristics.  
Characteristic e-POCT (N=868) 
ALMANACH 
(N=859) 
Demographic 
  
Male Sex 486 (56%) 466 (54%) 
Agegroup   
 2 – 11 months 387 (45%) 408 (48%) 
 12 – 23 months 300 (35%) 272 (32%) 
 ≥24 months 181 (21%) 179 (21%) 
Received PCV vaccine* 443/461 (96%) 451/470 (96%) 
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Received HiB vaccine* 447/461 (97%) 456/470 (97%) 
Primary caregiver other than mother* 40/850 (5%) 41/841 (5%) 
Mother’s highest grade of education*   
 
 
None 79/847 (9%) 76/841 (9%) 
 Primary 559/847 (66%) 550/841 (65%) 
 Post-primary 209/847 (25%) 216/841 (26%) 
Number of children in household* 2 (1-3) 2 (1-3) 
Medical History 
  
Reasons for consultation other than cough and 
fever 
  
 Rhinorrhea/nasal congestion 487 (56%) 504 (59%) 
 Diarrhea or vomiting 230 (27%) 222 (26%) 
 Skin problem 26 (3%) 30 (4%) 
Duration of fever   
 1 day or less 530 (61%) 502 (58%) 
 2-4 days 327 (38%) 345 (40%) 
 5 days or more 11 (1%) 12 (1%) 
Duration of cough*   
 2 days or less 585/847 (69%) 570/846 (67%) 
 3-6 days 252/847 (30%) 271/846 (32%) 
 7 days or more 10/847 (1%) 5/846 (1%) 
Clinical characteristics 
  
Weight for age z-score** -0.6 (1.2) -0.6 (1.2) 
Respiratory rate 41 (36-50) 43 (36-52) 
Heart rate* 145 (17) 143 (16) 
Tachypnea per IMCI*** 386 (45%) 375 (44%) 
Lower chest wall indrawing 7 (1%) 10 (1%) 
Laboratory values 
  
mRDT positive 85 (10%) 85 (10%) 
HIV-1/2 antibody positive* 10/807 (1%) 6/794 (1%) 
Data are n (%), median (IQR), mean (SD), or n/N (%).*Data not available for all randomized patients; **WHO 
2006 growth curve(World Health Organization, 2006);  *** <12 months and RR≥50/min, ≥12 months and 
RR≥40/min. 
Participants had the typical features of children presenting to outpatient clinics with 
infectious complaints in areas with good health care supply: young age, a high frequency of 
multiple complaints, and presentation shortly after the onset of illness (Table 16). The 
vaccine record was available at consultation in 54% (931/1727) of patients; PCV and HiB 
coverage among these patients was >95%. HIV rapid tests were available at 92% 
(1595/1727) of consultations; 1% of patients tested had a positive result (10/807 and 6/794 
in the intervention and control arm, respectively).  
In the PP population, 2·9% (25/865) of patients experienced clinical failure by day seven 
treated using e-POCT versus 4·9% (42/855) of patients treated with the control algorithm 
(RD -2·0, 95% CI -3·8, -0·2; Table 17).  
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Table 17 Primary and secondary study outcomes 
 e-POCT  ALMANACH   
Primary Outcome % (n/N) % (n/N) Risk Difference  (95% CI) 
Risk Ratio         
(95% CI) 
Clinical failure by day seven (PP) 2·9 (25/865) 4·9 (42/855) -2·0 (-3·8, -0·2) 0·59 (0·36, 0·96) 
Clinical Failure by day seven (mITT) 3·2 (28/868)  5·4 (46/859) -2·1 (-4·0, -0·2) 0·60 (0·38, 0·95) 
Secondary Outcomes (PP) % (n/N) % (n/N) Risk Difference  (95% CI) 
Risk Ratio       
(95% CI) 
Antibiotic prescription at day 0  2·3 (20/865) 40·6 (347/855) -38·2 (-41·7,-34·8) 0·06 (0·04, 0·09) 
Antibiotic prescription by day 7* 6·8 (59/865) 43·9 (375/855) -37·0 (-40·7, -33·3) 0·16 (0·12, 0·20) 
Severe adverse events by day 30  0·5 (4/865) 1·5 (13/855) -1·0 (-2·0, -0·1) 0·30 (0·10, 0·93) 
 Secondary admissions 0·5 (4/865) 1·4 (12/855) -0·9 (-1·9, 0) 0·33 (0·11, 1·02) 
 Deaths 0 (0/865) 0·2 (2/855) - - 
* 17 patients in the e-POCT and 20 patients in the ALMANACH received antibiotics by non-study physicians 
between day 0 and day seven. Per protocol (PP), modified intention to treat (mITT). 
There was a reduction in the relative risk of clinical failure of 41% using e-POCT compared 
to ALMANACH (RR 0·59, 95% CI 0·36, 0·96). The main difference in clinical outcome 
between the two arms occurred before day three (RR 0·35, 95% CI 0·17, 0·72, Table 18)—
there was no significant reduction in the risk of clinical failure from days four to seven (RR 
1·04 95% CI 0·50, 2·13.). The Mantel–Haenszel estimate for RR in clinical failure by day 
seven when stratifying by clinician was not significant (p=0·49). The crude OR (0·59, 95% CI 
0·36, 0·95) was similar to the adjusted OR (0·59, 95% CI 0·36, 0·97) when adjusting for 
relevant covariates and random effects (age, axillary temperature, weight for age z-
score(World Health Organization, 2006), respiratory rate, clinician, and health center). In the 
PP population, 2·3% (20/865) of participants in the intervention versus 40·6% (347/855) in 
the control arm were prescribed an antibiotic treatment at day 0 (Table 17). Using IMCI RR 
cutoffs for antibiotic treatment, 44% of patients in the ALMANACH arm would have been 
prescribed an antibiotic at day 0 (Table 16). Additional 39 and 28 (out of which 17 and 20 
through consultation with non-study-physicians) patients received antibiotics between day 
one and day seven in the e-POCT and control arms, respectively. There was a significantly 
lower proportion of secondary admissions and deaths in the e-POCT arm compared to the 
control arm: 0·5 % (4/865) versus 1·5% (13/855, RR 0·30, 95% CI: 0·10, 0·93), respectively 
(Table 17). We did not note statistical heterogeneity between clinicians for any of the 
secondary outcome measures.  0·2% (2/865) of patients in the e-POCT versus 1·2% 
(10/855) of patients in the ALMANACH arm experienced severe symptoms at follow-up (RR 
0·20, 95% CI 0·04, 0·90, Table 18).  
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Table 18 Details of clinical failure and severe adverse events 
 e-POCT  ALMANACH  
Criteria for clinical 
failure 
Clinical 
Failure 
Secondary 
Admission Death  
Clinical 
Failure 
Secondary 
Admission Death 
RR for clinical 
failure (95% CI) 
Hypoxemia/severe 
tachypnea 1 1 -  4 2 -  
Other severe symptom 1 1 -  5 4 2  
Cough and tachypnea/ 
chest indrawing 8 2 -  19 1 -  
Total at day 0-3 % (n/N) 1·2% (10/865) 
0·3%    
(3/865) -  
3·3% 
(28/855) 
0·8%     
(7/855) 
0·2% 
(2/855) 
0·35            (0·17, 
0·72) 
Other severe symptom - - -  1 1 -  
Persistent fever 11 - -  10 3 -  
Cough and tachypnea/ 
chest indrawing 1 - -  2 - -  
Diarrhea/vomiting 2 - -  - - -  
Significant skin infection 1 - -  1 1 -  
Total at day 4-7 % (n/N) 1·8% (15/855) 
0·1%    
(1/862) -  
1·7% 
(14/827) 
0·6%     
(5/848) - 
1·04           (0·50, 
2·13) 
Total severe failure 
criteria day 0-7 % (n/N) 
0·2% 
(2/865) 
   1·2% 
(10/855) 
  0·20           (0·04, 
0·90) 
Data are n and % (n/N).  
Figure 21 displays the Kaplan-Meier curves for time to fever clearance for the intervention 
and control group- we did not observe a difference in time to fever clearance.  
CRP-guided antibiotic therapy for respiratory infections 108
 
Figure 21 Kaplan-Meier estimates of time to fever clearance 
Out of 780 patients with negative mRDT in the e-POCT arm, 50% (393) met criteria for CRP 
testing, i.e. had a RR ≥75th %ile for age and temperature (Table 19).
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Table 19 Clinical failure and antibiotic prescription by algorithm classification at day 0 for patients with negative mRDT. 
 e-POCT (n=780)  ALMANACH (n=770)  
Algorithm classification at day 0 
Antibiotic 
prescription at day 
0 
Antibiotic 
prescription by  
day 7 
Clinical failure by 
day 7  
Antibiotic 
prescription at    
day 0 
Antibiotic 
prescription by 
day 7 
Clinical failure 
by    day 7 
RR for clinical 
failure (95% CI) 
Upper respiratory tract infection 0·5% (2/387)** 5·4% (21/387) 3·1% (12/387)  4·6% (22/480)** 10·4% (50/480) 3·8% (18/480) NA* 
Viral LRTI 1·6% (6/383)** 6·8% (26/383) 3·4% (13/383)  NA NA NA NA 
 CRP <10 mg/L 1·2% (3/256)** 7·0% (18/256) 3·9% (10/256)     NA 
 CRP 10-39mg/L 1·8% (2/111)** 6·3% (7/111) 2·7% (3/111)     NA 
 CRP 40-79mg/L 6·2% (1/16)** 6·2% (1/16) 0% (0/16)     NA 
Bacterial LRTI (CRP≥80mg/L) 100% (10/10) 100% (10/10) 0% (0/10)  NA NA NA NA 
Clinical pneumonia NA NA NA  100% (290/290) 100% (290/290) 8·1% (23/284) NA 
Antibiotic treatment at day 0 NA NA 0% (0/18)  NA NA 7·7% (24/312) NA 
No antibiotic treatment at day 0 NA NA 3·3% (25/762)  NA NA 3·7% (17/458) 0·8  (0·48, 1·62) 
Data are % (n/N) unless otherwise specified. *No statistical comparison was made between the two study arms because the criteria for upper respiratory tract classification 
were different between e-POCT and ALMANACH. **Antibiotic treatment was prescribed for concomitant bacterial infections (skin infections, dysentery, and ear infections). 
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Two percent (10) of the 409 tested patients had a CRP of ≥80 mg/L and were thus treated 
with an antibiotic. Only three out of the 10 patients with CRP values of ≥80 mg/L had a RR of 
more than 50/min. Ten additional patients in the e-POCT met criteria for antibiotic treatment 
based on other algorithm classifications: five had dysentery, four skin infections, and one 
suspicion for osteomyelitis (Table 5). All clinical failures occurred in patients with CRP 
values below 40mg/L (Table 19). One patient with low CRP-values on day 0 was 
hospitalized on day one for bronchiolitis with severe respiratory distress. Seven additional 
patients with low CRP values met clinical failure criteria at day three. Five out of these seven 
patients recovered without antibiotic treatment by day seven (clinical failure criteria were not 
used for clinical decision making), suggesting that they suffered from a viral respiratory 
infection. Another five patients with CRP values of less than 40mg/L met clinical failure 
criteria at day seven. Among patients who received antibiotic treatment in the e-POCT arm, 
0% (0/20) patients experienced clinical failure by day seven versus 6·9% (24/348) in the 
ALMANACH  
Within the ALMANACH arm, patients who received antibiotic treatment were approximately 
twice at risk of clinical failure compared to patients who did not receive antibiotic treatment at 
day 0 (RR 2·07, 95% CI 1·13, 3·79). There was no statistically significant difference in the 
risk of clinical failure between the two arms among patients who did not receive antibiotics at 
day 0 (Table 19).  
 
8.6. Discussion 
 
This is the first randomized, clinical trial designed to evaluate a CRP-based antibiotic 
prescription strategy in terms of clinical outcome among children with febrile respiratory 
infections. We found that a two-step approach of refined age-and temperature-based RR 
percentiles, followed by POC CRP testing to decide on antibiotic treatment improved clinical 
outcome when compared to the currently recommend WHO approach. Children treated with 
the CRP-based strategy had a lower risk in: clinical failure by day seven, in the development 
of severe symptoms by day seven, and in severe adverse events (secondary 
hospitalizations and deaths) by day 30. Using the CRP-based strategy, antibiotic 
prescription at day 0 was reduced substantially from 41% to 2% in these controlled settings.  
No previous studies have assessed clinical outcome of children with respiratory infections 
when treated using a CRP-based antibiotic prescription strategy. A safety study in children 
was an important first step because reported accuracies of CRP to detect bacterial 
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pneumonia in children have been very heterogeneous(Flood, Badik and Aronoff, 2008). This 
is largely due to the lack of an adequate gold standard(McIntosh, 2002). Several clinical trial 
have been performed in adult outpatients, summarized in a 2014 Cochrane review 
(Aabenhus et al., 2014). CRP-based strategies in adults with respiratory symptoms were 
non-inferior in terms of clinical recovery to standard care (Aabenhus et al., 2014). Keeping 
these previous studies in adults in mind, we designed our study as a non-inferior study since 
we were primarily interested in investigating the safety of our CRP-based approach. We 
hypothesized that the CRP-based strategy would be beneficial in terms of reduction of 
antibiotic prescription. Several mechanisms could have resulted in a better clinical outcome 
of patients in the intervention arm: first, the overreliance antibiotic treatment could have 
resulted in a neglect of supportive measures for viral respiratory infections, such as 
salbutamol treatment for asthma (Nantanda et al., 2013). Second, the adverse effects from 
inappropriate antibiotic prescription could have had a negative effect. Both are supported by 
the fact that antibiotic prescription was associated with clinical failure in the control arm. 
However, we cannot be sure whether the improved outcome in the intervention arm was 
truly due the “respiratory package” or rather the entire electronic algorithm. Both treatment 
strategies were integrated into overall disease management algorithms. As an unblinded 
study the trial was certainly at risk of ascertainment bias. However, this was likely minimal 
since clinicians were unaware of the criteria used to assess the primary outcome.  
In this efficacy trial, the CRP-based strategy was associated with an approximately 
twentyfold reduction in antibiotic prescription when compared to the control arm. A recent 
study in Vietnam, that investigated the effect of indiscriminate POC CRP testing on antibiotic 
prescription rates for respiratory infections, found a moderate reduction in antibiotic 
prescription (Do et al., 2016). The study included 287 children less than six years of age. 
The study was limited by the fact that the applied CRP cut-off (10mg/L in children) was low, 
allowing a “rule-in” of many low-risk children for antibiotic treatment. Furthermore, the study 
only selected children with a very low pre-test probability of pneumonia. i.e. patients without 
fast breathing (RR≥40/min). The majority of these children have a very low benefit from CRP 
testing. Biomarker tests should ideally be used to rule-in a high risk of severe infection in 
situations when there is uncertainty whether antibiotic prescription is likely to be beneficial. It 
should not be used as an initial screening test. To make best use of CRP testing, we hence 
used a two-step diagnostic approach in which we first selected patients at higher risk of 
having bacterial pneumonia (fever, cough, and tachypnea/ lower chest indrawing). Within 
this population, we employed a higher CRP cut-off (80mg/L) to rule-in bacterial pneumonia, 
making use of the specificity of the test. Indiscriminate pre-consultation CRP-testing did 
indeed not reduce antibiotic prescription rates when compared to physician-guided testing 
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for febrile and respiratory infections in pediatric outpatient patients in a recent study in 
Norway (Rebnord et al., 2016). Similar to a physician-guided approach, the integration of 
CRP testing in an overall disease management algorithm, e-POCT, allowed guidance for 
selection of patients who would benefit most from CRP testing, and assisting low-level 
health workers in interpreting test results. In addition, the integration of the “CRP package” 
into an overall disease management algorithm maintains an integrated approach to the 
management of children with infectious complaints: the majority of patients in our study had 
complaints in addition to cough that required medical attention.  
Very few children in our trial met CRP criteria for antibiotic treatment. This raises the 
question whether CRP testing (or antibiotic treatment) is actually useful at all. Indeed, a 
controlled-randomized trial in Pakistan found placebo to non-inferior to amoxicillin in 
treatment of WHO non-severe pneumonia among 873 under-fives (Hazir et al., 2011). 
However, epidemiological data suggests that a proportion of children with respiratory 
infections continue to suffer from bacterial pneumonia and require antibiotic treatment—even 
after the introduction of HiB and PCV vaccines (McIntosh, 2002). The Pakistani trial may 
have been limited in terms of power to detect differences in unfavorable outcomes. 
Furthermore, severe adverse events were not systematically assessed. The generalizability 
of the findings is unclear given the high percentage of patients with viral wheeze. Further 
studies are currently ongoing that will assess the usefulness of antibiotics in patients with 
WHO pneumonia further (Jehan et al., 2016). Around half of clinical failures in the e-POCT 
arm occurred in the URTI category, i.e. in patients with a RR<75th %ile for age and 
temperature (Nijman et al., 2012). A similar number of patients experienced clinical failure in 
the control group using a simple RR cutoff of 50/min. The WHO age-based RR cutoffs were 
developed initially to be sensitive in detecting pneumonia (Rambaud-Althaus, Althaus, et al., 
2015). This was because the focus was on detecting as many children with bacterial 
pneumonia. The benefit of increasing the number of children treated for bacterial pneumonia 
outweighed the risk of over-treating children with viral respiratory tract infections. However, 
more recent data, both from high-resource and low-resource settings, suggests that RR has 
a low accuracy, i.e. is neither sensitive nor specific, in diagnosing pneumonia (Rambaud-
Althaus, Althaus, et al., 2015). Future approaches may consider using different rule-out 
criteria for bacterial pneumonia, for example the absence of wheezing. Children with 
auscultatory wheezing have a low chance of bacterial pneumonia and would not require 
CRP testing (McIntosh, 2002). Low-level health workers have difficulty in accurately 
detecting auscultatory wheezing (Simoes et al., 1991). However, new applications based on 
digital stethoscopes are currently under development (Abeyratne et al., 2013) that could be 
integrated into future electronic algorithms. Such future technologies could also help detect 
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children with reactive airway disease who benefit most from salbutamol treatment. We chose 
ALMANACH as a control arm since it was the best validated IMCI-based algorithm available. 
However, RR-based detection of bacterial pneumonia, as recommended by WHO, is 
certainly inferior to a complex clinical assessment as practiced in high-resource settings. 
Generalizability of our findings to high-resource settings is thus limited- we would not expect 
the same benefit in terms of clinical outcome in such settings- however, a benefit in terms of 
antibiotic prescription is more likely. The generalizability of this study is further limited by the 
fact that it was a single country, urban study with low HIV prevalence. Ultimately, the impact 
of this CRP-based strategy will depend on clinician compliance. Previous evidence in adults 
suggests that POC CRP works best with educational components (Little et al., 2013); 
electronic algorithms provide exciting opportunities in terms of continuous provider 
education.  
This trial provides first evidence that POC CRP-based strategies, integrated into an overall 
disease management algorithm, have the potential to improve clinical outcome in children 
with febrile respiratory infections in low-resource settings, while substantially improving the 
rational use of antibiotics.  This was also the first trial that included children at significant risk 
of bacterial pneumonia. Given the morbidity and mortality of respiratory infections in 
developing countries, and the high-volume antibiotic overuse, our findings have significant 
implications on child health and antimicrobial stewardship efforts. Based on studies in adults, 
it is probable that a CRP-based approach would not necessarily improve health outcomes in 
children with access to high-quality pediatric care. However, CRP-based strategies have the 
potential to improve antibiotic use in high-resource settings. Future research efforts should 
focus on outcome-based studies in high-resource settings, and implementation studies.  
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9. Complementary findings from the e-POCT project 
 
9.1. Use of point-of-care tests 
 
The following three sections describe the use of different POCTs more in detail. The use of 
CRP for the diagnosis of bacterial pneumonia is covered in Chapter 8. 
9.1.1. Oximetry  
 
Background 
Hypoxemia (SaO2 < 90%) may occur as a complication of an acute febrile illness, primarily 
respiratory infections. Children with hypoxemia should receive hospital-based oxygen 
therapy. Oxygen therapy has become increasingly available; but the implementation of 
oximeters, especially at primary care level, has lagged behind (Mccollum et al., 2016). The 
most recent 2014 WHO guidelines for the Integrated Management of Childhood illness 
(IMCI) at primary care level mention that any child with hypoxemia should be referred if 
oximetry is available (World Health Organization, 2014). However, the utility of routine use of 
pulse oximetry as a triage tool at peripheral health care level remains to be determined. 
First, the prevalence of hypoxemia at peripheral health care level has only started to be 
documented. A recent primary care-based study on the implementation of oximetry in 
Malawi reported that 5% (652/13,266) of SaO2 measurements were <90% in children with 
WHO criteria for pneumonia (Mccollum et al., 2016). A previous systematic review estimated 
the prevalence of hypoxemia among children with WHO non-severe pneumonia at 2.0% and 
among children with severe or very severe pneumonia at 13% (Subhi et al., 2009). However, 
this study included almost only hospital-based studies. Second, measuring SaO2 in small 
children (who are at highest risk of hypoxemia) can be challenging and may take up a 
considerable amount of consultation time (Mccollum et al., 2016). Though hypoxemia cannot 
be detected reliably on clinical exam alone, several clinical predictors for severe pneumonia 
are also associated for hypoxemia (Ayieko and English, 2006; Chisti et al., 2013; Wandeler 
et al., 2015). However, these clinical signs may be difficult to detect for health workers with 
limited pediatric experience. The true “added value” of using oximetry in addition to current 
referral criteria remains to be determined.  
The objective of this analysis was to determine the usefulness of oximetry in detecting febrile 
children with severe respiratory distress requiring referral to a higher level of care among the 
patients enrolled in the e-POCT arm. 
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Methods 
Clinical study personal was trained in oximeter use. Oxygen measurement was performed in 
all children in the e-POCT arm at enrollment. The oximeter probe, connected directly to the 
tablet, displayed pulse waveforms, which allows for the assessment of the signal quality.We 
considered a measurement interpretable when a consistent, high-amplitude 
plethysmographic waveform and a stable oxygen saturation was seen. Moreover, oxygen 
measurement was observed in 50 patients (4 clinicians) in the last 3 months of the study and 
the duration of the procedure was assessed. 
 
Figure 22 pulse oximetry measurement in a study patient 
 
Results 
Pulse oximetry measurements could be performed in all 1,591 patients who were treated 
using the e-POCT algorithm at day 0. 58% (923/1,591) patients had a cough at day 0. The 
distribution of SaO2 above 92% was not different between patients with and without a cough 
(Figure 23 and Table 20). There were more patients with SaO2 below 92% in patients with a 
cough compared to patients without a cough (p=0.024). 
Table 20 Distribution of SaO2 in patients with and without a cough 
 
All patients 
(N=1,591) 
No cough 
(N=668) 
Cough 
(N=923) 
SaO2 level (%)    
<90 0.3% (4) 0% (0) 0.4% (4) 
90-91 0.3% (3) 0% (0) 0.3% (3) 
92-93 1.9% (30) 2.3 % (15) 1.6% (15) 
94-95 7.5% (119) 6.4% (43) 8.2% (76) 
96-97 26.5% (422) 26.1% (174) 26.9% (248) 
≥98 63.7% (1,013) 65.3% (436) 62.5% (577) 
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Figure 23 Boxplot of SaO2 at day 0 in patients with and without a cough 
 
 
 
 
 
 
 
 
Figure 24 Flowchart of clinical outcome according to SaO2 level in the e-POCT arm. 
Figure 24 displays the clinical outcome of children according to level of SaO2. Among the 4 
children with SaO2<90%, 2 were eventually diagnosed with congenital heart disease and 
both met criteria for clinical failure: 1 child died and 1 child had persistent fever at day 7. 
Three children had SaO2 levels between 90-91%: e-POCT classified 1 as viral respiratory 
5 lost to 
follow-up 
35 clinical failures      
(2 death)   
2 clinical failures        
(2 death)  
0 clinical 
failures/death  
0 clinical 
failures/death  
4 with SaO2<90%  1,554 with 
SaO2≥94%  
30 with SaO2 92-93%  3 with SaO2 90-91%  
1,591 received intervention (e-POCT) 
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infection, 1 as bacterial pneumonia, and 1 as uncomplicated malaria; all recovered by day 3. 
There were also no clinical failures among children with SaO2 between 92-93%. Table 21 
shows the distribution of clinical signs for severe pneumonia with and without hypoxemia 
among the 923 children with a cough. All children with hypoxemia and 8% (73/919) children 
without hypoxemia had at least one sign of severe respiratory distress. Three out of 4 
children with hypoxemia met other criteria for severe pneumonia per e-POCT; however none 
would have been referred based on IMCI criteria alone. Three out of 12 children with severe 
respiratory distress requiring referral had hypoxemia.  
Table 21 Signs of respiratory distress and severe illness among 923 patients with a cough and with and 
without hypoxemia in the e-POCT arm. 
Clinical sign
 
Sa<90% (N=4) 
n (%)
 
Sa≥90% (N=919) 
n (%)
 
Severe tachypnea
1
 
2 (50) 61 (7) 
Chest indrawing 3 (75) 16 (2) 
Severe tachypnea and chest indrawing 2 (50) 4 (3) 
Unable to speak/ cry 2 (50) 4 (3) 
At least one clinical sign of severe respiratory distress 4 (100) 73 (8) 
Severe pneumonia per e-POCT (outside SaO2) 3 (75) 9 (1) 
Severe pneumonia per IMCI (outside SaO2) 0 (0) 7 (1) 
 
Table 22 shows the observed duration of SaO2 measurements. The majority (78%, 39/50) of 
SaO2 measurements took more than one minute (Table 22).  
Table 22 Observed oxygen measurements (4 clinicians)  
Observation N n (%) 
Duration of measurement 50 
 
 
<1 min 
 
11 (22) 
 
1min-2min 
 
29 (58) 
 
>2min 
 
10 (20) 
Reason for prolonged measurement time 10 
 
 
Patient crying/agitated 
 
7 (70) 
 
Inadequate signal 
 
3 (30) 
 
Discussion 
In the Dar es Salaam outpatient setting, hypoxemia was rare among under-fives with febrile 
illness. All patients with hypoxemia and a cough also had other signs of respiratory distress 
(severe tachypnea and/or chest indrawing). These signs are no longer part of IMCI danger 
signs. None of the patients with hypoxemia had other IMCI danger signs, and therefore 
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would not have been classified as “severe pneumonia” per the 2014 IMCI. However, a 
substantial proportion of children without hypoxemia also had at least one sign of severe 
respiratory distress. This also supports our approach of using a combination of at least two 
signs to make a severe pneumonia diagnosis to avoid over-referral. Half of the patients with 
hypoxemia were eventually detected with congenital heart disease. Though congenital heart 
disease is an important cause of mortality, referral facilities often do not have the appropriate 
means for management of these patients yet. There is discussion as to whether a higher 
threshold for SaO2, e.g. 92%, should be used in primary care; because at this level of care 
the role of oximetry may be to detect children with severe disease, rather than detecting 
children in need for immediate oxygen therapy. We did not find evidence that using lower 
thresholds would have been helpful in the e-POCT arm of the study as there were no clinical 
failures among children with ‘intermediate’ oxygen levels.  
Our observations are certainly limited by their generalizability related to the single 
geographic setting, the low number of subjects, and the controlled study setting. However, 
they provide further insight into some of the possible challenges when considering larger-
scale implementation of oximetry in the IMCI setting. The main challenge is certainly 
operational. Pulse oximetry measurement took between 1-2 minutes in the majority of 
patients in our study, but more than 2 minutes in 20% of patients. This is fairly long when 
compared to an average consultation time of 5 minutes in routine care in Tanzania (Lange, 
Mwisongo and Mæstad, 2014). In the Malawi implementation study, 55% of health workers 
reported a measurement time of more than 2 minutes—however, no direct observations 
were done (Mccollum et al., 2016). In low prevalence settings, like in our study, the benefits 
of measuring SaO2 in all patients with respiratory symptoms at primary care level may not 
justify the effort. Pulse oximetry could, however, be limited to patients after an initial clinical 
rule-in step with high sensitivity, such as a combination of fast breathing or lower chest 
indrawing. However, such an approach would have to be re-assessed in routine care, since 
the reliability of the measurements of clinical signs outside of research settings may be low. 
Though oximetry and oxygen should be implemented in hospitals in resource-poor settings, 
its feasibility and usefulness for routine screening at primary care level should be further 
assessed. 
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9.1.2. Hemoglobin 
 
Background 
The rationale for introducing Hb testing into the e-POCT algorithm is detailed in Chapter 5.4. 
Though severe anemia is known to be associated with death and bacteremia, the usefulness 
of introducing routine Hb testing in the consultation process has not been determined. The 
definition of anemia in childhood is not straightforward. WHO has published Hb reference 
values, however the majority of the data is derived from small studies conducted before the 
1990s (World Health Organization, 2011). Overall, there is little data on normal Hb values in 
African children. Due to physiological changes postnatally, Hb drops to a nadir of around 9 
g/dL at 2 to 3 months of life and then rises again and stabilizes out around 6 month of age 
(Ferry and Virginia, 2010). Very little data on anemia cutoffs exist for children under the age 
of 6 months and they are not included in the WHO anemia guidelines (World Health 
Organization, 2011). The objective of this analysis was to describe the characteristics of 
children in the e-POCT arm with anemia using different cutoffs and to evaluate the 
usefulness of this POCT in our study.  
 
Methods 
Hb screening was performed in all children in the e-POCT arm (Chapter 7.3).  
 
Results   
Among the 1,591 children in the e-POCT arm, 1% (20/1,591) met the e-POCT severe 
anemia classification (Table 23). Having a Hb of <6g/dL was not associated with age, 
tachycardia, nor tachypnea (data not shown). Ninety-five percent (19/20) of the children in 
the e-POCT arm with severe anemia per the e-POCT classification were detected based on 
Hb screening alone and met no other severe disease classification (Table 23). Not 
surprisingly, the proportion of mRDT positive values increased with decreasing Hb values. 
However, 50% (10/20) patients with Hb <6g/dL were mRDT negative.  
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Table 23 Overlap of anemia classifications with other severe diagnoses, primary admissions, and mRDT 
result in the 1,591 patients of the e-POCT arm 
  Hemoglobin value (g/dL) 
 N 
<6 (e-POCT 
severe anemia*) 
N=20 
≥6 and <7g/dL 
(WHO severe 
anemia) 
N=51 
≥7 and <10 
(WHO moderate 
anemia) 
N=817 
≥10g/dL (WHO 
mild or no 
anemia) 
N=703 
CNS danger signs 9 0% (0) 3.9% (2) 0.5%(4) 0.4% (3) 
Severe pneumonia 13 0% (0) 2.0% (1) 0.9% (7) 0.7% (5) 
Severe dehydration 6 0% (0) 2.0% (1) 0.4% (3) 0.3% (2) 
Severe malnutrition 55 5.0% (1) 7.8% (4) 3.4% (28) 3.1% (22) 
Primary admission  46 70.0% (14) 9.8% (5) 2.2% (18) 1.3% (9) 
mRDT positive 191 50.0% (10) 19.6% (10) 13.1% (107) 9.1% (64) 
Data are displayed as % (n), *all patients with Hb<6g/dL were classified as severe anemia by e-POCT. 
Interestingly, patients with a WHO severe anemia classification (Hb<7g/dl), but who did not 
meet e-POCT nor WHO transfusion (Hb<5g/dL) cutoffs, had a higher proportion of 
associated other severe classifications compared to children with Hb<6g/dL, p=0.05 (Table 
23). 30% (6/20) of patients with severe anemia per the e-POCT algorithm were referred to 
the hospital on day 0 but the referral hospital staff decided not to admit them. All patients 
who were not admitted recovered from the acute febrile episode by day 7.  
Discussion 
This preliminary data provides first evidence on the usefulness of routine Hb screening at 
primary care level and the characteristics of patients with severe anemia. Severe anemia 
made up a large proportion of severe classifications in the e-POCT arm: 19% (20/103). All of 
these children except one had no other criteria for severe disease that would have triggered 
referral. Severe anemia was not associated with any objective clinical signs and could have 
hence not been detected on physical exam alone. A considerable percentage of patients 
were not admitted at the referral hospital. This is probably because the WHO transfusion 
threshold is at <5g/dL. Though all not-admitted patients did well, at least on short term, it is 
difficult to translate these findings from our controlled study settings with good follow-up to 
routine care. Whether the cut-off used represented an over-referral and whether lower 
cutoffs should be used cannot be concluded from our data. The fact that patients with a 
WHO severe anemia classification (Hb<7g/dl), but who neither meet e-POCT nor WHO 
transfusion cutoffs, had a higher proportion of severe classifications when compared to 
children with Hb <6g/dL may indicate that this is a special patient group. Such Hb values are 
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typical values of patients with sickle cell (HbSS) disease (McCavit, 2012). It is possible that 
this patient group, who is at higher risk from infectious complications, may be 
overrepresented in this group. Further microbiological analyses and HbSS detection on the 
samples obtained in the e-POCT study will help shed further light on POC Hb testing in our 
study. However, this preliminary data shows that it may be useful to perform systematic Hb 
screening at primary care level as an objective sign to detect children with severe disease.  
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9.1.3. CRP and PCT measurements for patients with fever without source 
 
Background 
Chapter 5.4.3 describes the rationale for using combined CRP and PCT testing to detect 
bacterial infections in patients with FWS. One central question is whether there is truly a 
benefit of using two biomarkers over a single one. The full microbiological characterization of 
this sub-cohort is currently in process, which will help shed further light on possible “missed 
diagnoses”. The aim of this section was to provide a first description of use of combined 
CRP and PCT testing in the patients with FWS. 
 
Methods 
Please refer to Chapters 5.4 and 7.3 for details on the classification and testing of patients 
with FWS.  
 
Results 
Among the 402 patients with FWS and negative mRDT in the e-POCT arm, 12% (48/402) 
had PCT values of ≥4µg/L, 2% (8/402) had CRP values of ≥80mg/L and 1% (3/402) both 
(Table 24). Through the combination of PCT to CRP testing, 13% (53/402) of patients met 
criteria for antibiotic treatment.  
Table 24 CRP and PCT values at enrollment in 402 patients with FWS and negative mRDT 
  CRP (mg/L) 
  0-9 10-39 40-70 ≥80 
 
N N=247 N=117 N=30 N=8 
PCT (µg/L)      
<0.5 282 82% (202) 60% (70) 29% (9) 13% (1) 
0.5-0.9 35 7% (18) 10% (12) 13% (4) 13% (1) 
1-1.9 21 4% (11) 6% (7) 4% (1) 25% (2) 
2-3.9 16 1% (2) 9% (10) 10% (3) 13% (1) 
≥4 48 6% (14) 15% (18) 45% (13) 38% (3) 
Data are displayed as %(n). 
When, hypothetically, lowering the CRP cutoff for antibiotic treatment to ≥40mg/L, 4% 
(17/402) additional children would have met the CRP cutoff. CRP and PCT cutoffs change 
with duration of disease. It is thought that PCT rises earlier in an infectious disease process 
compared to CRP (Meisner, 2014). Figure 25 displays the CRP and PCT values by duration 
of symptoms. Children generally presented early in the course of the illness. For CRP, only a 
very small effect of the duration of symptoms on high CRP values was seen (Figure 25A). 
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Interestingly, the effect for PCT was more pronounced (Figure 25B). One could imagine 
using different cutoffs for both markers depending on the duration of symptoms. For 
example, a higher cut-off would be considered for a child with more than two days of 
symptoms, and a lower cut-off for a child presenting earlier on. When selecting a 
cutoff≥40mg/L for CRP and ≥2µg/L for PCT in children with less than two days of symptoms, 
and leaving the same cutoffs for children with a longer duration of symptoms, 14% (58/402) 
children would have met criteria for antibiotic treatment.  
Figure 25 CRP (A) and PCT (B) values by duration of symptoms among patients with FWS in the e-POCT 
arm. 
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There were 3 clinical failures in this subgroup of patients with FWS: 2 had both low CRP 
(<9mg/L) and PCT (<0.5µg/L) values. One patient met criteria for antibiotic treatment per 
PCT but had a negative CRP.  
Discussion 
The descriptive data above provide a first insight in the use of CRP and PCT testing to 
decide on antibiotic prescription in patients with FWS in the e-POCT arm. The cutoffs used 
for both tests for antibiotic treatment were relatively high (see Chapter 5.4 for a detailed 
discussion). However, 13% of patients met cutoffs for antibiotic treatment which corresponds 
approximately to the expected prevalence of bacterial infections in this cohort of patients 
(D’Acremont et al., 2014). More patients met criteria per PCT than per CRP cutoffs. There 
were only a small number of overlaps in the “positive” categories between the two tests. 
Using PCT alone would have ‘missed’ 1% of patients only, which may indicate that this is a 
more sensitive test to detect bacterial infection in children with FWS. Lowering the cutoffs 
based on duration of symptoms would have hardly changed the number of patients treated 
with antibiotics. At this stage, no definite conclusion can be made from our data whether 
using both CRP and PCT in patients with FWS was necessary, though it appears that PCT 
may have been more useful than CRP. Further microbiological characterization will shed 
light on this issue. However, ultimately this question could only be answered through further 
outcome-based studies comparing different biomarker testing strategies.  
 
9.2. Severe malnutrition in the e-POCT and ALMANACH arms 
 
Background 
Malnutrition is associated with severe outcomes from infections (Chapter 5.4). The different 
strategies used by e-POCT and ALMANACH to detect malnutrition are summarized in Table 
6. The optimal diagnostic strategy remains to determined (Chapter 5.4). The goal of this 
analysis was to compare the clinical outcome of patients with severe malnutrition between 
the two study arms.  
 
Methods 
In both arms weight and MUAC measurements were taken for all patients at enrollment, and 
clinical signs for malnutrition recorded (severe wasting/ edema). Severe malnutrition for this 
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sub-cohort analysis was defined for all patients as having either severe malnutrition criteria 
per e-POCT (either WFA<-3 z-score (World Health Organization, 2006) or MUAC <11.5cm 
for patients 6 months and over) or per ALMANACH (visible wasting and/or edema). Follow-
up and outcomes were defined per the main study (Chapter 7.3).  
Results 
56 patients in the e-POCT and 50 patients in the ALMANACH arm met anthropometric 
criteria for severe acute malnutrition (Figure 26). Nineteen percent (18/94) had low MUAC, 
95% (89/94) low WFA and 14% (13/94) both. Using the ALMANACH algorithm 2 children 
with severe malnutrition were diagnosed based on wasting. These 2 children also met 
anthropometric criteria for severe malnutrition per e-POCT. In the e-POCT arm, wasting was 
reported in 1 child who also met anthropometric criteria.  
 
Figure 26 Flowchart of patients with severe malnutrition 
 
All patients in the e-POCT arm received antibiotics at day 0 versus 48% (24/50) in the 
ALMANACH arm. e-POCT achieved a 99% reduction in relative risk of clinical failure by day 
7 compared to ALMANACH among patients with anthropometric severe malnutrition (Table 
25). 
 
 
 
1/55 failed by D7 (1 death) 9/49 failed by D7 (1 death) 
ALMANACH: 50 patients with severe 
malnutrition 
1 lost to follow-up by D7 1 lost to follow-up by D7  
e-POCT: 56 patients with severe 
malnutrition 
55 treated with antibiotics at day 0 24 treated with antibiotics at day 0 
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Table 25 Comparison of clinical failure by day 7 between study arms among patients with severe 
malnutrition 
 
e-POCT ALMANACH RD (95% CI) RR (95%CI) 
Clinical failure by day 7 1.8% (1/55) 16.3% (8/49) -14.5% (-25.4, -3.5) 0.11 (0.01, 0.85) 
Data are displayed as % (n/N). 
 
Severe malnutrition was associated with clinical failure in the ALMANACH arm (RR 4.47, 
95% CI 2.26-8.86), but not in the e-POCT arm (RR 0.77, 95% CI 0.11-5.54). All patients 
were referred at day 0 in the e-POCT arm, 14% (7/49) in the ALMANACH arm. In the e-
POCT arm 20% (11/55) patients were admitted at day 0 versus 10% (5/49) in the 
ALMANACH arm (RR 1.96, 95% CI 0.73-5.24).  
Discussion 
Among patients with severe malnutrition, e-POCT achieved a significant reduction in the 
relative risk of clinical failure by day 7. All patients in the e-POCT arm received antibiotics at 
day 0 and were referred. This did, however, not lead to a significant difference in the total 
number of admissions at day 0. Whether this represented an over-referral is difficult to 
determine since the criteria for admission were not standardized and vary significantly 
among practitioners. Nevertheless it is likely that not all children with severe acute 
malnutrition benefit from inpatient therapy. However, they do require integration into a 
nutrition program. Overall, it may be beneficial to better integrate IMCI-based algorithms with 
nutrition care, in order to provide directly adequate nutrition care for such children. This 
analysis is certainly biased by the fact that the vast majority of children were selected for the 
subgroup analysis based on anthropometric criteria. These criteria were used to classify 
children as having severe malnutrition in the e-POCT arm. The awareness of caregivers that 
these children had severe malnutrition may have lead to more careful care overall, in 
addition to the systematic antibiotic therapy. Unfortunately, we did not take length 
measurements in all children in the study and could hence not use alternative 
anthropometric criteria. In Dar es Salaam, energy malnutrition would be expected, leading to 
marasmus. It is hence not surprising that all children with clinical criteria (wasting) also met 
anthropometric criteria for severe malnutrition. Notwithstanding these limitations, these data 
however provide strong evidence that anthropometric measurements should be used 
systematically to detect children with severe malnutrition among children with acute febrile 
illness. Antibiotic treatment should be provided to all children with severe malnutrition and 
acute febrile illness, per WHO guidelines.  
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9.3. Skin disease diagnostic tools within the e-POCT algorithm 
 
Skin diseases are common problem in tropical settings. Though not a high cause for 
mortality, they cause significant morbidity—and concern parents. Yet, skin diseases have 
been under-addressed within IMCI since its start (Hees and Naafs, no date; Perkins et al., 
1997; Steer et al., 2009). Electronic algorithms have the potential to improve the diagnosis of 
skin infections through visual diagnostic aids, and the provision of detailed treatment 
recommendations. We sought to explore this potential within the e-POCT algorithm. This 
section will describe the e-POCT skin component and its use by clinician.  
We chose diagnostic skin categories based on previous studies (Hees and Naafs, no date; 
Steer et al., 2009) and clinical observations in children during the pilot phase. We 
constructed a single input screen where probable diagnoses could be selected (Figure 27). 
Based on the selection on the initial screen, the clinician was asked to confirm the diagnosis 
based on a second screen with visual prompts. A pop-up window could be opened with 
more detailed text information. Detailed treatment recommendations were given based on 
the diagnoses chosen.  
 
Figure 27 Example of input screens in the e-POCT algorithm 
Using e-POCT, the study clinicians diagnosed 94 patients with a skin problem in 12 
categories, versus 89 in 3 categories in the ALMANACH arm (Table 26).  
Table 26 Skin diagnoses in the e-POCT and ALMANACH arms 
e-POCT ALMANACH 
Classification n Classification n 
Simple abscess 9 Severe skin/soft tissue infection 12 
Abscess requiring antibiotic treatment 3 Impetigo/ minor abscess 45 
Scabies      ? 
yes 
  
no 
  
  
• Parasitic infection 
• Mite burrows just below 
the skin surface. 
• Very itchy! 
look for:  
• Burrow: fine line with a 
terminal tiny bump 
(smaller than a pin 
head) 
• small red bumps and 
blisters on the flexor 
wrists, elbows, between 
fingers, and feet in 
small children (including 
soles) 
• classically not on head 
and neck 
Select skin problem 
Scabies 
 
Impetigo 
 
Eczema 
 
Tinea capitis 
 
Varicella 
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Extensive impetigo/ pyoderma 4 Other skin infection 29 
Simple impetigo 7   
Cellulitis 0   
Varicella 6   
Fungal skin infection 10   
Tinea capitis 11   
Scabies 8   
Larva migrans 2   
Urticaria/ papular pruritic rash 20   
Eczema 14   
Total 94 Total 89 
 
The clinicians expressed satisfaction of having additional information on skin diagnoses, as 
this was an area where they felt they were lacking expertise (Samaka, personal 
communication). Having such an added value of using an electronic tool will be pivotal for 
the uptake of e-POCT. The skin section should be further refined in the future through small 
validations studies against expert opinion.  
 
9.4. Retrospective validation of e-POCT on IMALDIA dataset 
 
In order to compare the performance of e-POCT in detecting SBI in the IMALDIA dataset to 
that of other scores assessed before the development of e-POCT (Chapter 6), we also 
performed a retrospective validation of e-POCT using the same methodology. Table 27 
shows the predictors for SBI per the e-POCT algorithm (compare to Table 7). Besides SaO2 
all predictor variables were available in the IMALDIA dataset and all patients were included 
in the validation. 
Table 27 Criteria for antibiotic treatment per e-POCT 
Prediction 
Rule 
Age 
group 
Predictors 
e-POCT 2mo-5y CNS Hydration/ nutrition Respiratory Other 
Danger Signs  -Lethargic or 
unconscious 
-History of 
convulsions or 
currently seizing 
-Stiff neck 
-Severe 
tachycardia 
-Unable to 
drink/breastfeed 
-Severe 
malnutrition 
-SaO2<90% 
-Cough or chest 
indrawing and 2 of the 
following: severe 
tachypnea, 
grunting/difficulty 
speaking/crying 
 
-Hemoglobin<6g/dL 
Indication for 
antibiotic 
treatment 
   -Cough/chest 
indrawing AND 
tachypnea AND 
CRP≥80mg/L 
-Diarrhea and blood in 
stool 
-Significant skin 
infection 
-Fever without source 
and PCT≥4µg/L or 
CRP≥80mg/L 
 
e-POCT recommended antibiotic treatment in 28% of patients in the IMALDIA dataset. Its 
sensitivity was 57.8% (49.9%-65.4%) at a specificity of 78.2% (75.2%-80.9%). e-POCT had 
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the highest LR+ (2.65, 2.21-3.18) and lowest LR- (0.54, 0.45-0.65) of all scores. However, 
the LRs were below cutoffs that would be considered adequate at the primary care level 
(LR+>5, LR-<0.2).  
 
  
Figure 28 Overlap of SBI classification per IMALDIA (blue) and antibiotic treatment classification per e-
POCT (pink). 
e-POCT “correctly” diagnosed a similar amount of patients with SBI compared to 
ALMANACH, but treated less patients with antibiotics (Figure 28 and Figure 13).  
 
10% 
18% 
7% 
General Discussion and Conclusions 131
10. General Discussion and Conclusions 
The aim of this thesis was to improve health outcomes of children with acute febrile illnesses 
through developing and evaluating a novel disease management tool with enhanced ability 
to detect: i) children with severe disease requiring hospital referral and ii) those in need of 
antibiotic treatment, through the integration of key clinical signs with point-of-care host 
biomarkers into an electronic algorithm. 
For the design of this project we drew on experience acquired through previous work of our 
group in Tanzania. The IMALDIA project, which assessed the implementation of mRDT in 
Tanzania and noted a rise in antibiotic prescription with falling antimalarial prescription 
(D’Acremont, 2010). To further inform case management of such non-malaria febrile 
episodes, the IMALDIA project then investigated causes of fever among pediatric outpatients 
in Tanzania. This led to recommendations on modifications of the existing IMCI chart 
booklet. An updated algorithm, ALMANACH, was developed (including an electronic version) 
and evaluated through the PEDIATRICK project. Though ALMANACH improved clinical 
outcome while substantially lowering the amount of antibiotic prescriptions when compared 
to routine care in Tanzania, it also called for further improvements of the case management 
algorithm. This pertained especially to the identification of children with severe disease, as 
well as the management of children with respiratory infections and undifferentiated fever 
(FWS). Important insights in to the application of electronic tools and the overall disease 
consultation process were also acquired during the PEDIATRICK project. As a next step, the 
e-POCT project then sought to further enhance the case management of children with acute 
febrile illnesses through addressing the challenges identified in the IMALDIA and 
PEDIATRICK project, and through detecting further areas of improvement.  
The first step of the e-POCT project was to review comprehensively existing evidence on the 
management of acute febrile illnesses that had been acquired since the development of 
IMCI (Chapter 5). This included clinical signs and the use of host biomarker POCTs. Though 
there was a large body of published studies, ‘actionable’ evidence was scant. This was 
primarily because the few validation studies with sufficient quality were either performed at 
inpatient level, or included clinical signs that would not be assessable by health workers with 
limited training. Furthermore, validation studies had inherent limitations due to the lack of 
adequate gold standards (e.g. serious bacterial infection) that could be used as proxies for 
important clinical outcomes (e.g. cure or death, see Chapter 10.2 below). Outcome-based 
research and studies at the outpatient level in low-resource settings were scarce. During this 
process, we also evaluated the diagnostic accuracy of available disease management tools, 
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including IMCI and ALMANACH, in identifying children with serious bacterial infections 
through a retrospective validation on the dataset from the IMALDIA fever etiology study 
(Chapter 6). The diagnostic accuracy of all tools was surprisingly low. Those that included 
both clinical and laboratory elements performed better than tools using either one only. This 
retrospective validation exercise further confirmed our overall strategy for the development 
and validation of e-POCT in that: i) the integration of key clinical elements with simple host 
biomarker POCTs would be the best way forward and ii) outcome-based evaluation, and not 
gold-standard based validation, would be the most adequate methodology to assess e-
POCT against current best practice.  
We then constructed e-POCT based on the evidence retrieved, complemented with expert 
experience when requisite. Despite the limitations of available evidence, we could identify 
several key areas of improvement and innovation. The major innovations were as follows; 
first, we integrated POCTs to identify children with severe disease (oximeter, Hb) and those 
requiring antibiotic treatment (CRP and PCT). Second, we reduced the overall number of 
clinical elements and prioritized clinical signs that can be measured objectively (e.g. heart 
rate). Third, we made use of the software’s ability to incorporate more calculations as 
background software steps, while maintaining simple user interfaces.  
Next, given the innovative nature of e-POCT, we performed a safety study against the 
current best available gold standard (ALMANACH), Chapter 7. We planned a non-inferiority 
comparison between e-POCT and ALMANACH; because we did not expect necessarily 
benefits in terms of clinical outcome, but rather in terms of antibiotic prescription and the 
efficiency of the disease consultation process. Yet we noted an improved clinical outcome of 
the 1,586 children managed by e-POCT compared to the 1,583 patients managed by 
ALMANACH, in addition to a reduction of antibiotic prescriptions by two-thirds (30% to 11%). 
This also re-emphasized that very few children with acute febrile illnesses at the primary 
health care level benefit from antibiotic treatment. We cannot conclude definitively which 
elements of e-POCT led to the improved clinical outcome in the intervention arm, as we 
studied the algorithm as a whole; but the following factors played a role: e-POCT identified 
more patients with severe disease; this was primarily through the use of Hb testing and the 
improved identification of children with severe malnutrition. Moreover, a focus was laid on 
counseling parents in supportive treatments for viral infections.  
The largest reduction in antibiotic prescription occurred in children with respiratory infections 
(Chapter 8). Among children with a cough, but without severe symptoms requiring hospital 
referral, the antibiotic use was reduced from 41% in the ALMANACH arm, which used the 
IMCI-based clinical diagnostic strategy for pneumonia, to 2% in the e-POCT arm. e-POCT 
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employed a two-step diagnostic approach of respiratory rate followed by CRP testing. 
Interestingly, in this subgroup the clinical outcome of children was also improved in the e-
POCT arm compared to the control arm. Again, this probably resulted from an increased 
focus on the management of viral respiratory illnesses in the e-POCT arm (such as 
bronchodilator treatment for viral-induced wheeze). Through the randomized, controlled trial 
we also showed that the use of host inflammatory marker testing to determine antibiotic 
prescription in patients with respiratory symptoms (CRP) and fever without source (PCT) 
was safe in terms of clinical outcome. Though these biomarkers were developed more than 
30 years ago, this was the first clinical outcome-based evaluation of these biomarkers in 
children, which is indeed a crucial step before their routine use in clinical practice.  
The discussion of the main results of the e-POCT project is contained in the corresponding 
sections of Chapters 5 through 9. The following parts will discuss the adequacy of the 
project’s methodology, host biomarkers, and opportunities for further improvement of the 
algorithm in more depth. They also highlight considerations related to antibiotic prescription 
practice, the integration of electronic disease management algorithms into the health 
system, and scale-up.  
 
10.1. Adequacy of the project’s methodology: how should an innovative 
disease management algorithm be developed and evaluated?  
 
Constructing an evidence-based electronic algorithm 
The initial construction of IMCI was based on a WHO-based large technical review (Gove, 
1997). Several formal technical reviews of IMCI components have been carried out since 
(World Health Organization, 2014) and another major review process is currently ongoing 
(Costello AM and Dalglish SL on behalf of the Strategic Review Study Team, 2016). Such 
formal guideline processes have the advantages of a large capacity to review evidence 
comprehensively, and to reach formal consensus between different stakeholders. The goal 
of the development process of e-POCT was different in that we aimed at generating new 
evidence through the construction of an innovative tool, rather than developing a fully 
evidence and global consensus based disease management algorithm. An additional risk of 
formal guideline construction processes is that they result in the perception of an evidence 
base when there is in fact none. An example is the very cumbersome WHO dehydration 
scale, which was has been recommended by IMCI since its inception based expert 
consensus alone. We interviewed several pediatric providers in Tanzania on the clinical 
symptoms and signs they employ to identify children with dehydration. Almost all admitted 
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that they found the WHO scale to be of little practical value, though they thought it was 
‘evidence-based’; as it is recommended by the WHO.  
Given our different aims in developing e-POCT from more classical guidelines development 
processes, we performed an ‘individual’ structured literature review that allowed to quickly 
identify key areas for evidence-based improvement or innovation. Overall, we found very 
little evidence for the majority of disease management components reviewed. On the other 
hand, such components are routinely employed in pediatric clinical care and we were able to 
draw on this informal experience from clinicians. For example, little evidence from the 
literature could be retrieved on which cutoffs to use for CRP and PCT at peripheral health 
care level. However, both CRP and PCT have been evaluated and used in pediatric practice 
for the past 30 years. Ultimately, we relied on this experience to choose cutoffs for our 
disease management tool. Such an informal consultation process, in contrast to a formal 
consensus process, also helped to identify quickly research areas at need of additional 
evidence. The disadvantage of such an informal approach is obviously its subjectivity. 
Though we attempted construct e-POCT with as much objectivity as possible, and to 
carefully document our rationale, large areas remain that are based largely on our own 
experience. Again, we chose this process to allow the generation of new hypothesis and 
innovation. But for future implementation, the evidence retrieved from this project should be 
integrated into formal, coordinated guideline review activities (see Chapter 10.6 below). 
The electronic format implicates specifics in terms of logical flow and content of an algorithm 
(Rambaud-Althaus, 2015). Algorithms increase the consistency of assessments, as 
clinicians have to follow recommendations step-by-step. On the other hand, given that there 
is less room for the clinician’s interpretation, the logical flow of the algorithm has to be 
coherent and not delay patient management. A paper algorithm designed for clinicians 
cannot be simply handed to a software specialist for programming. We therefore developed 
a detailed paper reference manual to limit the introduction of errors through the software-
programming step. Close collaboration of a clinician and software programmer is required 
for the development of electronic algorithms. e-POCT included background calculations and 
the integration of data which would have not been feasible in a ‘manual’ consultation. At the 
same time we paid attention to keep the user in and output screens simple. It is important to 
include such software features into electronic algorithms as simply translating paper 
algorithms into electronic versions will result in little advantage for the end-user. Before 
using the electronic algorithm version in the clinical trial, we performed careful internal 
validation and evaluated the algorithm with supervision from medical doctors among 100 
pilot patients. In general, there is little regulatory guidance on how electronic algorithms (or 
electronic decision support systems in general) should be developed and validated (Karnik, 
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2014). Until such regulatory guidance becomes available, the future creation of an ‘auto-
regulatory’ guide by different groups involved in algorithm development and validation may 
increase patient safety, and the acceptability for scale-up.  
Algorithm evaluation 
The innovative character of e-POCT called for a safety evaluation through a controlled study 
design. We did not perform prospective validation studies since our goal was not to measure 
diagnostic accuracy, but to evaluate our tool against patient outcome. We chose an 
individual randomization design to avoid clinician and facility-level cluster effects. This was 
indeed a source of type I error in the ALMANACH design where intervention clinicians 
received training on the new tool but no training activities were done in the control arm. In 
addition, clinicians in the intervention arm may have been more motivated by the fact that 
they were testing a new electronic tool. Finally, the number of health facilities required for a 
clustered design would have overloaded the safety monitoring capacities of this study. Given 
that electronic format guided the clinician through the consultation process and allowed 
exact monitoring of adherence, our concern for a type II error through contamination of 
practice was low. However, to be on the safe side, clinicians used one algorithm for two 
weeks at a time to avoid confusion.  
 
Figure 29 Two study clinicians treating patients at Magomeni health center during the trial. 
We chose ALMANACH, instead of IMCI, as a control group since several improvements had 
already been made to ALMANACH, such as the introduction of urine dipstick testing. On the 
other hand ALMANACH is likely less powerful for the detection of severe malnutrition than 
the new version of IMCI (Chapter 9.2), which may have introduced a type I bias. The 
PEDIATRICK project had already demonstrated a reduction in antibiotic prescription and 
improved clinical outcome of ALMANACH compared to routine care in Tanzania (Shao et al., 
2015). A comparison of e-POCT with routine, IMCI-based care would have hence neither 
been appropriate nor ethical. We chose a non-inferiority design since we expected benefits 
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in terms of the disease consultation process and antibiotic prescriptions, but not necessarily 
in terms of clinical outcome, when compared to ALMANACH. We constructed the primary 
outcome, clinical failure by day 7 (Table 10) based on previous pneumonia management 
trials (Hazir et al., 2011; Fox et al., 2013) and the experience from the PEDIATRICK project. 
The validity of some of the criteria used for non-severe disease classifications should be re-
evaluated for future studies (see Chapter 7.5) and a global consensus on outcome 
definitions for future studies would be highly desirable. We chose to evaluate e-POCT in its 
integrity, rather than performing studies to evaluate its individual components. This was out 
of the recognition that children often present with multiple, overlapping symptoms. This 
requires an integrated disease management approach, which is a cornerstone of IMCI. A 
resulting drawback is that the study was not sufficiently powered to draw strong conclusions 
on the utility of certain tools or subgroups, such as Hb screening, or patients with FWS, or 
severe disease. This was also because of its design as a safety, rather than an 
effectiveness trial. Given its innovative character we decided to evaluate e-POCT in a 
relatively healthy population (high vaccine coverage and low HIV rates) and in an area that 
with enough infrastructures to allow effective adverse events monitoring with our available 
resources. However, this limits the generalizability of the findings. Future evaluations (or at 
least component evaluations) should be carried out in other settings. However, tools to 
mitigate high-volume antibiotic overuse are urgently needed. The need to strengthen the 
evidence in certain sub-parts of the e-POCT algorithm should not delay implementation 
efforts with careful monitoring and iterative algorithm improvements.  
On the spectrum of efficacy to effectiveness trial, this study was certainly more an efficacy 
trial than an effectiveness trial. Only limited conclusions on the benefit of e-POCT in routine 
care settings can be drawn. This should be the subject of future research efforts. For the e-
POCT components for which safety was not the primary concern (oximeter, Hb, severe 
malnutrition diagnosis), an effectiveness study would have been more adequate. However, 
given that novel biomarker testing strategies were integrated, an efficacy study was required 
as the first step. In general, before routine introduction of future, novel disease management 
tools, outcome-based clinical trials should be carried out to assess new disease 
management tools before routine introduction. Interestingly, the IMCI case management 
algorithm itself has actually never been assessed in clinical trials. The initial evaluation 
studies that were carried to measure an effect on childhood mortality directly assessed the 
IMCI strategy as a whole, including packages for health system strengthening and drug 
supply (Gera et al., 2016).  
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10.2. Host biomarkers 
 
Host biomarkers for the diagnosis of bacterial infection 
For the development, validation, and implementation of host biomarkers for the diagnosis of 
bacterial infection, several important findings have emerged from this project. First, findings 
from validation studies did not correlate with the results of our outcome-based study. The 
test performance of CRP and PCT in validation studies retrieved in the structured review 
was only moderate (Chapter 5.4). Similarly, e-POCT only showed moderate performance in 
identifying children with serious bacterial infections when applied retrospectively to the 
dataset from the IMALDIA project (Chapter 9.4). Yet, using CRP to decide on antibiotic 
treatment for children with non-severe respiratory symptoms resulting in better clinical 
outcome and a drastic reduction in antibiotic prescriptions (Chapter 8.5). For patients with 
FWS, the use of combined CRP and PCT testing resulted in similar clinical outcome and 
antibiotic prescription when compared to the ALMANACH strategy of a combination of 
clinical signs, urinary dipstick testing, and a rapid test for typhoid (Chapter 7.4); however, the 
study was not powered to detect differences in clinical outcome in this subset of patients. 
The difference between validation and outcome studies is certainly in large parts attributable 
to the imperfect gold standards available to define serious bacterial infection in children. This 
is because microbiological testing is neither perfectly sensitive nor specific and cannot 
differentiate between true infection (causing the present fever episode), incidental infection, 
and carrier state. Furthermore, the true proportion of bacterial infections among children with 
radiographic pneumonia is unknown (Chapter 5.4). Another explanation is that the majority 
of biomarker validation studies have been carried out in hospital-based settings (Van den 
Bruel et al., 2011). Findings may not be directly translatable to lower prevalence, outpatient 
settings, as test characteristics vary with disease prevalence. In addition, missing certain 
infections, such as UTIs or mild typhoid infections, may not have a direct impact on patient 
outcome. For example, some experts actually argue that it is reasonable to delay testing for 
UTI in children aged two month and older who have no signs of severe infection and if the 
fever is present for less than four to five days (Newman, Shreves and Runde, 2013). This is 
because the evidence for a positive effect of antibiotic treatment on preventing adverse 
events such as renal damage is insufficient. Validation studies of new biomarkers are 
certainly an important initial step before evaluation in outcome based studies. Nevertheless, 
this discrepancy between validation results and outcome results should be kept in mind for 
future studies.  
Second, host biomarkers are best used in combination with clinical signs. In the 
retrospective validation study, scores combining clinical signs with laboratory testing 
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generally had better performance compared to scores using either one alone (Chapter 6.4). 
Unlike mRDT for malaria, host biomarkers should not be used as initial screening tests for 
bacterial infection. Unselective testing will not only result in squandering of resources, but 
also unnecessary antibiotic treatment. This was illustrated in a recent randomized trial in 
Vietnam that found little impact of using a CRP POC testing to reduce antibiotic prescriptions 
among patients with respiratory symptoms (Do et al., 2016). The trial only included children 
with respiratory rate thresholds below the WHO cutoff for pneumonia, i.e. children that 
should not be tested or treated for bacterial pneumonia at all. With e-POCT, using clinical 
rule-out steps first allowed to use higher cut-offs (80mg/L for CRP and 4ug/L for PCT) to 
rule-in patients that likely require antibiotic treatment (instead of ruling out patients with a 
very low probability of having a bacterial infection using lower CRP cutoffs, such 10mg/L in 
the Vietnam trial, Do et al., 2016). Guidance should be provided to clinicians on which 
patients to select for host biomarker testing, and on the interpretation of test results based 
on the clinical and epidemiological context. Electronic disease management algorithms are 
suitable tools for this purpose as they allow integration of more complex data and 
calculations.  
Third, more research should focus on making available POCTs operational in low-resource 
settings. Efforts have focused on identifying new, improved biomarkers for infection (Dittrich 
et al., 2016; Kapasi et al., 2016). In our study we were able improve management of 
infections through the use of available biomarkers. Until such new tests become available, 
platforms for existing biomarkers, especially PCT, have to be improved before 
implementation into routine practice.  
Figure 30 Nurse performing PCT testing at Magomeni health center 
The PCT platform used was the closest to POC available at the time of the study; but 
operating the machine was challenging in the dusty Dar es Salaam health facilities with 
frequent electrical power cuts (Figure 30). Newer platforms have emerged since but they still 
require a large amount of blood (500µL). Ideally, a biomarker should use 5-10µL capillary 
blood ( Figure 31). Urine tests are less suitable the low-resource outpatient setting as urine 
collection is challenging in small children with acute febrile illnesses. Clean urine should 
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ideally be obtained through straight catheterization, or at least bag urine collection; both are 
not appropriate for the routine use in resource-constrained settings.  
  
Figure 31 Capillary blood collection in a small patient at Magomeni 
Other central question related to host biomarkers could not be answered conclusively 
through this project. For example, whether a combination of biomarkers should be used to 
detect children with bacterial infections or whether the use of a single marker suffices. The 
use of a combination of tests from unrelated inflammatory pathways has been advocated in 
recent validation studies. For example a combined assay of CRP + IP-10 + TRAIL has been 
evaluated for the detection of bacterial infections in high-income countries over the past 
years (van Houten et al., 2016). We used a combination of CRP and PCT testing to detect 
children with bacterial infections in the FWS subgroup. Though high CRP and PCT values 
had little overlap (Chapter 9.1.3), we could not answer definitively whether using both 
markers was necessary. This is important, especially for questions related to the cost of 
biomarker testing. Complementary microbiological analyses on the e-POCT samples will 
shed further light on this issue. The combination of information from several medium-sized 
studies in children with FWS will also provide further clarification. However, ideally, this 
question would be answered through future outcome-based studies comparing the use of 
one over a combination of biomarkers. Furthermore, biomarkers undergo dynamic changes 
during a disease process and the accuracy of cutoffs to predict disease will depend on the 
timing of the measurement (Chapter 9.1.3). Whether different cutoffs should be used based 
on the duration of a patient’s symptoms cannot be answered with the data available at this 
point but should be kept in mind during future research on host biomarkers.   
Host biomarkers to identify severe disease presentation 
e-POCT also uses POCTs for detecting children with severe disease presentation: an 
oximeter to detect hypoxemia and severe tachycardia, and a POC hemoglobinometer to 
identify children with severe anemia. e-POCT indeed classified around twice as many 
children as having severe disease compared to ALMANACH in the randomized trial. 
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However, this was only partially due to the POCTs employed: only very few children with 
hypoxemia and/or severe tachycardia were identified. All four children with hypoxemia also 
had other signs of severe respiratory distress and oximetry had little added value (Chapter 
9.1.1). This in contrast to a recent large-scale implementation study in Malawi that showed a 
clear benefit of using oximetry to identify children with hypoxemia at peripheral health care 
level (Mccollum et al., 2016). Oximetry will likely be implemented at peripheral level in the 
near future. Increasing the sensitivity of detecting children with severe pneumonia through 
the implementation of oximetry will also help improving the correct identification of children 
with non-severe respiratory infection who benefit most from inflammatory biomarker testing. 
Severe anemia was detected in only 1% of children in the e-POCT arm, however it 
represented around 20% of severe diagnoses in the e-POCT arm (Chapter 9.1.2). The vast 
majority of patients with severe anemia had no other danger signs. Having severe anemia in 
our study was not related to clinical signs, which confirms findings from earlier reports 
(Chapter 5.4). Consequently, children cannot be selected for Hb testing based on clinical 
signs alone. The usefulness of routine Hb testing for the management of acute febrile 
illnesses will have to be assessed in future studies. A key factor will also be whether 
detection of moderate or mild anemia would change clinical care. Possible implications could 
be a selecting of children for sickle cell testing, or iron supplementation.  
In general, with e-POCT we provided evidence for the safety of using host inflammatory 
markers for treating children with febrile illnesses. Safety was a concern for these 
biomarkers, but not for other: oximetry and Hb. Future efforts should focus on the public 
health benefits of including these biomarkers, for example through careful monitoring during 
initial implementation efforts.  
 
10.3. e-POCT algorithm: opportunities for improvement and further research 
 
Beyond the area of biomarkers, there are several areas of opportunity for improvement of 
the content of e-POCT.  
First, the clinical rule-out step to select children with respiratory symptoms for biomarker 
testing should be improved. We enhanced the sensitivity of the rule-in step through using 
age and temperature corrected cutoffs for respiratory rate, rather than simple dichotomous 
cutoffs. However, respiratory rate is neither sensitive nor specific for the diagnosis of 
bacterial pneumonia (Rambaud-Althaus, Althaus, et al., 2015). Its reliability is low in that 
measurements vary between providers and over time (Simoes et al., 1991). Given this low 
diagnostic accuracy, asking providers to perform respiratory measurements in all patients 
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with a cough is not justified. A possible alternative clinical rule-out step (proposed in 
European studies) would be parental, or provider, judgment that the child has difficulty 
breathing—with its obvious questions around subjectivity. Studies in Europe found that 
pneumonia is very unlikely if the child is not short of breath and there is no parental concern 
(Van den Bruel et al., 2010). Other prospects are the development of electronic 
stethoscopes that can detect abnormal breath sounds (Gervaix, personal communication). 
Such an electronic stethoscope could either be used to detect a lower respiratory tract 
involvement as a rule-in test for CRP testing, or as a rule-out step for bacterial pneumonia 
through the detection of breath sounds that are typical for bronchiolitis (viral respiratory tract 
infection). The stethoscope could also detect children in need of bronchodilator treatment 
through the detection of respiratory patterns (prolonged expiratory phase) that are typical for 
reactive airway disease. For respiratory rate there is, however, evidence that it may be a 
useful marker for the severity of respiratory illness, irrespective of microbiological etiology 
(Chapter 5.4.2). Its use as a severity marker, rather than an etiological marker in a subset of 
children should be envisioned.  
Second, the identification of children with dehydration should be further improved. 
Recommending the use of the tedious WHO clinical dehydration scale is not backed-up by 
sufficient evidence. Within e-POCT we proposed a simple symptom-based at-risk approach 
using 24-hour parental recall to detect children at risk for dehydration (Chapter 5.4). Though 
there were no obvious adverse effects from using such a simpler approach, our study was 
not designed to address this question specifically. Simple screening tools to detect children 
with severe dehydration in the outpatient setting should be developed further and validated. 
The integration of parental judgment as a criterion should also be considered here. Overall, 
it is questionable whether the identification of children with “moderate dehydration” is of any 
use, as increased fluid intake should be recommended for all children with acute febrile 
illnesses.  
Third, chronic conditions should be addressed. Beyond HIV, chronic conditions such as 
developmental delay and sickle cell disease should be considered as risk factors within 
disease management algorithms. 1% (39/3192) of children in our study reported chronic 
conditions; out of these 39 children, 20 had developmental delay, 14 sickle cell disease, and 
2 HIV. Children with such chronic conditions are at higher risk of poor outcome from 
infections (Williams et al., 2009; Makani et al., 2011). A great focus has been laid on 
developing algorithms for patients with HIV infection within IMCI. Sickle cell disease is 
common in Africa but has been neglected within IMCI. New, simple and low-cost POCTs for 
the detection of sickle cell disease are currently under development (Piety et al., 2016). 
Integration of such POCTs in future algorithms could not only improve management of 
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patients with infections, but also increase the overall detection and management of patients 
with sickle cell disease. Birth asphyxia remains common in developing countries and 
survivors often have significant neurological impairments (Chalovich et al., 2009). Such 
children are at higher risk of complications from infections (e.g. dehydration or aspiration 
pneumonia) and require specific considerations for their care. In general, electronic 
algorithms allow a true integrated patient assessment, i.e. integration of vertical disease 
management algorithms. This should also be explored further to include existing disease 
management algorithms for malnutrition. From a public health perspective, such an 
integrated approach is important to avoid the ‘verticalization’ of child health programs.  
Fourth, the user-friendliness of the algorithm should be further enhanced. During the design 
of the algorithm, we paid attention to the logical flow of the consultation process, reduced 
clinical elements to enhance consultation efficiency, and made use of software features to 
maintain simple user interfaces. This was out of the recognition that disease management 
tools must go beyond a compendium of evidence-based recommendations and should 
consider the end-user for optimal uptake. Before routine implementation studies, further 
research should be conducted around health workers’ experience with the clinical algorithm. 
Similar strategies have been applied in the design of mobile health application geared to 
patients (Dabbs and Myers, 2009). Such an approach should also consider sources of 
health workers’ intrinsic and extrinsic motivations, which likely has contextual variation 
(Shao. et al., 2014).  
Finally, to increase the impact disease management algorithms, more attention should be 
paid to the organization of the overall workflow of the consultation process. In Dar es 
Salaam, consultation times peak between 9AM and 1PM due to public transport and 
resource constraints at public facilities. Triage systems to identify high-risk patients are 
hardly in place and patients simply queue to be seen. The field workers in our study, who 
had very little or no clinical training, plaid an important part in the overall logistics around the 
consultation process through triaging patients and assisting with POC testing (Figure 32).  
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  Figure 32 Field worker triaging patients  
Smartphone-based applications should be developed to allow triaging of patients at health 
facility by providers with little or no formal education.  
 
10.4. Antibiotic prescription practice  
 
e-POCT allowed reduction of antibiotic prescription by two-thirds in comparison to 
ALMANACH in the controlled study setting. Very few antibiotics were prescribed in this trial 
overall compared to routine practice in Tanzania, (Chapter 4.2 and Shao et al., 2015). 
Behavior change in relation to antibiotic prescription is a complex process that involves a 
plethora of extrinsic and intrinsic factors that go beyond this discussion (Stålsby Lundborg 
and Tamhankar, 2014). Yet, some observations from the study with regards to antibiotic 
prescription should be highlighted.  
First, reinforcement through personal experience was key in conveying the message for less 
antibiotic use. One clinician of the study had already participated in the ALMANACH project 
and experienced first-hand that withholding antibiotics is safe. Among her peers, she had 
already become an advocate of reducing unnecessary antibiotic prescription in pediatric 
practice. Through the systematic follow-up of all patients, the other three clinicians also saw 
with their own eyes that a larger number of children recover without antibiotic treatment from 
infections. Moreover, among the clinicians an environment was formed where improved 
targeting of antibiotic prescription was a motivator. The importance of this ‘peer factor’ or 
social support has been highlighted in previous studies (Stålsby Lundborg and Tamhankar, 
2014). Through being a part of this large study that aimed at rational drug use, antibiotic 
resistance and rational antibiotic use became important to the practice of the study 
clinicians. The systematic follow-up of patients during the trial also automatically allowed 
General Discussion and Conclusions 144
safety netting. Clinicians established an, at least short-term, therapeutic relationship with 
their patients. Patients could be re-evaluated in case of deterioration and there was no need 
to prescribe antibiotics during the initial consultation to prevent perceived possible future 
complications. Indeed, only 2% (57/2517) of patients who were not prescribed an antibiotic 
at day 0 sought an antibiotic prescription outside of the study. Furthermore, several 
algorithm components algorithm allowed increasing the clinician’s and parent’s confidence in 
the diagnoses reached: first, the systematic assessment and laboratory POCTs. Indeed, 
parents did not necessarily request antibiotic treatment but rather laboratory tests, “vipimo” 
(Samaka, personal communication). Moreover, detailed counseling on symptomatic care 
was integrated into e-POCT. This allowed provision of other tools to parents beyond 
antibiotic treatment. Providing diagnostic decision tools that are perceived as relevant and 
‘competent’ by clinicians will be essential for adherence to any electronic disease 
algorithm—the lack of trust in the IMCI guidelines and weak beliefs in the importance of 
following IMCI has been identified as an important factor to non-adherence (Lange, 
Mwisongo and Mæstad, 2014). 
  
Figure 33 A nurse using soap bubbles to distract a patient during the consultation 
Finally, a strong focus was set during the training phase to increase the provider’s 
confidence in completing pediatric assessments, and therefore overall self-efficacy. For 
example, though laughed at in the beginning, age-specific distraction methods actually were 
an important asset to provide care more efficiently and with greater competence (Figure 33).  
How much of the substantial reduction in antibiotic prescription observed in the controlled 
settings of this study can be translated into routine care remains to be seen. However, it is 
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clear that “soft factors”, such as peer motivation, training, patient counseling skills, and 
safety netting will be a key ingredient to the success of future efforts to reduce antibiotic 
prescriptions through the use of electronic decision support tools.  
 
10.5. Visions for electronic algorithms in the health-system 
 
Much work has been carried out to improve the quality of pediatric outpatient consultations. 
They have focused on training, supplies, and supervision. Very little efforts have entered the 
consultation room and looked the actual patient-provider interaction (beyond the description 
of shortcomings). Electronic algorithms have the potential to improve the quality of care from 
inside to outside, as they influence and report on the actual consultation process. It has 
already been shown that electronic tools improve the consistency of assessments and the 
accuracy of drug prescriptions (Rambaud-Althaus et al., 2017). They may also empower 
clinicians through increasing their confidence in the diagnostics process. Providers, 
especially in remote areas, may feel connected to a network of practitioners. Many 
endeavors are underway to develop online training modules (World Health Organization, 
2017b). Such modules could be integrated into the disease management tools and would 
assist with efforts to provide continuous education and certification for providers. 
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Figure 34 Vision for an electronic disease management tool within the health system 
Electronic algorithms may also improve transparency. Patients would no longer be 
dependent on subjective provider opinions as clinicians are using an objective tool. 
Provider’s performance (ideally at facility level, rather than individual level) could be 
monitored transparently as data from electronic algorithms would be aggregated for 
monitoring and evaluation purposes. The lack of extrinsic motivation due to missing 
oversight (both in form of ‘carrots’ and ‘sticks’) has indeed been found to be an important 
factor for a lack of adherence to IMCI (Lange, Mwisongo and Mæstad, 2014). However, 
careful attention should be paid to create culturally sensitive performance monitoring that 
allows constructive feedback, rather than ‘spy agencies’. Another risk of such performance 
measurement in one area, e.g. child health, is that it may create incentives for facilities to 
focus on one, vertical disease program. Direct automated data feedback to the provider, 
such as number of patients seen, diagnoses, drug prescriptions would be another 
fundamental factor to improve adherence. Data in the ‘cloud’ could also be used at the 
district/national level for human resource management (e.g. to inform supervision visits), 
disease surveillance, monitoring and evaluation, and logistics. Additionally, large-scale data 
analysis would further inform the continuous improvement and evaluation of disease 
General Discussion and Conclusions 147
management algorithms. At the health center level, the efficiency of patient care may be 
improved through integration of electronic triage tools with the provider algorithm, and 
electronic communication with referral facilities (or community health workers). In general, 
other algorithm users, such as nurses should be envisioned to allow higher impact of the 
intervention. Having an electronic tool would also allow to maintain patient records—a 
routine part of primary care which has not been implemented in resource-limited settings. 
Provider-level data could be linked with logistics at the facility level, such as supply chain 
and human resource management. Finally, having a pertinent and attractive tool would 
provide opportunities to include the private health care sector. The latter plays an increasing 
role in health care delivery in developing countries but quality of care is low and regulations 
are missing (Awor and Miller, 2014). In summary, having effective and relevant disease 
management algorithms may provide unique opportunities to tackle challenges around 
quality of care from the core, to increase provider adherence, to shake-up health systems 
through increased accountability, and to build up effective processes from the inside 
outwards. 
 
10.6. Implementation of e-POCT: opportunities and barriers 
 
One of the first questions when speaking to my Tanzanian colleagues is: “when do you bring 
the tablet?” Indeed, though there are several opportunities for further improvement of the 
algorithm, the principal effort should now focus on implementing improved disease 
management tools at hand, including e-POCT. To date, only one electronic algorithm is 
close to scaled-up through Terre des Hommes in Burkina Faso (Table 28). In the future, 
further large scale-up activities should be targeted, rather than multiple, small pilot studies.  
The current most obvious but crucial obstacles to implementation are technical in nature. In 
terms of the electronic algorithm itself, several software programs are available, but none 
are yet ideal. Some key areas require improvement. First, software tools should be 
developed for the end-user, i.e. based on the clinician’s way of thinking and the patient 
consultation process. The integration of clinicians into the development process of software 
applications is essential. Second, software tools should be transparent and ideally open-
source to avoid dependency on a single institution. They should be maintainable without 
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highly-specialist programmers. Third, safe and local data storage capacities have to be 
increased.  
Figure 35 Vision of an ideal disease management tool. The tool should automatically connect and integrate 
data from different sensors: oximeter (1), rapid tests (2), digital stethoscope (3), and the camera (4), for example 
for the interpretation of skin findings). Data should upload directly to a local, safe cloud (5), reports should be 
generated automatically (6). The tool should interconnect with other elements of the electronic health systems 
(7); consultation reports with prescriptions per SMS to the patient’s phone would also be a desirable feature (8).  
 
Fourth, robust sensors and POCTs have to be developed that can be connected directly to 
the tablet. The algorithm should be located within the tablet, and not within the sensor. This 
will allow integration of multiple sensors at once and the additional and removal of modules. 
Fifth, analysis tools should be developed that allow the management of the large amount of 
raw data. This is crucial for the feedback process to end-users and local authorities. Sixth, 
information technology capacities at the local level should be strengthened that allow local, 
real-time solution of technical issues. Finally, and importantly, software should interconnect 
with other electronic components in the health system. This will become crucial as national 
governments are scaling-up electronic health systems. All of these are pre-requisites for 
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routine implementation of existing electronic disease management algorithms. Other 
features such as communication capacity with local mobile phones, or the transfer of reports 
to parents would be desirable for high impact.  
To make use of the ‘big data’ arriving in clouds during routine implementation, data 
management- and analysis capacities at local and national level have to be enhanced. The 
data created by electronic algorithms is quite different from routine large-scale health 
surveys in that they contain many observations per subject, rather than many subjects with 
few observations. This entails specific requirements for data management. Clear data 
analysis plans based on research hypothesis should be formulated to make use of the large 
volume of data. An additional, exciting prospect is the use of large datasets for machine 
learning. However, such large data analysis efforts are at risk of creating diagnostic 
monsters when basic clinical and epidemiological principles are not considered. For 
example, the use of imperfect gold standards (see above) would be very problematic.  
Scale-up efforts require the establishment of multi-disciplinary teams and cross-institutional 
collaboration. Such teams should contain specialists in the following areas: public health/ 
health systems, pediatrics, software programming, information technology, monitoring and 
evaluation, data analysis, finance, social science, training, logistics and product 
development.  
The implementation of electronic disease management algorithms has relied largely on non-
governmental organizations (NGOs) for several reasons, mostly related to logistics, human 
resource capacity, funding, and the lack of interest by the WHO for electronic IMCI solutions. 
ALMANACH was handed over to the Dar es Salaam City Council after the close of 
PEDIATRICK project. However, it has not been implemented in routine care in Tanzania to 
date due to a lack of strategic support. An advantage of cooperating with NGOs for 
implementation is their openness to innovation and change. However, there are also clear 
disadvantages to this strategy, most importantly the lack of sustainability; but also the 
multiplication of parallel, small efforts that compete for funding at the pilot phase without 
leading to scale-up. Over the past 9 years of e-algorithms, several algorithms have been 
developed in parallel prompting the question: “which algorithm should we use?” (Table 28).  
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Table 28 Overview of current IMCI-related electronic algorithms 
 Organization Description Platform Implementation status 
ALMANACH Swiss TPH 
ICRC 
Pharmaccess 
Improved IMCI, 
including urine 
dipstick 
ODK, 
Commcare, 
Teamscope 
ICRC: pilot implementation in 3 
health centers in Nigeria and 3 in 
Afghanistan 
 
Pharmaccess: pilot implementation 
of community ALMANACH planned 
for 20 community health workers in 
Hanang District, Tanzania; in a 
second phase the deployment of 
the “normal” ALMANACH version in 
the 5 corresponding health facilities 
is planned 
 
MSF e-CARE Médecins 
Sans 
Frontières 
Improved 
ALMANACH 
version, including 
MSF-specific 
disease 
management 
protocols 
Mangologic Pilot implementation in 3 health 
centers in the Central African 
Republic  
IEDA Terre des 
Hommes 
e-IMCI algorithm Commcare Implemented in 8 districts (13% of 
health system) in Burkina Faso as 
part of a larger quality of care 
improvement strategy using mobile 
technology, further scale-up 
planned in Burkina Faso, Mali, and 
Mauritius 
 
D-Tree e-IMCI e-IMCI Mangologic Not documented 
 
Kenya e-IMCI Ministry of 
Health, Kenya 
e-IMCI, 
downloadable for 
android phone 
Unknown Not documented 
 
Going forward, having multiple competing algorithms with different contents will not be 
sustainable for routine implementation. Though IMCI has faced many implementation 
challenges, it remains a trusted tool at country level. Ideally, existing electronic algorithms 
should be integrated into one “e-IMCI-PLUS-AND-POCT” backbone: a revised electronic 
algorithm on an IMCI base that would integrate new findings from the e-POCT project and 
other implementation efforts, including the use of POCTs. Such an algorithm would have a 
common backbone of high-mortality diseases, similar to IMCI. Its overall form should be 
modular to make it more amenable to modifications based on local epidemiology, new 
innovations, and contextual needs. Integrating e-POCT with other algorithms would also 
allow addition of non-febrile disease management charts. Before moving on to routine 
implementation, efforts should be made to assure that the tool is end-user friendly. 
Effectiveness studies in representative settings should be carried out before larger-scale 
routine implementation.  
The WHO child health group is currently undertaking a large review of the IMCI strategy, 
including a technical review of the IMCI algorithm (Costello AM and Dalglish SL on behalf of 
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the Strategic Review Study Team, 2016). This would provide an excellent opportunity to 
integrate research on electronic algorithms, including e-POCT. A recently published WHO 
working paper on the strategic review reported first results from an IMCI-related survey of in-
country teams (Costello AM and Dalglish SL on behalf of the Strategic Review Study Team, 
2016). The survey included questions on how existing IMCI tools could be improved in terms 
of format and content. The respondents named several areas that we sought to address 
through the development and evaluation of e-POCT:  “simplify decision algorithms for clinical 
diagnosis, […] review decision algorithms to reduce consultation time, […] digitize the IMCI 
chart booklet, […] continue evidence generation, […] include common non-fatal conditions: 
skin conditions, urinary tract infections, other fevers (typhoid).” However, electronic 
algorithms, beyond simple electronic adaptation of IMCI, were not mentioned in the working 
paper as tools for consideration in updated guidelines (and to address the challenges 
identified through the in-country survey). Overall, communicating research findings to the 
WHO technical review committee has been challenged by a lack of transparency of the 
review process. It would be highly desirable if the WHO would coordinate the establishment 
of a global, independent, scientific advisory committee that involves representatives from 
multiple stakeholders (including local governments, academia and NGOs). This would permit 
broader input from the scientific community, allow a more systematic consideration of new 
ideas, and help integrate innovations like the e-POCT tool into guidelines. It would also 
increase coordination and consensus, and help setting quality standards for future research 
in this area. Other departments at WHO have developed tools to improve coordination of 
digital health projects through the development of an online Digital Health Atlas (World 
Health Organization, 2016b). The WHO’s child health department should play an equally 
active and transparent role in coordinating contents of electronic child health algorithms.  
Ultimately, gaining trust of local providers, and a country-level leadership will be key to a 
successful implementation. The lack of ownership of local governments, and donors taking 
over the lead in implementation was related to failures to scale up IMCI (Costello AM and 
Dalglish SL on behalf of the Strategic Review Study Team, 2016). A good example of a 
successful bottom-up implementation approach through a combination of local leadership, 
close collaboration of scientists with local government, and effective communication with 
frontline providers was the introduction of mRDTs through the IMALDIA project (D’Acremont, 
2010). Results from this successful national implementation effort were translated eventually 
into international guidelines. Experiences from this project could be leveraged for future 
implementation efforts of e-POCT or an “e-IMCI-PLUS-AND-POCT” in Tanzania. Tanzania 
set forth a national eHealth strategy (Tanzania Ministry of Health & Social Welfare, 2013) 
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and is one of the leading countries in Africa in terms of establishing a future electronic health 
system. It will be vital for e-POCT to be integrated in such a strategy to allow scale-up.   
Finally, it will be crucial that e-POCT would be recognized as an important tool to reduce the 
irrational prescription of antibiotics. The bulk of antibiotic over-prescription in Tanzania and 
elsewhere happens at the outpatient level. Providing effective disease management tools to 
clinicians is a crucial ingredient to any effective strategy for rational drug prescription. WHO 
has initiated a worldwide campaign against antimicrobial resistance and the launch of the 
Tanzania country-level strategy is imminent. It will be important to leverage this strategic 
interest in combatting antimicrobial resistance to promote efforts to promote quality of care 
overall; e-POCT should be integrated to the Tanzanian strategy as a tool for rational 
antibiotic prescription.  
 
10.7. Conclusions 
 
With changing disease epidemiology very few children with acute febrile illnesses in 
outpatient settings benefit from antibiotic treatment. Previous experience from research in 
Tanzania combined with a structured literature review allowed to develop an innovative 
electronic algorithm (e-POCT) that uses host biomarker POCTs to identify children with 
severe disease and those in need of antibiotic prescription. e-POCT has the potential to 
improve the clinical outcome of children with febrile illnesses in low-resource settings while 
reducing antibiotic use through improved identification of children with severe infections and 
increased targeting of children in need of antibiotic prescriptions. This disease management 
tool will be an important asset to improving the rational use of antimicrobials. Using CRP and 
PCT cutoffs, integrated into an overall disease management algorithm, for the management 
of children with respiratory infections and FWS was safe in terms of clinical outcome. Using 
a two-step diagnostic approach including CRP to decide on antibiotic treatment for non-
severe respiratory infections resulted in better clinical outcome when compared to using 
respiratory-rate thresholds alone, and allowed a large reduction of antibiotic prescription in 
this subgroup. Electronic algorithms in general are an important prospect to increase 
compliance to IMCI—the integration of POCTs would make even better use of such 
technologies. POCTs should include both tests for identification of patients with severe 
disease (for example with severe anemia) and for detection of children with bacterial 
infections (such as CRP and PCT). To make best use of these POCTs, they should be 
integrated into a patient management tool that will not only help to select patient subgroups 
for which testing is useful, but also to interpret results within an overall patient assessment. 
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This will also allow promoting an integrated approach to the treatment of childhood infections 
as it has been implemented through IMCI. To allow sustaining the e-POCT’s potential to 
improve health outcomes and reduce of antibiotic prescription during routine implementation, 
attention should be paid to ‘soft factors’ such as: user-friendliness of the algorithm, 
counseling skills, intrinsic and extrinsic motivators for adherence, and safety-netting. Future 
efforts should be made to replicate findings of the innovative components of e-POCT 
(especially the use of inflammatory markers) in other populations at higher risk of bacterial 
infections. Public health benefits of other POCTs should be assessed further during pilot 
implementation projects. Notwithstanding these areas of future research and other 
possibilities for future improvements, the focus should now shift towards the implementation 
of novel electronic disease management tools, including e-POCT, in close collaboration with 
WHO and local governments.  
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11. Recommendations 
 
11.1. Electronic algorithms for child health 
 
e-POCT: future steps related to content and format: 
- Key innovative components of e-POCT should be replicated in other settings 
(especially areas with higher malaria prevalence), and populations at higher risk for 
bacterial infections through outcome-based studies. These key innovative 
components include the use of inflammatory biomarkers to decide on antibiotic 
prescription in children with respiratory infections and fever without source. Such 
studies could be part of pilot implementation processes. 
- An alternative clinical rule-out step for pneumonia that selects children for biomarker 
testing should be developed, as there is not enough evidence to continue supporting 
the use of respiratory rate. This could either be an alternative clinical symptom 
(parental or clinician judgment), or an electronic stethoscope; the latter would either 
detect lower respiratory tract involvement or bronchiolitis.  
- The public health benefit of using routine oximetry and Hb screening at the peripheral 
health care level should be further studied.  
- Within future version of e-POCT, a great focus should be maintained on providing 
supportive care for children with viral infections, such as bronchodilator treatment for 
children with viral respiratory infections. This will not only allow to improve clinical 
outcome from viral infections, but also to strengthen efforts to reduce antibiotic 
prescription in routine care.  
- Simple screening tools to detect children with significant dehydration in the outpatient 
setting should be developed further and validated. 
- MUAC in combination with WFA should be used to screen for severe malnutrition in 
patients with acute infections. The optimal strategy to treat these children 
(ambulatory antibiotics and nutrition therapy versus hospital-referral) should be 
further assessed.  
- Chronic conditions, such as sickle cell disease and developmental delay should be 
included as risk factors for infection. Specific disease management charts for these 
patients should be designed and incorporated into future electronic algorithms. 
Overall, the integration of vertical disease management components into one overall, 
integrated disease management strategies should be furthered through electronic 
algorithms.  
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- Diseases of low mortality but high concern to parents and clinicians, such as skin 
diseases, should be included into the electronic algorithms. This will provide added 
value to the clinician of using a tablet and increase trust in the competence of the 
disease management tool.  
- Further qualitative studies should be conducted to improve the user-friendliness 
before routine implementation studies. Electronic algorithms should reflect the logic 
of the consultation process. Unique features of electronic algorithms should be better 
used, such as the performance of complex background calculations.  
- More focus should be laid on supporting the overall consultation process through the 
development of triage components. Other users of electronic disease management 
algorithms, such as nurses should also be considered to increase impact.  
General recommendations for the development and evaluation of new algorithm 
components 
- International consensus should be reached on outcome definitions for studies that 
evaluate disease management algorithms, or their components.  
- Future innovative disease management components, which may pose safety 
concerns (such as the use of biomarkers to decide on antibiotic prescription), should 
be evaluated through controlled randomized trials against current gold standard as a 
first step. Other components should be evaluated in terms of their public health 
benefit before routine implementation.  
- Key researchers and agencies involved in developing and evaluating electronic 
disease management algorithms for child health should develop auto-regulatory 
consensus guidelines on the internal and external algorithm validation process until 
formal regulatory guidelines become available.  
 
Implementation and scale-up 
- Based on a consensus process between stakeholders, e-POCT should be combined 
with other existing electronic disease management algorithms into one single 
algorithm backbone, “e-IMCI-PLUS-AND-POCT”. This will also allow covering other 
sections (such as the management of non-febrile patients). The backbone algorithm 
should contain the most important disease classifications. Other components should 
be modular and adaptable to local needs. Careful attention should be paid not to 
remove e-POCT components that showed a clear benefit in our study.  
- The WHO child health department should assume the leadership in such a 
coordination effort to harmonize the content of electronic algorithms. For this purpose 
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an independent, scientific advisory committee for IMCI should be established that 
involves representatives from multiple stakeholders (including academia, local 
governments, and NGOs).  
- Implementation efforts for electronic algorithms should be centered around local 
governments to guarantee sustainability of the intervention. Independent, long-term 
funding, and fostering local human resource capacity will be a pre-requisite for such 
country-based efforts. The few countries that have demonstrated leadership in 
establishing national eHealth systems (for example Tanzania) should be chosen as 
initial partners.  
- Effectiveness studies (such as cluster-randomized studies, or carefully monitored 
implementation studies) should be performed to assess the public health benefits of 
e-POCT, or “e-IMCI-PLUS-AND-POCT”, compared to current IMCI-based routine 
care. Outcomes should involve health outcomes such as severe adverse events and 
antimicrobial/ resources use. The unit of analysis should be health centers or 
districts. A before and after design would also be possible.  
- Current software and hardware components should be improved to allow routine 
implementation of electronic algorithms. As a first step, current users of existing 
software should coordinate to create target-product-profiles for an ideal algorithm 
software as well as hardware components. This would allow leveraging the 
development of improved software and hardware tools. The software used should be 
able to interconnect with other components of the electronic health system. 
- Beyond the content and format of the electronic algorithm, other factors related to 
provider adherence should be carefully taken into account during implementation 
efforts; these include intrinsic and extrinsic motivators for adherence, monitoring, 
supervision, and safety-netting. 
- Multi-disciplinary teams should be created for scale-up efforts. Such teams should 
include specialists in the following areas: public health/ health systems, pediatrics, 
software programming, information technology, monitoring and evaluation, data 
analysis, finance, social science, logistics, training, and product development.  
- Data management and analysis plans should be established, as well as mechanism 
for monitoring and evaluation. This should include systems for health worker 
performance management based on the local culture and needs. Systematic data 
feedback to providers should be guaranteed.  
- The private health care sector should be included into implementation efforts.  
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11.2. Point-of care tests  
 
General recommendations 
- Existing biomarkers should be made fully operational for the POC level in resource-
poor settings. Biomarkers should be combined with other POCTs into a single small 
device that is connectable to smartphones and uses no more than 5-10µL of whole 
blood.  
- New biomarkers under development should be designed and validated for 
implementation at the peripheral care level. The prevalence of infection at this level 
should be taken into account when choosing cutoffs to rule-in and rule-out disease. 
- Cost analyses should be conducted that compare the cost of biomarker testing 
integrated into electronic algorithms to routine testing. A target price range for a test 
combining all biomarkers to be used by future electronic algorithms should also be 
set through such efforts.   
Host biomarkers to detect bacterial infection  
- Host biomarkers to detect bacterial infection should be evaluated in outcome-based 
studies before routine implementation. Results from validation studies do not always 
correlate with results from outcome-based studies due to the inherent limitations 
related to gold standards for serious bacterial infections.  
- Host biomarkers should not be used as screening tests for bacterial infection. Rather, 
they should be integrated into disease management algorithms that help to select 
patients for testing and to interpret test results.  
- Further studies should be conducted in children with fever without source with the 
goal of identifying the optimal biomarkers for this patient population, and to assess 
the utility of using a combination of biomarkers. The studies should be outcome 
based and compare i) the use of combined CRP and PCT testing, ii) the use of either 
CRP or PCT, iii) and new host biomarkers available as POCTs through a randomized 
design.  
- The threshold of CRP to decide on antibiotic prescription may be lowered in 
populations at higher risk for bacterial pneumonia. However, this threshold should 
not be lower than 40mg/L.  
- Future studies should also compare the use of different biomarker thresholds based 
on the duration of symptoms.  
 
Other point-of care tests 
Recommendations  158
- The usefulness of routine oximetry screening at peripheral health care level should 
be further evaluated during the pilot implementation phases of oximeters. The time 
required to obtain adequate measurements should be compared to the added value 
in terms of detecting more children with severe respiratory disease. Limiting oximetry 
measurement to a subset of patients based on obvious clinical signs should be 
considered.  
- The usefulness of routine Hb testing to detect children with severe infections should 
be evaluated further in pilot implementation studies. Different Hb thresholds for the 
definition of severe anemia should be compared. Representative population-based 
studies should be performed to provide normal reference for Hb, including small 
children under the age of 6 months.  
- New, available POCTs that can help detect and manage patients with sickle cell 
disease should be validated and evaluated as part of the IMCI strategy.
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